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Mycobacterium tuberculosis (Mtb) is a deadly pathogen that causes the infectious 
diseases Tuberculosis (TB) in humans. The emergence of drug resistant TB has created 
an urgent need for the development of new chemotherapeutics that can counter the 
resistance, and combat the spread of TB by shortening the treatment. One of the major 
determinants of the virulence of Mtb is its thick cell envelope which contains a wide 
varity of complex lipids and carbohydrates. Thus, the enzymes of cell wall lipid 
biosynthsis in Mtb represent attractive targets for drug discovery. In this dissertation, our 
studies on the structural and functional charatcterization of three different proteins from 
complex lipid synthesis pathways in the Mtb are presented.          
Firstly, we have crystallized the 225 kDa methyl-branched fatty acid synthesizing 
mycocerosic acid synthase (MAS) from Mtb. We developed methods to improve the 
diffraction properties of the MAS crystals. A medium resolution dataset allowed initial 
crystallographic characterization of MAS. The results suggest that these methods could 
be adapted for crystallographic studies of other type I polyketide synthase from Mtb.   
Secondly, the crystal structure of Mtb acyl carrier protein synthase (AcpS) is 
presented. This important enzyme activates the acyl carrier protein domains of the FAS I 
and FAS II systems in Mtb. The structure revealed that the Mtb AcpS adopts two pH 
dependent different conformations – open and closed. In vitro studies established a 





Thirdly, we have determined the structural basis for the inhibition of the 
thioesterase (TE) domain of Pks13 by benzofuran class of inhibitors. Pks13 represents a 
novel target in the essential mycolic acid biosynthesis pathway in Mtb. The crystal 
structure established that the TE domain belonged to the α/β-hydrolase class of enzymes.  
We also determined the structural basis for the mechanism of resistance of TE domain 
towards these inhibitors. We used the structure-guided approach to design new analogs 
of the benzofuran scaffold, and our best analog exhibited 12-fold increased inhibitory 
activity against Mtb. We also established that the benzimidazole scaffold containing 
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 Tuberculosis (TB) is deadly infectious disease that remains a serious threat to the 
public health worldwide. Despite the availability of active antibiotics, TB continues to 
cause significant morbidity and mortality globally. According to the latest World Health 
Organization (WHO) report, in 2012 there were about 9 million new cases and about 1.3 
million deaths due to TB. In addition, it has been estimated that nearly two billion people 
worldwide are latently infected with the bacillus Mycobacterium tuberculosis (Mtb), the 
causative agent of TB. In this infected population, about 5-10% of the 
immunocompetent individuals are expected to develop active disease; although the 
population retains a lifetime risk of reactivation of the disease. Furthermore, the latently 
infected population represents a significant reservoir of this obligate human pathogen. 
Therefore, the WHO recommends prompt detection and treatment of the infectious cases 
through implementation of the DOTS (Directly Observed Treatment, Short-Course) 
strategy for TB control.   
The current therapy for TB involves a minimum of six months of intensive 
treatment with four first-line antitubercular drugs isoniazid (INH), rifampicin (RIF), 




compliance and access to good health care, this treatment regimen can achieve a 
successful cure rate of >95%. However, patient non-compliance due to the long duration 
of the treatment coupled with resource poor settings in places with the highest burden of 
TB has resulted in the emergence of multidrug-resistant (MDR-) and extensively drug-
resistant (XDR-) TB. MDR-TB is resistant to INH and RIF, as a result, its treatment is 
much longer (20 months), expensive and uses toxic drugs. XDR-TB is even more 
difficult to treat as the Mtb bacilii are resistant to the first-line drugs INH and RIF, and to 
the second-line fluoroquinolones and one of the three injectable TB drugs (Zumla et al., 
2013a).  The emergence of resistant strains of Mtb and the co-infection of HIV patients 
with TB can seriously undermine global efforts to control TB pandemic. Thus, there is 
an urgent need for the discovery and development of novel anti-TB agents that can help 
shorten the treatment duration and are effective against drug-resistant TB. 
 Mtb is one of the most successful and persistent human pathogen in the world. It 
was identified by Robert Koch in 1882 as the principal etiological agent of TB in 
humans. Mtb belongs to class Actinobacteria and is a member of the Mycobacterium 
tuberculosis complex which includes M. bovis, M. bovis BCG, M. africanum, M. canetti, 
M. caprae, M. microti, and M. pinnipedii (Table 1-2) (Shenai and Rodrigues, 2011). Mtb 
is an aerobic, rod-shaped bacterium that has no capsule or flagellum. It is classified as a 
non-sporulating, weak Gram-positive bacterium with a G+C-rich genome. The Mtb cells 
have a thick waxy cell wall that retains Carbol fuchsin dye even in the presence of acidic 
alcohol, giving the bacterium its acid fast property. It is a slow-growing intracellular and 




 Table 1-1. Current recommendations for TB treatment.  
Type of Infection Recommended Regimen Comments 
Active disease  
  
Newly diagnosed 
cases that are not 
multidrug-
resistant 
Isoniazid, rifampin, ethambutol, and 
pyrazinamide for 2 mo (intensive 
phase), followed by isoniazid and 
rifampin for 4 mo (continuation 
phase) 
Pyridoxine supplementation 






Four second-line antituberculosis drugs 
(as well as pyrazinamide), 
including a fluoroquinolone, a 
parenteral agent, ethionamide or 
prothionamide, and either 
cycloserine or para-aminosalicylic 
acid if cycloserine cannot be used 
Initial treatment based on local 







Latent infection Isoniazid at a dose of 300 mg daily for 
at least 6 mo and preferably for 9 
mo 
Recommended for 9 mo or 
more in HIV-infected 
persons; daily 
administration for 6 mo 
also an option but with 
lower efficacy; extension 
to 36 mo further reduces 
risk among HIV-positive 
patients in regions in 
which tuberculosis is 
endemic 
 lsoniazid at a dose of 900 mg plus 
rifapentine at a dose of 900 mg 
weekly for 3 mo (directly 
observed therapy) 
Studied with directly observed 
therapy in predominantly 
HIV-uninfected persons; 
higher completion rates 
and equal efficacy, as 
compared with isoniazid 
for 9 mo 
 Rifampin at a dose of 600 mg daily for 
4 mo 
Shown to be effective in 
persons with silicosis 
 Isoniazid at a dose of 300 mg plus 
rifampin at a dose of 600 mg daily 
for 3 mo 
Effective alternative for HIV-
infected persons 
 Isoniazid at a dose of 900 mg plus 
rifampin at a dose of 600 mg 
twice weekly for 3 mo  
Another effective alternative 











Clinically relevant species M. tuberculosis complex. M. leprae, M. avium, M. 
kansasii, M. marinum, M. ulcerans, M fortuitum 
complex, M. abscessus. M. intracellulare, etc. 
  
 
 Transmission of TB occurs from person to person via aerosolized droplets 
containing Mtb that are generated when an individual with an active disease coughs or 
sneezes. When these droplets are inhaled, the tubercular bacilli enter the terminal air 
spaces of the lungs to establish the primary site of infection. After the bacilli have 
lodged into the lungs, they are phagocytosed by the resident alveolar macrophages, 
which recruit other immune cells through cytokine and chemokine signaling. These cells 
surround infected macrophages to form containment structures called the granuloma, or 
tubercle, which is the pathological hallmark of TB (Russell, 2007). Once the 
macrophage engulfs Mtb, there can be four potential outcomes: (i) the initial immune 
response can be completely effective in eradicating the bacteria, and in such a case the 




TB infection and begin to multiply and grow in the lungs of the infected person; (iii) the 
bacilli may enter a non- or slowly-replicating dormant state in the granuloma and do not 
cause the disease, a condition referred to as the latent infection; (iv) there could be 
reactivation of the latent bacteria causing a post-primary infection (Schluger and Rom, 
1998). However, the eventual outcome of the TB infection and its clinical manifestation 
is strongly dependent on the host immune response and the virulence of Mtb, both of 
which are influenced by the many complex lipid effectors in the mycobacterial cell 
envelope (Astarie-Dequeker et al., 2010). As the cell envelope is critical for the bacterial 
physiology, targeting the enzymes involved in its biosynthesis has been an effective 
strategy for promoting rapid killing of the bacterial cells, as exemplified by the 
mechanism of action of β-lactam antibiotics. Similarly, the first-line TB drugs INH and 
EMB target enzymes essential for the biosynthesis of the Mtb cell wall core (Banerjee et 
al., 1994; Belanger et al., 1996). However, increasing development of resistance to these 
drugs has led to intensive efforts over the last few decades for elucidating the 
biosynthesis pathways of several pathogenesis related cell surface lipids of Mtb 
(Neyrolles and Guilhot, 2011). This understanding of the biogenesis and the structural 
organization of the Mtb cell envelope is critical for the research focused on targeting cell 








Mtb cell envelope 
 The cell envelop of Mtb is the primary interface between the bacterium and its 
surrounding environment including the host. Therefore, to thrive under the harsh 
intracellular environment of the human macrophage, the bacterium produces a uniquely 
thick cell wall containing a wide range of complex lipids that also impart an intrinsic 
resistance to many antimycobacterial agents (Brennan and Nikaido, 1995). Due to its 
importance for the virulence and the survival of the bacterium, the Mtb cell wall has 
been studied intensively to determine its unique architecture and chemical composition 
(Brennan, 2003). Application of advanced NMR and mass spectrometric techniques has 
resulted in the identification and complete chemical characterization of many novel 
complex metabolites in the Mtb envelope (Chopra and Gokhale, 2009). The genetic and 
biochemical investigations have also furthered our understanding of the synthesis and 
the distribution of complex lipids like PDIMs, mycolic acids and sulfolipids in the 
mycobacterial envelope (Chopra and Gokhale, 2009; Gokhale et al., 2007; Portevin et 
al., 2004). These studies have revealed many of the previously unidentified enzymes and 
transporters involved in the mycolic acid and PDIM biosynthetic pathways that can 
provide highly prioritized targets for the drug discovery against TB (Favrot and 
Ronning, 2012). In addition, sequencing of the Mtb genome has revealed many new 
genes specifically involved in the cell envelope biogenesis, thereby identifying more 
potential targets for the design and development of new anti-tubercular drugs (Cole, 




mycobacterial cell envelop exists as a highly complex network of sugars, lipids and 
proteins. 
 The cell envelope of Mtb is a lipid rich multilayered structure composed of a 
plasma membrane surrounded by a covalently linked cell wall skeleton and a 
polysaccharide-rich capsule (Fig. 1-1). The mycobacterial cell wall core is composed of 
three covalently linked macromolecules – peptidoglycan, arabinogalactan and mycolic 
acids, termed the mycolyl-arabinogalactan-peptidoglycan (mAGP) complex (Brennan, 
2003) (Fig. 1-1). The peptidoglycan (PG) layer is a polymer of the repeating units of β-
1,4-linked N-acetylglucosamine and N-acetyl/glycolylmuramic acid which are cross-
linked via L-alanyl-D-isoglutaminyl-meso-diaminopimelyl-D-alanine tetrapeptides attached 
to the muramic acid. The arabinogalactan (AG) is a branched chain heteropolysaccharide 
composed of covalently linked D-furanosyl galactan and arabinan polymers. The AG is 
linked to the PG through the reducing residue of the galactan chain, whereas the α-D-
arabinofuranosyl residues at the nonreducing terminus of the arabinan chains are esterified 
to the mycolic acids, which are very long chain α-branched and β-hydroxylated fatty acids 
that are unique to mycobacteria (McNeil et al., 1990, 1991). In addition, the Mtb mAGP 
layer is surrounded on the exterior by a mobile layer consisting of free glycolipids, 
carbohydrates, and proteins like porins and the antigen 85 complex. The lipids of this 
outer layer include free mycolic acids, phenolic glycolipids (PGL), phthiocerol 
dimycocerosates (PDIM), diacyl trehaloses (DAT), sulfolipids and trehalose esters of 




to as the cord factor. These intercalate into the cell wall through their interactions with 
the mycolyl moiety of the mAGP complex (Brennan, 2003) (Fig. 1-1).   
 
 
   
  
 
Figure 1-1. Schematic representation of the Mtb cell envelope. Architecture of the 
mycobacterial cell wall shown along with the chemical structures of the major lipid 
components identified in the Mtb envelope. AG, arabinogalactan; PG, peptidoglycan; 
LM, lipomannan; PAT, polyacyltrehalose; DIM, phthiocerol dimycocerosates; MPM, 
mannosyl-β-1-phosphomycoketides. Figure reproduced from Gokhale et al., (2007), Nat. 
Prod. Rep.24, 267-277, with the permission of © [2007] The Royal Society of 





Mycolic acids of mycobacteria 
 Mycolic acids are major lipids of the mycobacterial cell envelope which are 
critical for maintaining its cell wall integrity. Though they are primarily found etserified 
to the terminal units of arabinogalactan as part of the mAGP complex, they are also 
present in the unbound forms in the cell envelope as trehalose esters TMM and TDM 
(Takayama et al., 2005). Mycolic acids are long chain fatty acids comprised of a 
saturated α-branch of C22-26 atoms condensed to a longer C40-60 meromycolate chain. The 
meromycolate chain contains two cis- or trans-double bonds, and it can be further 
functionalized with different groups, such as keto, ester, methoxy and cyclopropane 
rings, which define the different classes of mycolic acids (Barry et al., 1998). In Mtb, the 
mycolic acids are comprised of a C22-24 α-branch condensed to a very hydrophobic C54-63 
meromycolate chain (Fig. 1-2a). Based on the chemical modifications, they are divided 
into three major classes - α-, mthoxy- and keto-mycolic acids (Takayama et al., 2005) 
(Fig. 1-2b). In Mtb cell envelope, highly apolar α-mycolates are the most abundant 
(>70%), followed by the oxygenated methoxy- and keto-mycolic acids (10-15%). The 
structural features and the content of mycolic acids have been determined to be critical 
for the virulence of Mtb. In a study with mutant Mtb H37Rv and M. bovis BCG strains 
defective for the ketomycolate synthesis, it was shown that the mutants were severely 
defective for growth within macrophages (Yuan et al., 1998). Analysis of a mutant of 
Mtb that caused deletion in the proximal cyclopropane ring in the α-mycolates indicated 
that despite the normal initial replication, the mutant was significantly attenuated and 




of Mtb defective in the biosynthesis of oxygenated keto- and methoxymycolic acids was 
found to have a significantly altered envelope permeability, and displayed profound 




Figure 1-2. Mycolic acids of Mtb. (a) The chemical features of the dicyclopropanated α-
mycolic acid of Mtb. (b) Chemical structures of the different classes of mycolic acids 
found in Mtb. Figure (b) is adapted with permission from Takayama, et al., (2005), Clin. 







In addition to their role in the virulence, mycolic acids also play an important 
role as the structural components of the cell wall and envelope. They provide a highly 
hydrophobic barrier around the bacterium, and studies with the mycobacterial mutants 
defective in mycolate synthesis have established a strong link between the cell wall 
mycolic acid content and resistance to antibiotics. In a study on the effect of mycolate 
composition on the cell wall function, it was found that a deficiency of the keto-mycolic 
acids altered envelope fluidity and made the mutant cells hypersensitive to ampicillin 
and rifampicin (Yuan et al., 1998). A M. smegmatis mutant defective in mycolic acid 
biosynthesis displayed enhanced permeability to hydrophobic compounds, and became 
hypersensitive to hydrophobic drugs like chloramphenicol and novobiocin (Liu and 
Nikaido, 1999). Disruption of the mycolyltransferase fbpA in M. smegmatis caused a 
45% decrease in the TDM (cord factor) production in the mutant which resulted in a 
smooth colony phenotype in the mutant. The fbpA mutants also displayed increased 
sensitivity to both front-line antitubercular drugs as well as other broad-spectrum 
antibiotics (Nguyen et al., 2005). These studies have strongly established the importance 
of mycolic acids for the viability and pathogenesis of Mtb. This has raised significant 
interest in understanding the enzymes of the mycolic acid biosynthesis pathway.  Indeed, 
inhibition of mycolic acid biosynthesis has been the mainstay of TB therapy since the 
introduction of INH as a first-line antitubercular drug in 1952 (Takayama et al., 1972). 
Therefore, this metabolic pathway represents an important reservoir of novel targets for 
the development of new anti-Mtb drugs especially in the context of the emergence of 




Mycolic acid biosynthesis 
 In Mtb, mycolic acid biosynthesis occurs by the concerted action of more than 20 
different proteins that are components of different multi-enzyme complexes (Takayama 
et al., 2005). Even though some details of the pathway remain to be elucidated, it has 
been well established that the pathway uses both FAS I and II systems, as well as a PKS 
for the mycolic acid biosynthesis (Barry et al., 1998; Portevin et al., 2004). The 
mycobacteria are atypical in that they possess both type I and type II FAS systems 
(Barry et al., 1998). The FAS I of Mtb perform the de novo synthesis of fatty acids 
containing 16 and 24 carbon atoms as fatty acyl-CoAs in a bimodal distribution. In 
contrast, the Mtb FAS II system is unable to perform de novo biosynthesis of fatty acids; 
instead it preferentially extends palmitoyl-CoA derived from FAS I to synthesize C18-30 
long fatty acids (Barry et al., 1998).      
The biosynthesis of mycolic acids in Mtb can be divided into three major steps 
(Takayama et al., 2005) (Fig. 1-3a). First, the FAS I synthesizes alpha-alkyl and 
meromycolate precursors as the C16-C18 and C24-C26 fatty acids, respectively. Next, the 
FAS II system extends the C16-C18 fatty acids to generate very long (C48-C64) 
meromycolic chain which is further modified by different enzymes that introduce cis or 
trans unsaturation, methylation, cis or trans cyclopropanation and oxygenated functional 
groups. The antituberculosis drug INH targets the FAS II in the mycolic acid sysnthesis 
pathway by inhibiting the enoyl reductase InhA via formation of a covalent adduct with 
NAD
+
 (Dessen et al., 1995). The final condensation step is performed by the modular 




precursor to meroacyl-AMP and transfers it to the N-terminal ACP domain of Pks13. 
The C24-C26 fatty acids from FAS-I are activated through carboxylation to generate 2-
carboxyl-C26-S-CoA which are transferred by the AT domain of Pks13 to its C-terminal 
ACP domain. The KS domain of Pks13 then performs the final assembly step through a 
decarboxylative Claisen-type condensation of the meroacyl and the alpha chain to form 
α-alkyl β-ketoacids, which are then reduced by the ketoacyl reductase CmrA to form the 
mature mycolic acids (Takayama et al., 2005). Mtb Pks13 is a large modular PKS 
enzyme which has domain architecture of NACP-KS-AT-ACP-TE (Portevin et al., 
2004) (Fig. 1-3b). This protein is essential for the viability of mycobacteria; therefore, it 
represents an attractive target for the development of novel inhibitors targeting the 
essential mycolic acid biosynthesis pathway, especially against MDR-TB. Indeed, a 
recent report indicated that Pks13 is susceptible to chemical inhibition and that its 
inhibition could kill Mtb (Wilson et al., 2013). We have identified a novel benzofuran 
inhibitor of the essential Pks13 enzyme that targets the functionality of its TE domain. In 
addition, we have performed structural studies on the TE domain in complex with the 
inhibitor to elucidate the molecular basis of inhibition. These studies are described in 
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Figure 1-3. Schematic of mycolic acid biosynthesis pathway in Mtb. (a) Mycolic acid 
biosynthesis in Mtb starts with the de novo synthesis of fatty acid precursors by FAS I. The C16-18 
fatty acids are elongated by FAS II system and further functionalized to produce the very long 
meromycolic precursors. The C24-26 fatty acids synthesized by FAS I are carboxylated to form 
acyl-CoAs that provide the α-branch. The activated meromycolic chain is subsequently 
condensed with the C24-26-CoA by the condensing enzyme Pks13. (b) Pks13 is a type I modular 
PKS that performs a single round of Claisen-like condensation of the meromycolic chain with 
the α-branch and the product is then released by the TE domain for reduction to yield the 
characteristic mycolic acids. AT, acyl transferase; KS, β-ketoacyl synthase; N-ACP, N-terminal 





Polyketide synthases of Mtb 
 The polyketide synthases (PKSs) are a class of multifunctional enzymes with a 
structural organization similar to fatty acid synthase (FAS) systems (Khosla et al., 1999; 
Smith and Tsai, 2007). The PKS can be synthesized as a multifunctional enzyme in 
which all the constituent catalytic domains are present on a single polypeptide (type I 
PKS) similar to FAS I, or they can occur as enzyme clusters of discreet monofunctional 
subunits (type II PKS) similar to FAS II (Fig. 1-4a). In addition, there are type III PKS 
systems belonging to the plant chalcone synthase family of enzymes that are present as 
freestanding homodimeric condensing enzymes (Shen, 2003). In the PKS and FAS 
systems, the domains are defined based on their catalytic function and they are generally 
dedicated to a single transformation or transfer function in the multifunctional assembly 
line. The catalytic domains in type I PKS and FAS I systems are defined based on the 
chemical transformation they perform and include acyl transferase (AT), β-ketoacyl 
synthase (KS), dehydratase (DH), β-ketoreductase (KR), enoyl reductase (ER), acyl 
carrier protein (ACP) and thioesterase (TE) activities. The FAS I is comprised of a single 
copy of all the seven domains, whereas the minimal type I PKS module can consist of a 
core set of KS, AT and ACP domains essential for elongating a growing polyketide by 
one –CH2-CO- unit (Smith and Tsai, 2007) (Fig. 1-4b). Since the reducing domains (KR, 
DH and ER) are optional, the PKS I systems can alter the extent of the β-carbon 
processing to retain it in β-keto, β-hydroxy, enoyl or fully saturated form to introduce 
chirality and generate different functionalities in the polyketide product (Fig. 1-4c). In 




by incorporation of phosphate or peptidyl moieties, or via cyclization etc. (Gokhale et 





Figure 1-4. Domain organization and reactions of FAS and PKS systems. (a) Domain 
organization of FAS I and FAS II systems. (b) A minimal PKS module that can extend 
the growing polyketide chain by the addition of one extender unit/building block. (c) 
Reactions catalyzed by the ancillary domains in FAS and PKS systems to process the β-
keto center. Different reductions states (hydroxyl, enol, fully reduced alkyl) can result 
from the action of one or more of these domains introducing chirality and functionalities 
in the product. AT, acyl transferase; KS, β-ketoacyl synthase; DH, dehydratase; KR, β-





 The earliest studies suggesting that the Mtb utilized PKS systems to synthesize 
complex lipids were done by Kolattukudy and coworkers (Kolattukudy et al., 1997). 
Prior to their work, decades of intensive analysis of the waxy components of the Mtb cell 
wall had led to elucidation of the structures and the chemical nature of many complex 
lipids, however, their biosynthetic pathways remained unknown (Demartreau-Ginsburg 
et al., 1959; Goren et al., 1976; Marks and Polgar, 1955). The first indication that the 
PKS are involved in the biosynthesis of cell wall lipids in Mtb came from the studies on 
the biosynthesis of the methyl-branched fatty acyl chains of phthicerol wax esters 
(PDIM) (Azad et al., 1997; Kolattukudy et al., 1997). A multifunctional synthase, MAS 
was identified as an iterative type I PKS containing all the six domains required for the 
biosynthesis of multiple methyl-branched mycocerosic acids in M. bovis BCG (Mathur 
and Kolattukudy, 1992). Further, probes for the KS and AT domains of the mas and fas 
genes identified a cluster of five genes (pps1-5) encoding for type I PKSs in the M. bovis 
BCG genomic cosmid library. The homologues for these were also identified in Mtb 
(ppsA-E) and they were shown to be modular type I PKSs involved in the biosynthesis 
of the phthiocerol branch of the PDIM (Kolattukudy et al., 1997).  Subsequently, the 
sequencing of the Mtb genome revealed a number genes encoding for the enzymes of 
lipid metabolism, consistent with the presence of a diverse range of complex lipids in 
Mtb (Cole et al., 1998). Analysis of the Mtb genome also identified the presence of a fas 
I gene, fas II system genes, two non-ribosomal peptide synthase clusters (nrps) and 25 




of the pks genes suggested that the Mtb contains examples of all three types of PKS 
systems (Table 1-3).  
 
 










ppsA Rv2931 ACP-KS-AT-KR-ACP (Camacho et al., 1999), 
(Trivedi et al., 2005) 
ppsB Rv2932 KS-AT-KR-ACP (Azad et al., 1997), 
(Trivedi et al., 2005) 
ppsC Rv2933 KS-AT-DH-ER-KR-ACP (Azad et al., 1997) 
ppsD Rv2934 KS-AT-DH-KR-ACP  
ppsE Rv2935 KS-AT-ACP-C (Trivedi et al., 2005) 
mas Rv2940c KS-AT-DH-ER-KR-ACP (Mathur and Kolattukudy, 
1992) 
pks1 Rv2946c AT-DH-ER-KR-ACP (Constant et al., 2002) 
pks15 Rv2947c KS (Constant et al., 2002) 
pks2 Rv3825c KS-AT-DH-ER-KR-ACP (Sirakova et al., 2001) 
pks3 Rv1180 KS (Rousseau et al., 2003a) 
pks4 Rv1181 AT-DH-ER-KR-ACP (Rousseau et al., 2003a) 
pks5 Rv1527c KS-AT-DH-ER-KR-ACP (Rousseau et al., 2003b) 
pks6 Rv0405 ACP-KS-AT- ACP-TE (Camacho et al., 1999) 
pks7 Rv1661 KS-AT-DH-ER-KR-ACP (Rousseau et al., 2003b) 
pks8 Rv1662 KS-AT-DH-ER (Dubey et al., 2003) 















pks10 Rv1660 KS (type III) (Saxena et al., 2003; 
Sirakova et al., 2003a) 
pks11 Rv1665 KS (type III) (Saxena et al., 2003) 
pks12 Rv2048c KS-AT-DH-ER-KR-ACP-KS-AT-
DH-ER-KR-ACP 
(Chopra et al., 2008; 
Sirakova et al., 2003b) 
pks13 Rv3800c ACP-KS-AT-ACP-TE (Portevin et al., 2004) 
pks17 Rv1663 ER-KR-ACP (Dubey et al., 2003) 
pks18 Rv1372 KS (type III) (Saxena et al., 2003) 
MbtC Rv2382c KS (Chopra and Gokhale, 
2009) 
MbtD Rv2381c AT-KR-ACP (Chopra and Gokhale, 
2009) 
pks14 Rv1342c wrongly annotated (Onwueme et al., 2005) 
pks16 Rv1013 wrongly annotated (FadD) (Onwueme et al., 2005) 
 
a 




 Since the cell wall lipids of Mtb provide a thick hydrophobic shell around the 
bacterium imparting it resistance against hostile environments and also actively 
modulate host immune response, intensive studies have been done to decipher their 
biosynthesis as well as to identify novel drug targets. In the Mtb genome, more genes 




known metabolites, raising the possibilities for uncovering novel mechanisms or 
metabolites (Cole, 1999). Indeed, studies over the last decade have identified other 
enzymes and functional domains in Mtb that either mediate cross-talk between multi-
enzyme systems involved in the biosynthesis of PKS synthase derived lipids (Mohanty 
et al., 2011; Trivedi et al., 2004), or functionalize core structures with specific chemical 
groups (Boissier et al., 2006; Glickman et al., 2000; Keating et al., 2002). For example, 
Trivedi et al. used sequence analysis to identify homologues of E. coli FadD proteins, 
which convert fatty acids to their corresponding fatty acyl-CoAs for β-oxidation, in the 
Mtb genome in close proximity to pks or nrps gene clusters. A total of 34 such genes 
were identified in the Mtb genome that clustered in two groups with distinct biochemical 
activities, fatty acyl-CoA ligases (FACLs) and fatty acyl-adenylate ligases (FAALs) 
(Arora et al., 2009; Trivedi et al., 2004). Further, it was shown that the FAALs have a 
novel acyl loading mechanism whereby they can transfer long-chain fatty acids to their 
cognate PKS for further extension, in an ATP-dependent manner (Trivedi et al., 2004). 
Similarly, comparative sequence analysis of the Mtb genome was used to identify pks13 
gene as the one encoding for the elusive central condensing enzyme of the mycolic acid 
biosynthesis pathway (Portevin et al., 2004).  More than 40 years of biochemical and 
genetic investigations by several groups had failed to identify this central condensase. 
Moreover, analysis of the nucleotide sequences flanking the pks13 gene also helped to 
identify two genes predicted to encode for an acyl-CoA synthase (fadD32) and a subunit 
of an acyl-CoA carboxylase (accD4) involved in the activation of the substrates of the 




 In recent years, studies on the cell envelope lipids of Mtb have clearly established 
that their production involves novel biosynthetic mechanisms in which PKS and FAS 
multienzyme systems work in concert to synthesize a remarkable diversity of complex 
lipids (Chopra and Gokhale, 2009; Takayama et al., 2005). However, despite their 
importance for the virulence and pathogenesis of Mtb, there has been no structural data 
available on the type I PKSs of Mtb. Till date, there has been only a single study on the 
inhibitor discovery targeting PKS systems in Mtb which reported identification of an 
inhibitor that disrupted the interaction between FadD32 and the N-terminal ACP domain 
of Pks13 (Wilson et al., 2013). However, in the absence of the structural data, the 
inhibitors could not be rationally modified to improve their potency. Moreover, the 
proposed mechanism of inhibition derived from the modeling studies was speculative. 
For a proper understanding of these megasynthases, it is essential to obtain atomic level 
structural details. Even though a porcine FAS I crystal structure has become available to 
provide a general framework for the type I PKSs (Maier et al., 2006), it was found to be 
lacking in fine atomic level details as determined from the comparison with a high 
resolution structure of the KS-AT didomeric domain of 6-deoxyerythronolide B synthase 
(Smith and Tsai, 2007). Moreover, the available structural data does not provide a model 
for the stacking of a series of PKS modules that lack one or more of the ancillary 
domains. Therefore, it is critical to determine structures of these complex multienzymes 
to understand their mechanism, and to obtain insights into their intra- and inter-domain 
recognition mechanisms, which are currently lacking for most of the PKSs in Mtb. The 




substrate recognition and provide insights into the protein-protein recognition 
mechanisms (Tsai and Ames, 2009). In addition, the structural details of the active sites 
and protein-protein interaction interfaces can help guide structure-based inhibitor 
discovery against these megasynthases which are essential for the virulence and viability 
of the Mtb in its host (Cox et al., 1999).  In this dissertation I describe our efforts 
towards crystallographic studies on the two type I PKS synthases of Mtb, mycocerosic 
acid synthase (MAS) from the PDIM biosynthesis pathway, and Pks13 of the mycolic 
acid biosynthesis pathway. These studies are discussed in Chapters II and IV, 
respectively.   
 
Methyl-branched cell surface lipids of Mtb 
 Mtb contains many PKS derived methylated complex lipids and lipoglycans in its 
cellular envelope (Fig. 1-5). The PKSs involved in their biosynthesis introduce methyl 
branches on the esterified fatty acyl chains by using methylmalonyl-CoA, instead of 
malonyl-CoA, as the chain extending substrate (Jackson et al., 2007). These surface 
exposed lipids are non-covalently associated with the cell wall and form a waxy low 
permeability barrier that imparts resistance against therapeutics (Brennan and Nikaido, 
1995). In addition, these diffusible complex lipids are critical for the virulence and the 
pathogenesis of Mtb, since they also play important roles in mediating specific host-
pathogen interactions (Forrellad et al., 2013; Rousseau et al., 2004). The phthiocerol 
diesters (PDIM) of Mtb consist of long-chain β-diols (C33-C41) etserified to multimethyl-




composed of long-chain phenolic β-diols (C33-C41) with a variable sugar moiety 
consisting of one to four O-methylated deoxysugars, and etserified by mycocerosic acids 
or phthioceranic acids (Onwueme et al., 2005). Both, PDIM and PGL, are located in the 
outermost layer of the Mtb capsule partly exposed to the surface of the cell, and partly 





Figure 1-5. Chemical structures of multiple methyl-branched fatty acid containing lipids 
from Mtb.  DAT, diacyl trehalose; PAT, polyacyltrhalose; PGL, phenolic glycolipids; 
PDIM, phthiocerol dimycocerosates; SL, sulfolipids; MPM, mannosyl-β-1-
phosphomycoketides. Reprinted from Jackson et al., Tuberculosis 87, 78-86, with 





PDIM and PGL are primarily found in the pathogenic species of mycobacteria 
and are implicated in promoting Mtb virulence in the early stage of infection (Daffe and 
Laneelle, 1988; Rousseau et al., 2004). PDIM were shown to insert into the human 
macrophage membrane thereby altering its lipid organization and facilitating the 
phagocytic uptake of Mtb into the host macrophage (Astarie-Dequeker et al., 2009). PGL 
were also found to enhance Mtb virulence through modulation of host immune response. 
A knock-out mutant of the pks15/1 gene involved in the PGL synthesis in a highly 
virulent Mtb clinical isolate of the W-Beijing family, resulted in a mutant strain 
attenuated in its ability to kill mice following aerosol infection (Reed et al., 2004). 
Synthesis of PGL was also found to inhibit proinflammatory cytokine production in the 
infected mouse macrophages and the effect was attributed to the saccharide moiety of 
the PGL (Reed et al., 2004). Sulfolipids (SL) are found exclusively in the human 
pathogenic Mtb. SLs are the second most abundant free lipids in the Mtb cell envelope 
which are found associated with the mycolic acid layer in the envelope (Chopra and 
Gokhale, 2009).  Gene disruption and complementation studies have identified Pks2 as 
the synthase involed in the synthesis of methyl-branched phthioceronic acids (PA) or 
hydroxyl phthioceronic acids (HPA) of SL-1 (Sirakova et al., 2001). The SL-1 family 
was determined to be sulfated trehalose esters of a straight chain (C16 or C18) fatty acid at 
the 2-position and different combinations of the three chains of PA or HPA at the 3-/4-, 
6- and 6-'positions (Goren et al., 1976; Jackson et al., 2007) (Fig. 1-5). Although SL 
have been suggested to mediate host-pathogen interactions due to their presence on the 




established (Forrellad et al., 2013). PATs (polyacyltrehaloses) and DATs (diacyl 
trehalose) are trehalose ester lipids of waxy nature that are localized on the outer surface 
of the cell wall. PATs are penta-acylated trehaloses consisting of one medium-chain (C16 
or C19) fatty acid  and different combinations of trimethyl C27-mycolipenic and C27-
mycolipanolic acids at the 2, 2', 3', 4 and 6' positions (Jackson et al., 2007) (Fig. 1-5). A 
PAT mutant strain with defects in capsule attachment was shown to cause clumping of 
the Mtb cells (Dubey et al., 2002), and in another mutant strain PAT deficiency was 
correlated with the efficiency of binding and entry into the host cells (Rousseau et al., 
2003a). However, their contribution to the bacterial virulence remains to be determined. 
The MPMs (mannosyl-β-1-phosphomycoketides) are a group of antigenic phospholipids 
that are synthesized by the bimodular synthase Pks12 in Mtb (Chopra et al., 2008). The 
MPMs have been found only in the slow growing pathogenic mycobacteria. They have a 
mannose-phosphate head group identical to that found in the mammalian mannosyl-β-1-
phosphodolichols, however, they differ in their alkyl chain which is proposed to 
contribute to their antigenicity (Matsunaga et al., 2004).  The mycoketides have been 
proposed to function as virulence factors, or as bioactive compounds mediating 
biological signaling due to their extremely low levels in the Mtb cells. Though MPMs 
were shown to interact with human CD1c proteins, their precise function in the 
mycobacterial infection remains to be determined (Matsunaga and Sugita, 2012). The 
methyl-branched complex lipids of the mycobacterial cell envelope are important 
virulence effectors many of which are found only in pathogenic mycobacteria, such as 




metabolism and transport of these complex cell wall lipids could potentially offer 
important new targets for the antitubercular drug design.         
 
Biosynthesis of phthiocerol dimycocerosate esters (PDIMs) in Mtb 
 The genes encoding the various enzymes of the PDIM biosynthesis pathway 
constitute a large operon comprised of ~15 open reading frames, and they are found 
clustered on a 50 kbp fragment of the Mtb genome (Cole et al., 1998; Trivedi et al., 
2005) (Fig. 1-6). The five type I modular PKSs (PpsA-E) and the iterative type I PKS 
(MAS) encoded by this cluster exemplify the biochemical logic of the modular PKS 





Figure 1-6. Genetic organization of the PDIM synthesis locus in Mtb. The genes 
involved in the production of PDIM constitute a large operon (~50 kbp) and include a 
type I iterative PKS (mas) and five type I modular PKSs (ppsA-E). The genes are 
depicted as arrows with the genes encoding the proteins involved in PDIM synthesis in 







The biosynthesis of PDIMs can be divided into four key steps: (i) priming of 
PpsA with specific long-chain fatty acid; (ii) extension of the primer by PpsA-E, leading 
to the synthesis of phthiocerol; (iii) synthesis of mycocerosic acids by MAS; and (iv) 
esterification of mycocerosic acids to the diol of phthiocerol and final assembly 
(Gokhale et al., 2007) (Fig. 1-7). The first step in phthiocerol biosynthesis involves the 
transfer of a fatty acyl starter unit to the PCP domain of PpsA by FadD26. The starter 
unit is then loaded onto the active site Cys of the KS domain of PpsA, which then 
performs a decarboxylative condensation with a malonyl group attached to the 
phosphopantetheine arm of the ACP domain. This extends the fatty acyl chain by two 
carbon units, and the KR domain of PpsA then reduces the β-keto group to a hydroxyl 
group. After performing one extension cycle, PpsA covalently transfers the chain from 
its ACP domain to the active site of the KS domain of PpsB through an acyl transfer 
reaction (Gokhale et al., 2007; Trivedi et al., 2005).  The PpsB protein also utilizes 
malonyl-CoA to extend the chain by two carbon units, and generates another hydroxyl 
group on the growing chain.  Similarly, PpsC and PpsD also extend the acyl chain; 
however, they completely reduce the β-keto groups to saturated carbons due to the 
presence of ancillary dehydratase and enoyl reductase domains. In contrast to PpsC, the 
ER domain of PpsD is a trans-ER encoded by the Rv2953 gene in Mtb (Simeone et al., 
2007) (Fig. 1-7). The final step in the phthiocerol biosynthesis is catalyzed by PpsE, 
which can utilize both malonyl- as well as methylmalonyl-CoA as extender units. This 
catalytic flexibility of PpsE has been proposed to produce structural diversity in the 





Figure 1-7. Schematic of PDIM biosynthesis pathway in Mtb. FadD26 provides 
activated fatty acyl precursors to the modular PpsA-E PKS machinery for the synthesis 
of the phthiocerol branch of PDIM. The ER domain (Rv2953) is not a part of the PpsD 
polypeptide, but acts in trans with it. The type I iterative PKS, MAS synthesizes methyl-
branched mycocerosic acids using the activated acyl precursors provided by FadD28. 
PapA5 mediates the final condensation of phthiocerol with mycocerosic acids to form 
PDIM. AT, acyl transferase; KS, β-ketoacyl synthase; DH, dehydratase; KR, β-
ketoreductase; ER, enoyl reductase; ACP, acyl carrier protein.    
 
 
 The methyl-branched mycerosic acids of the PDIMs are synthesized by MAS by 
using variable length fatty acyl-CoA starters with methylmalonyl-CoA as extender units 
(described in more detail in Chapter II) (Chopra and Gokhale, 2009; Mathur and 
Kolattukudy, 1992). The final assembly of PDIM is performed by the polyketide-
associated protein A5 (PapA5) which interacts with MAS and transfers the mycocerosic 




2005). The fully synthesized PDIMs are further processed before being transported to 
the cell wall periphery by the transmembrane protein MmpL7 and other accessory 
proteins (Jain and Cox, 2005; Onwueme et al., 2005). 
 Even though the combination of biochemical and genetic studies over the last 
couple of decades have provided a detailed picture of the biosynthesis of PDIMs in Mtb 
(Fig. 1-7), it still remains to be elucidated how these complex enzymes work at the 
molecular level (Guilhot et al., 2008). For example, it is not known what structural 
motifs of the linkers are involved in conferring specificity for the hand-to-hand transfer 
of the acyl chain from one Pps protein to another. Moreover, there is no information 
available on the supramolecular organization of the PKS complexes, and how they 
interact with other partner proteins of the PDIM biosynthetic pathway. Also, the 
structural basis for substrate specificity, and the molecular mechanisms for generating 
subtle structural variations in the PDIM core are yet to be deciphered. Since the PDIMs 
of Mtb are critical for its virulence and pathogenesis, it has been suggested that 
inhibition of the enzymes of this pathway could synergize with, or potentiate other anti-
tubercular drugs to improve the treatment of TB (Favrot and Ronning, 2012). The PKSs 
are excellent targets for drug discovery since they are not found in the human host, and 
they provide multiple active sites for chemical inhibition on a single polypeptide. For 
inhibitor development, three dimensional structural studies are critical for elucidating the 
structure-function relationships in these enzymes. Such an approach was successfully 
applied in determining the structural basis for the acyltransferase activity of PapA5 that 




structural study identified LppX as the protein involved in PDIM transport and provided 
a structural basis for its activity (Sulzenbacher et al., 2006). However, despite the 
identification of the first PKS of this pathway (MAS) more than 25 years ago (Rainwater 
and Kolattukudy, 1985), so far no structural studies have been reported for any of the 
PKSs of the PDIM biosynthesis pathway.  This can be largely attributed to the 
challenges associated with the crystallographic studies of large macromolecular 
complexes, as exemplified by the fact that except for FAS I, structure of no other full 
length type I PKS from any organism has been solved (Maier et al., 2010; Mueller et al., 
2007).  In this dissertation, I report our efforts on crystallization and initial X-ray 
crystallographic characterization of the crystals of the Mtb MAS protein. We identified 
conditions for successful recombinant expression of this large protein in E. coli, and 
developed protocols for the improvement of the diffraction qualities of the protein 
crystals. These studies are described in detail in Chapter II.  
 
Activation of acyl carrier protein (ACP) domains in Mtb 
 The ACP domains function as flexible swinging arms that deliver the covalently 
tethered biosynthetic intermediates for sequential processing to different active sites of 
PKS and FAS enzymes, either in cis (type I systems) or in trans (type II systems) (Smith 
and Tsai, 2007). In all PKS and FAS systems, a posttranslational modification of the 
constituent ACP domains by the attachment of a 4'-phosphopantetheine (4'-ppt) 
prosthetic group to the hydroxyl of a conserved serine residue, is required for the 




posttranslational modification is mediated by 4'- phosphopantetheinyl transferases 
(PPTases) that convert inactive apo-ACP to the active holo-form by catalyzing transfer 
of the 4'-ppt arm from coenzyme A (CoA) to the ACP domain (Lambalot et al., 1996). 
During the biosynthesis cycles of PKS and FAS systems, the growing acyl chains and 
the biosynthetic intermediates remain covalently attached to the ACP domain by a 
thioester linkage with the terminal thiol of the 4'-ppt arm. After the synthesis is 
complete, the finished polyketide or the fatty acid chain is released from the ACP by a 
thioesterase or an acyltransferase domain (Smith and Tsai, 2007). 
 The genome of Mtb contains two PPTase encoding genes, acpS and pptT that 
encode the corresponding PPTases AcpS and PptT in Mtb (Cole et al., 1998). The AcpS 
(holo-acyl carrier protein synthase) enzyme was determined to be essential for the 
activation of ACP domains in both the FAS I and FAS II systems in Mtb, whereas the 
PPTase PptT was proposed to activate the carrier domains of PKS I and non-ribosomal 
peptide synthases in Mtb. Thus, both the enzymes play crucial roles in the biosynthesis 
of complex lipids that are essential for the survival and virulence of Mtb. (Chalut et al., 
2006). Since Mtb AcpS activates the acyl carrier protein AcpM of the FAS II system 
which is essential for the synthesis of mycolic acids, it represents a potential target for 
drug development. Therefore, to determine the structure-function relationship for the 
inhibitor development, we have solved the three dimensional structure of Mtb AcpS. The 
structure revealed that the Mtb AcpS can adopt two different pH-dependent 




identify lead fragments for further structure-guided development. These studies are 






Figure 1-8. Posttranslational modification of the ACP domain. The PPTase catalyzes the 
transfer of the 4'-phosphopantetheine moiety from CoA onto a conserved serine residue 
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Mycocerosic acids synthese (MAS, Rv2940c), is a type I PKS that synthesizes 
multimethyl-branched fatty acids (mycocerosic acids) in mycobacteria (Rainwater and 
Kolattukudy, 1985). The mycocerosic acids are an important component of the complex 
lipids PDIM and PGL that are found primarily in the cell walls of the pathogenic 
mycobacteria (Onwueme et al., 2005). MAS performs iterative condensation of medium- 
to long-chain fatty acyl-CoA primers with methylmalonyl-CoA as the extender units to 
synthesize fully reduced and saturated mycocerosic acids in a manner analogous to the 
vertebrate FAS I system (Mathur and Kolattukudy, 1992; Trivedi et al., 2005). In 
addition, it was also determind that the MAS protein required NADPH as a cofactor for 
the KR and ER activities (Rainwater and Kolattukudy, 1985). 
The cloning and sequencing of the mas gene identified a modular domain 
organization for the multifunctional MAS protein with a domain order: β-ketoacyl 
synthase (KS), acyl transferase (AT), dehydratase (DH), enoyl reductase (ER), β-




domains, similar to the FAS I enzyme (Mathur and Kolattukudy, 1992). Thus, MAS 
possesses all the ancillary domains (KR, DH and ER) that are necessary for the complete 
reduction of the resulting β-ketoacyl moiety, before another round of chain extension 
occurs. Sequence analysis revealed that, unlike FAS-1, the MAS polypeptide did not 
contain a thioesterase (TE) domain that could be involved in the release of the 
synthesized mycerosates. This was further confirmed by the experimental observation 
that in vitro the synthesized mycocerosic acids were not released from the protein 
(Mathur and Kolattukudy, 1992; Trivedi et al., 2005). It was postulated that another 
specific enzyme may be involved in transferring the mycocerosates from MAS onto the 
hydroxyl groups of phthiocerol and phenolphthiocerol chains (Kolattukudy et al., 1997). 
Indeed, a subsequent study identified the enzyme catalyzing this acyl transfer as PapA5, 
encoded by the gene adjacent to the mas gene in the PDIM operon (Onwueme et al., 
2004) (Fig. 1-6). It was shown that in vitro PapA5 was able to transfer the MAS bound 
mycocerosic acid analogs to the 2-dodecanol (a phtiocerol surrogate), suggesting a hand-
to-hand transfer mechanism for the mycocerosates (Trivedi et al., 2005). However, the 
structural basis for the PapA5 interaction with the MAS protein, and the molecular 
mechanism of chain termination in MAS are presently not known.    
In the studies performed with the purified MAS, it was observed that in vitro 
MAS was able to utilize many different primers ranging from C6-C20 acyl-CoAs and 
generated di-, tri- or tetra-methyl branched mycocerosic acids (Onwueme et al., 2005; 
Trivedi et al., 2005). A similar structural diversity in the mycocerosic acids was also 




2007). These studies established that MAS could utilize primer units of varying lengths, 
and modulate the number of iterative cycles to generate chemical diversity depending on 
the growth conditions. But the molecular basis for such substrate promiscuity has not 
been determined.  
Initial studies with MAS suggested that its preferred substrates were acyl-CoAs 
of C16-C20 fatty acids (Rainwater and Kolattukudy, 1985). The FadD28 protein, encoded 
by a gene adjacent to mas, was proposed to be the activating enzyme for converting the 
fatty acids to their corresponding acyl-CoA forms, since many genetic studies had shown 
it to be essential for the biosynthesis of both PGL and PDIM in Mtb (Camacho et al., 
2001; Cox et al., 1999; Fitzmaurice and Kolattukudy, 1998).  It was later demonstrated 
in an in vitro study that FadD28 did activate fatty acids but as fatty acyl-AMP, and not 
as acyl-CoA (Trivedi et al., 2004). These findings and the close chromosomal proximity 
of FadD28 and MAS strongly suggest that FadD28 is the activating enzyme for the 
substrates of MAS. However, a direct evidence for the interaction between MAS and 
FadD32 is not yet available, and the molecular mechanism for the acyl transfer also 
remains to be elucidated.  
Thus, on the basis of its importance in PDIM biosynthesis and the critical role of 
this complex lipid group in Mtb virulence, the multifunctional MAS protein presents an 
important target for structure-function studies. Determination of MAS structure will 
enable us to understand the structural and mechanistic aspects underlying its function, 





MATERIAL AND METHODS 
 
Cloning, expression and purification of Mtb MAS 
 The 6336 base pair mas gene was PCR amplified from the genomic DNA of Mtb 
strain H37Rv. Due to the large size of the gene, a combination of FailSafe PCR reaction 
mix D (Epicenter) and Phusion high fidelity DNA polymerase (NEB) was used to ensure 
fidelity of the amplified gene and eliminate non-specific products in the PCR reaction. 
The PCR primers for full length mas gene (forward primer, 5'-
CATTCGCTAGCATGGAATCACGTGTCACTCCCGTTGC 3'; reverse primer, 5'-
CATTCGGTACCCTATGATGCCGCCGGTGCCGC 3') were used to create restriction 
sites for NheI and KpnI (underlined), respectively. The amplified DNA fragment was 
cloned into the corresponding restriction sites in a chimeric pET28b_pET30b expression  
vector (pET28_30b) to create N-terminally His6-tagged full length MAS (2111 residues) 
to simplify purification.  
The C-terminal ACP domain truncations of MAS were cloned in the pET28_30b 
vector in the same way as was done for the full length MAS from the PCR fragments 
amplified using the following primers: 
For all five truncations, the forward primer was, 
5'-CATTCGCTAGCATGGAATCACGTGTCACTCCCGTTGCGGTGATC 3' 
Reverse primer for C-terminus truncation 1 of MAS (1-2011, T1), 
5'-CATTCGGTCCCTCAGCCCCTTGACCGCTGCCCAGTGGATGCGAA 3' 





Reverse primer for C-terminus truncation 3 of MAS (1-1906, T3), 
5'-CATTCGGTACCTCAGCCGAGCAATGCCGCTCCCGAGGAGAACAA 3' 
Reverse primer for C-terminus truncation 4 of MAS (1-1842, T4), 
5'-CATTCGGTACCTCACCCGGTAGCGGTCGCCGCACTCACCAGCCG 3' 
Reverse primer for C-terminus truncation 5 of MAS (1-1780, T5), 
5'-CATTCGGTACCTCAGGGCTGGGAACGTGCGGTCAGCACGATCCG 3' 
 In the MAS protein expressed in the Mtb cells, its ACP domain is 
posttranslationally modified with the covalent attachment of a 4'-phosphopantetheine (4'-
PPT) group that functions to tether the fatty acyl substrate during the processing cycles. 
The MAS protein over-expressed in E. coli does not get this modification because of the 
non-specificity of the E. coli phosphopantetheinyl transferase (PPTase) for MAS. So in 
order to get the post-translational modification on MAS expressed in E. coli, a PPTase 
from Mtb (PptT, Rv2794c) (Chalut et al., 2006) was PCR amplified from the Mtb 
genomic DNA (forward primer, 5'-
GGAATTCCATATGATGACGGTAGGCACGCTGGTGGCGTC 3'; reverse primer, 5'-
CCGCTCGAGTCATAGCACGTACGCGGTCAGCACCAGTC 3') and cloned into the 
second multiple cloning site (MCS2) of the pCDFDuet-1 vector (Novagen, for plasmid 
compatibility and antibiotic selectivity) using NdeI and XhoI restriction enzymes, 
generating a tag-less expression construct. The integrity of all the cloned genes was 




For the protein production, the expression plasmid for the full length MAS 
protein (pET28_30b-MAS) was co-transformed with the pCDFDuet-1-Rv2794c 
plasmids into E. coli expression strain Rosetta 2(DE3)pLysS (Novagen) to compensate 
for rare codons in mas gene. The ACP domain truncations were also transformed 
(without Rv2974c) in E. coli Rosetta 2(DE3)pLysS cells for the protein expression. The 
transformed cells were cultured in the LB-Miller media containing 50 μg/ml kanamycin, 
34 μg/ml chloramphenicol and 50 μg/ml streptomycin for the full length MAS, and with 
50 μg/ml kanamycin, 34 μg/ml chloramphenicol for the truncations, until OD600 reached 
0.6. The culture was then induced with 0.5 mM IPTG and grown at 18 
o
C for 14-16 hrs. 
Cells were harvested by centrifugation at 4,000g and the cell pellet was re-suspended in 
the lysis buffer (50 mM HEPES, pH7.5, 200 mM NaCl, 40 μg/ml DNAse, 2 mM MgCl2 
and EDTA-free protease inhibitor cocktail (Calbiochem)). The cells were lysed using a 
French press at 11,000 psi and the lysate was centrifuged with Sorvall ss-34 rotor at 
15,000 rpm for 60 min to remove cell debris. The supernatant was filtered and loaded 
onto a HisTrap FF Ni column (GE Healthcare) that was pre-equilibrated with Buffer A 
(20 mM HEPES, pH7.5, 250 mM NaCl, 10% (v/v) glycerol, 2 mM β-mercaptoethanol). 
The protein was eluted with 40% Buffer B (20 mM HEPES, pH7.5, 250 mM NaCl, 500 
mM imidazole, 10% (v/v) glycerol, 2 mM β-mercaptoethanol) using a step gradient 
purification protocol. Fractions containing the protein were pooled, concentrated and 
loaded on a Superdex 200 gel-filtration column (GE healthcare) pre-equilibrated with 20 
mM HEPES (pH7.5) buffer containing 100 mM NaCl, 10% (v/v) glycerol and 10 mM 




Coomassie Blue stained SDS-PAGE gel. The fractions containing pure protein were pooled 
and concentrated using a 100K molecular weight cutoff Amicon concentrator (Millipore) 
to ~35-40 mg/mL, and used immediately for crystallization trials or stored at 193 K for 
later use.  
For the production of selenomethionine (Se-Met) incorporated full length MAS 
protein, the metabolic inhibition method was used (Doublie, 2007). The protocol for the 
purification of Se-Met-incorporated MAS was same as that used for the native full length 
MAS, however, the final concentration of DTT in the gel filtration and the storage buffers 
was 20 mM.     
 
Determination of 4'-PPT modification in recombinantly expressed MAS 
 The extent of 4'-ppt modification of the full length MAS protein expressed in E. 
coli was assessed by an in vitro 4'-ppt transferase assay using B.  subtilis PPTase Sfp and 
fluorescent BODIPY-labeled CoA (La Clair et al., 2004). In this assay, 50-100 µM of 
purified MAS expressed without a PPTase, as well as MAS co-expressed with either 
Mtb AcpS or PptT in E. coli, was incubated with 2 µM Sfp for 1 h at room temperature 
in the dark in a reaction mixture containing 20 mM HEPES pH 7.5 buffer with 20-40 µl 
BODIPY-S-CoA (120-240 µM final concentration) and 10 mM MgCl2. As a negative 
control, an ACP-domain truncated MAS protein without a 4'-ppt attachment site was 
also included in the assay. After incubation, cold 20% TCA was added to the mixture to 
stop the reaction. The samples were incubated for 15 min on ice and then spun at 




pellets were dried under vacuum, dissolved in a small amount of buffer and analyzed by 
SDS–PAGE. The resulting bands on the gel were analyzed for BODIPY-CoA labeling of 
the protein under a UV transilluminator.  
 
Determination of oligomeric state of MAS 
 The full length purified MAS (30 µL of 10 mg/mL) was injected on a 
Superose
TM
 6 10/300 GL (GE Healthcare) gel filtration column which was pre-
equilibrated with 20 mM HEPES (pH7.5) buffer containing 100 mM NaCl, 10% (v/v) 
glycerol and 10 mM DTT. The protein was eluted at the rate of 0.2 mL/min at 4 °C in 2 
mL fractions. Gel filtration standards from BioRad (bovine thyroglobulin (670 kDa), 
bovine γ-globulin (158 kDa), chicken ovalbumin (44 kDa), horse myoglobin (17 kDa) 
and vitamin B12 (1.35 kDa)) were run on the column using the same buffer system to 
obtain the calibration curve. 
 
Crystallization of Mtb MAS 
 Initial crystallization trials for the purified MAS were carried out at 18 °C by 
sitting drop vapor diffusion method using a nanoliter robotic screening setup. The 
screening was done using commercial sparse-matrix and grid crystallization screens, as 
well as custom made factorial and random screens, giving >1,200 conditions per sample. 
The crystallization trials were setup with a 1:1 ratio of MAS protein (10 mg/ml) and 
crystallization condition in 96 well Intelli-Plates ( Hampton Research) using a Mosquito 




setting up trials at two different temperatures (4 °C and 18 °C) using varying 
concentrations of MAS (12-35 mg/ml) in different drop ratios with the screening 
conditions, and by addition of substrates methylmalonyl CoA, NADPH and fatty acyl-
CoAs (C12-C20) to the crystallization drops.  In addition, the crystallization trials were 
also performed under oil (paraffin and silicon oils, Hampton Research) using the 
microbatch method. The two truncations of MAS (T1 and T2) that expressed as soluble 
proteins were also screened for crystallization in the same way as was done for the full 
length protein.   
  
In situ proteolysis for MAS crystallization 
 To facilitate crystallization of MAS, in situ proteolysis was performed by either 
pre-incubating the protein with trace amounts of a protease (trypsin or chymotrypsin or 
thrombin) (Sigma) before setting crystallization trials, or by direct addition of the 
protease to the trial drops.  The protease was added in three different ratios to the protein 
(1:2,000, 1:10,000 and 1: 100,000, w/w) and the crystallization trials were setup at 4 °C 
and 18 °C. The protease working stocks were prepared at 1-2 mg/mL according to the 
manufacturer’s instructions, and added immediately prior to setting up of crystallization 
trials. 
 
 Crystallization of MAS using heterogeneous nucleating agents 
 Seaweed and hydroxyapatite were selected for assessment as heterogeneous 




were ground to a fine powder using a pestle and mortar, and dried at 50 °C for 2-4 h to 
remove any moisture. For crystallization screening, each nucleating agent (seaweed, 
hydroxyapatite and a 1:1 (w/w) mixture of the two) was added separately to the protein 
(at 0.5 µg nucleating agent per µl of the protein) and the drops were set up at 4 °C and 
18 °C in 96 well Intelli-plates. 
 
 Optimization of MAS crystals by counter-diffusion and seeding techniques 
 For counter-diffusion technique, Granada crystallization box (GCB) (Hampton 
Research) was used to grow single crystals of MAS inside capillaries (Garcia-Ruiz et al., 
2002). In the GCB, a reservoir was filled with melted 1.5% (w/v) agarose in 0.1 M 
HEPES, pH 7.5 buffer and allowed to cool to room temperature. A glass capillary (0.5 
mm internal diameter, 100 mm length (Hampton research)) was filled with MAS 
solution (20-30 mg/mL) to a height of 5-6 cm and inserted into the agarose layer to a 
depth of 2-3 mm. The top open end of the capillary was sealed with superglue and 
crystallization buffer (0.1 M HEPES Na, pH 7.5, 10-8% (v/v) 2-propanol, 20-16% (w/v) 
PEG 4,000) was layered over the agarose (volume equal to the agarose volume). The 
GCB was then covered and placed at 18 °C.  
 Seeding technique was used to obtain single, large crystals of MAS 
(microseeding) and to screen for new crystallization conditions for MAS (microseed 
matrix screening) (Bergfors, 2003; D'Arcy et al., 2007). Seed stock was prepared by 
transferring MAS crystals to a Seed Bead tube (Hampton research) containing 50 µl of 




seed solution was maintained at 4 °C by cooling the tube on ice between the vortexing 
cycles. Microseeding was carried out by streaking of the seeds through the 
crystallization drops by a cat whisker. The crystallization drops contained 1 µl of MAS 
solution (15-20 mg/mL) and 1 µl of crystallization buffer (0.1 M HEPES Na, pH 7.5, 8% 
(v/v) 2-propanol, 15-20% (w/v) PEG 3,350 and 5% (v/v) glycerol) and were equilibrated 
against 50-100 µl crystallization buffer in the reservoir in a sitting drop vapor diffusion 
set up. The plates were incubated at 4 °C and 18 °C, and large single crystals of MAS 
were obtained in 7-10 days. Microseed matrix screening was done at 18 °C in a 96 well 
format using the Mosquito nanoliter robot to set up 1 µl crystallization drops containing 
0.5 µl of MAS solution (20-25 mg/mL) mixed with 0.4 µl of the screening condition and 
0.1 µl of the seed stock. 
   
Growing MAS crystals in gel 
 To obtain single, well-developed crystals with perfect habit, MAS was 
crystallized in a matrix of low melting agarose (LMA, Hampton Research) (Lorber et al., 
2009). To prepare the crystallization drops, equal volumes of the protein solution (20-25 
mg/mL) and the crystallization condition (0.1 M HEPES Na, pH 7.5, 8-10% (v/v) 2-
propanol, 15% (w/v) PEG 3,350 and 5% (v/v) glycerol) were mixed, and an appropriate 
volume of a 2% (w/v) stock of LMA was added to give a final concentration of 0.1-0.4% 






Post-crystallization treatment of MAS crystals 
 To improve diffraction quality of MAS crystals, the solvent content of the 
crystals was reduced in a controlled manner by implementing different step-wise 
dehydration strategies (Heras and Martin, 2005) (Fig. 2-1). After screening a large 
number of crystals, a dehydration protocol was designed wherein single well-formed 
crystals of MAS were transferred to 4 °C and slowly dehydrated by small step-wise 
increments in the concentrations of the precipitant PEG 3,350 and the cryoprotectant 
glycerol in the drop.  Three solutions with different concentrations of PEG 3,350 and 
glycerol were mixed in different ratios to give final concentrations of PEG 3,350 and 
glycerol from 12-25% and 19-30%, respectively (Table 2-1). At each step, the reservoir 
buffer was replaced with 50-100 µl of the dehydrating solution and the drop was allowed 
to equilibrate for 12-24 h between the steps. After the final step, the drop was left to 
equilibrate for an extra day against the stabilization buffer (0.1 M HEPES Na, pH 7.5, 
10% (v/v) 2-propanol, 30% (w/v) PEG 3,350 and 25% (v/v) glycerol) in the reservoir.       
 In addition to the gradual step-wise dehydration method, a modified open air 
dehydration protocol was also tested for improvements in the diffraction of MAS 
crystals (Fig 2-1). In this extreme dehydration protocol, MAS crystals were first 
transferred to a stabilizing solution (0.1 M HEPES Na, pH 7.5, 8-10% (v/v) 2-propanol, 
20% (w/v) PEG 3,350 and 15% (v/v) glycerol) and equilibrated over night against 100 µl 
of this solution at 18 °C. After incubation, the sealing tape was removed and the 
stabilized crystals were air dehydrated until only a thin film of the stabilizing solution 




Table 2-1. Crystal dehydration protocol. The solutions used are: solution A (0.1 M 
HEPES Na, pH 7.5, 10% (v/v) 2-propanol, 15% (w/v) PEG 3,350 and 10% (v/v) 
glycerol); solution B (same as A, but with 25% (w/v) PEG 3,350 and 15% (v/v) 
glycerol); and solution C (as A, but with 30% (w/v) PEG 3,350 and 25% (v/v) glycerol). 



















1 60 : 40 : 0 12 2 19 12 
2 20 : 80 : 0 12 4 23 14 
3 0 : 80 : 20 24 8 26 17 
4 0 : 50 : 50 24 10 27.5 20 
5 0 : 30 : 70 12 10 28.5 22 
6 0 : 10 : 90 12 10 29.5 24 
7 0 : 0 : 100 12 10 30 25 








Figure 2-1. Crystal dehydration methods. In these methods the crystal is either 
transferred to the dehydrating solution, or the dehydrating agent is added to the 
crystallization drop. The dehydrating solutions are made by adding increasing 
concentrations of the precipitant to the mother liquor, or by supplementing with 
increasing concentrations of the cryoprotectant. The concentration of the dehydrating 
solution is increased in small steps of 0.5-5% up to a final concentration of 5-30% (w/v) 
in the drop, and the soaking time ranges from few minutes to days. The methods outlined 
here are easily adapted to the sitting drop vapor diffusion experiments. Figure 
reproduced from Heras, B. and Martin, J. L., Acta Cryst. (2005). D61, 1173-1180, with 
permission of © [2005] IUCr. http://dx.doi.org/10.1107/S0907444905019451    
 
 
Crystallographic screening and data collection 
The crystals were mounted using cryo-loops (Hampton Research) and flash-
frozen by plunging in liquid nitrogen for screening and data collection. Prior to freezing, 
MAS crystals obtained after initial optimizations were briefly incubated (0.5-5 min) in a 
drop of mother liquor containing 15-20% glycerol as a cryoprotectant. For the crystals 




cryoprotection, so they were directly frozen from the drops. The crystals were screened 
for diffraction at cryogenic temperatures on beamlines 19-ID, 23ID-B and 23ID-D of the 
Advanced Photon Source (APS), Argonne National Laboratory (Argonne, IL). For all 
the screened crystals, the diffraction data was analyzed by the HKL2000 suite 
(Otwinowski and Minor, 1997). After screening hundreds of crystals, diffraction data 
was collected for a crystal that diffracted to better than 10 Å on the beamline 19-ID at 
the Advanced Photon Source, Argonne National Laboratory. A complete dataset was 
collected at 100 K using an ADSC Q315 CCD detector at a wavelength of 0.97929 Å 
and a detector distance of 800 mm. For data collection, the crystal was exposed 12 sec 
per image at 0.3° oscillation per frame and a total of 320 images were recorded. The 
diffraction images were indexed, integrated and scaled using HKL2000. The scaled 
dataset was analyzed by XPREP and Xtriage to determine the space group of the crystal 
(Sheldrick, 2008a). Solvent-content calculations (Matthews, 1968) to determine the 
number of molecules in the asymmetric unit were done in the CCP4 suit.  
 
RESULTS AND DISCUSSION 
 
Cloning and purification of Mtb MAS 
 An important prerequisite for the protein crystallization studies is the availability 
of sufficient amounts of pure and homogenous form of the protein under study. This is 
frequently achieved by overexpression of the protein of interest in a suitable 




approach was adopted for the production and purification of Mtb MAS protein from E. 
coli, a commonly used host for the recombinant expression of bacterial proteins.  
However, due to the inherent difficulties in the cloning and heterologous overexpression 
of large macromolecular complexes, standard cloning protocols were modified for 
successful cloning of the mas gene from Mtb H37Rv genomic DNA. Screening of 
different commercially available PCR reaction mixtures and DNA polymerases led to 
the identification of a combination of failsafe mix D and the high fidelity Phusion DNA 
polymerase that amplified the full length mas gene (6336 bp) successfully without 
amplifying non-specific fragments from the Mtb genome (Fig. 2-2a). It was also 
observed that keeping the number of extension cycles in the PCR to below 20 prevented 
mutations in the amplicons. For cloning the PCR product, a chimeric vector pET28_30b 
was created by incorporating the MCS of pET30b into the MCS of pET28b vector to 
create the restriction sites for NheI and KpnI, restriction enzymes that were found not to 
cut the mas gene.  The restriction digestion of the PCR product followed by its ligation 
into the empty vector produced the pET28_30b-MAS expression construct that 
incorporated an N-terminal His6-tag for aiding the purification of the recombinantly 
expressed MAS protein by Ni
2+
 affinity chromatography.  
 The MAS protein expressed in the Mtb cells undergoes a posttranslational 
modification (PTM) that covalently attaches a 4′-phosphopantetheine prosthetic group 
derived from CoA, to a conserved Ser residue on its carrier domain (ACP). In Mtb, this 
PTM is performed by the phosphopantetheinyl transferase (PPTase) PptT (Rv2974c) 




efficient due to the non-specificity of the E. coli PPTase towards the ACP domain of the 
MAS protein. As a result, a mixed population of apo- and holo-MAS is produced in the 
E. coli cells. The homogeneity of the protein sample is a critical parameter that can 
influence crystallization and diffraction properties of the crystals (McPherson, 2004). 
Therefore, to improve the homogeneity of MAS, Mtb PptT was cloned in a pCDFDuet-1 
vector and co-expressed with MAS in the E. coli cells. The vector pCDFDuet-1 was 
chosen as it provided plasmid compatibility and antibiotic selectivity with the 
pET28_30b-MAS expression plasmid, and allowed construction of a tag-less PptT 
expression system to facilitate its easy separation from MAS on a Ni
2+
 affinity 
purification system. The integrity of the cloned constructs was verified by double-
digestions (not shown) and DNA sequencing. 
 
 




Figure 2-2. PCR amplification of MAS. DNA electrophoresis on 0.8% agarose gel 
shows PCR amplified fragments of MAS from the H37Rv genomic DNA. (a) Full length 
(6336 bp) MAS product shown in lanes 1 and 2. (b) Amplified C-terminal ACP domain 
truncations of MAS, T1-T5 shown in lanes 1-5, respectively.  For reference, DNA 




  The cloned constructs pET28_30b-MAS and pCDFDuet-1-Rv2794c were co-
transformed into different expression strains of E. coli and tested for the overexpression 
of soluble MAS protein. After screening, the E. coli host strain Rosetta 2(DE3)pLysS 
was selected for large scale production of MAS since it not only enhances the expression 
of rare codon containing proteins, but also prevents leaky expression of the recombinant 
proteins through the suppression of basal T7 RNA polymerase production by T7 
lysozyme (Studier, 1991). It was observed that optimum MAS expression was obtained 
by induction with 0.5 mM IPTG followed by overnight growth of the cells at 18 °C. The 
overexpressed His6-tagged MAS protein was initially purified by Ni
2+
 affinity 
chromatography by a step-gradient protocol that was designed to significantly reduce the 
amount of co-eluted impurities (Figs. 2-3a and 2-3b). 
 After further purification using the protocols described in the methods section, 
the MAS protein was successfully purified to homogeneity and >95% purity as judged 
by the SDS-PAGE (Fig. 2-4b). The purified recombinant MAS protein showed a band at 
















Figure 2-3. Purification of MAS by Ni
2+
 affinity chromatography. (a) The elution 
profile of MAS obtained from the step-gradient purification protocol. The blue trace 
represents the absorbance at 280 nm and shows absorbance peak (black arrow) under 
which MAS elutes from the column. (b) A 4-20% gradient gel showing protein content 
of the fractions eluted using different concentrations of buffer B in (a) and visualized by 
coomassie staining. Most impurities eluted in 10% and 15% B wash (lanes 2-4) and 
purified MAS eluted with 40% B (lanes 5-15). For reference, Perfect protein markers 












Figure 2-4. Gel filtration of MAS. (a) MAS eluted as a single peak from Suprose 6 gel 
filtration column. Inset shows the calibration curve determined using BioRad gel filtration 
molecular weight standards (filled circles). MAS is shown on the curve (open circle) 
corresponding to a MW of ~446 kDa, consistent with MW of a dimer. (b) Fractions of MAS 
obtained after gel filtration analyzed on 4-20% gradient SDS-PAGE gel and visualized by 
coomassie staining. MAS ran as a single band at ~225 kDa on the gel. For reference, Perfect 





 It has been observed that the large multi-domain proteins have higher structural 
and conformational heterogeneity compared to the single domain proteins (Leibundgut 
et al., 2008). Such heterogeneity can either significantly lower the likelihood of 
crystallization, or it can lead to poorly formed crystals with internal disorder and lattice 
imperfections (Mueller et al., 2007). This suggested that a reduction in the flexibility of 
multi-domain MAS protein could facilitate its crystallization. The ACP domains of FAS 
I and PKS systems have inherent flexibility due to their functional requirement to deliver 
the tethered substrate to different active sites at different locations on these proteins. 
This is exemplified by the lack of electron density for the ACP domain in the high 
resolution mammalian FAS I structure that was attributed to its flexible nature (Maier et 
al., 2008). Therefore, to increase the likelihood of obtaining crystals of MAS, five 
different ACP domain truncations were designed, cloned and tested for expression.  
These truncations were designed based on the secondary structure and domain 
predictions. All five truncation were successfully PCR amplified from Mtb H37Rv 
genomic DNA using the same reaction mix that was used for amplifying the full length 
mas gene (Fig. 2-2b). These amplified PCR fragments were subsequently cloned into the 
pET28_30b vector as was done for the full length MAS, and tested for protein 
expression in E. coli Rosetta 2(DE3)pLysS cells. Analysis of the expression test by SDS-
PAGE revealed that only two truncations of MAS, T1 and T2 expressed as soluble 
proteins (Fig. 2-5). These two truncations were subsequently expressed on a larger scale 
and purified to homogeneity using the same purification protocols that were used to 






Figure 2-5. Expression analysis of the ACP domain truncation constructs of MAS. E. 
coli Rosetta 2(DE3)pLysS cells transformed with five different truncation constructs T1-
T5 were tested for soluble protein expression. Empty vector controls (lanes 1-5) were 
cultured the same way as the cells that were transformed with the expression constructs. 
Aliquots of the induced cultures containing equal number of cells (corresponding to 
OD600 = 0.3) were lysed and centrifuged at 13,000g to remove insoluble material from 
the soluble fraction in the supernatant. After transferring supernatant to another tube, the 
pellet from the lysate was re-suspended in a small volume of buffer (20 mM Tris-HCl, 
pH 7.5, 100 mM NaCl).  Equal amounts of proteins from the supernatants (lanes 7, 9, 11, 
13, 15 for T5, T4, T3, T2 and T1 respectively) and the re-suspended pellets (lanes 6, 8, 10, 
12, 14 for T5, T4, T3, T2 and T1 respectively) were loaded on a 4-20% gradient SDS-
PAGE gel after protein concentrations were determined using the Bradford assay kit 
(BioRad). Protein bands on the gel were visualized by staining with coomassie blue. It is 
seen in the figure that only MAS truncations T1 (lane 15) and T2 (lane 13) expressed as 
soluble proteins. For reference, purified full length MAS (F) and Perfect protein markers 
were run on the gel (M). The molecular weights of the standards are listed alongside the 
gel in kDa.     
 
 
Oligomeric state of Mtb MAS  
 The MAS protein that was recombinantly expressed and purified from E. coli 
was analyzed by analytical size-exclusion chromatography on a Superose 6 column to 
determine its oligomeric state. To calibrate the size-exclusion column, molecular weight 




MAS. The elution volumes of the standards were plotted and a calibration curve was 
obtained by linear regression (Fig. 2-4a). The elution profile of MAS contained a single 
peak and based on the elution volume, the molecular weight of MAS in solution was 
calculated to be ~446 kDa (Fig. 2-4a).  This result indicated the oligomeric state of MAS 
in solution to be a dimer. This finding was in agreement with earlier studies which 
reported that the MAS purified from Mtb strain BCG was a dimer in solution (Rainwater 
and Kolattukudy, 1985). Thus, the recombinantly expressed MAS protein purified from 
E coli was determined to have the same oligomeric state as the natively expressed MAS.  
 
Enhancement of 4'-PPT modification in recombinantly expressed MAS 
 The carrier domains of FAS, PKS and NRPS systems are converted to their holo-
forms via covalent attachment of a 4'-PPT modification by their cognate PPTase in the 
host organism (Lambalot et al., 1996). Thus, non-specificity of the PPTase of the 
expression host towards the carrier domain of a heterologously expressed PKS would 
lead to production of an inactive or partially active protein. This would lead to a 
stoichiometric heterogeneity in the protein sample that can significantly reduce the 
likelihood of crystallization. A convenient strategy for overcoming this limitation in 
expression host is to co-express the PKS with its cognate PPTase. The Mtb genome 
encodes two PPTases, AcpS and PptT, however, since the information regarding their 
ability to transfer 4'-PPT to the ACP domain of MAS was not known, a preliminary co-
expression study was conducted to evaluate their PPTase activity towards MAS. Both 




transformed with MAS in E. coli Rosetta 2(DE3)pLysS cells. The MAS protein from 
both sets of co-expressions was purified separately as detailed in the methods section. 
The efficiency of 4'-PPT transfer to the ACP domain was then determined for both of the 
PPTases using an in vitro fluorescence labeling assay. This assay utilized the ability of 
the promiscuous PPTase Sfp from B. subtilis to transfer a fluorescently labeled 4'-PPT 
from BODIPY-CoA to the ACP domain of the MAS protein in vitro. After the assay, 
samples were run on a SDS-PAGE gel and the extent of fluorescent labeling of the ACP 
domain of MAS was determined by visualization under UV-light. Analysis of the 
fluorescent bands showed that the MAS protein co-expressed with PPTase PptT had the 
lowest fluorescence labeling of the protein (Fig. 2-6). This indicated an efficient in vivo 
4'-PPT transferase activity of PptT toward MAS ACP domain, and suggested it to be the 
cognate holo-ACP synthase for the Mtb MAS protein. This finding was later confirmed 
in a published report that identified PptT as the cognate PPTase for all the PKS systems 
in Mtb (Chalut et al., 2006). Therefore, PptT was selected for co-expression with MAS 





Figure 2-6. Analysis of 4'-PPT modification in recombinantly expressed MAS. The MAS 
protein co-expressed with Mtb PPTase AcpS (lane 2) or PptT (lane 3) was incubated in vitro 
with B. subtilis Sfp and BODIPY-CoA to assess their 4'-PPT transferase activity towards MAS 
ACP domain. Equal amount of protein was loaded in each lane, and the controls included MAS 
expressed in E. coli without Mtb PPTase (lane 1) and a C-terminal ACP domain truncation of 




Crystallization of Mtb MAS 
 Large macromolecular complexes generally crystallize under a narrow range of 
parameters and only from a specific combination of precipitants and chemical additives 
in the crystallization cocktail (Maier et al., 2010).   Since each protein represents a 
unique chemical entity, it is not possible to predict conditions under which a protein of 
unknown structure will crystallize. Therefore, large scale screening trails are performed 
to identify initial crystallization conditions. A similar high throughput screening 
approach was used to identify conditions favorable for growing MAS crystals. In this 
approach, a number of crystallization trials of MAS were set up using commercial, as 
well as custom made crystallization screens in a 96-well format by a nanoliter screening 
robot. Commercial screens contain precipitants at concentrations that can be too high for 
large macromolecules. So, MAS was also screened with conditions diluted in different 
ratios. In addition, the substrates of MAS were also added during crystallization trails in 
order to facilitate crystal formation. Thus, the combination of different crystallization 
parameters resulted in >2,000 unique crystallization experiments per sample of MAS 
protein. However, despite extensive screening, initial attempts to obtain the MAS 
crystals were unsuccessful.  
 In large multifunctional proteins confirmation heterogeneity can occur due the 
domain movements, which can significantly lower the likelihood of crystal formation. In 
PKS and FAS I systems, the ACP domain displays inherent flexibility due to its 
functional requirement to deliver covalently tethered reaction intermediates for 




nature of the ACP domain was exemplified by the missing electron density for the ACP 
domain in both the fungal and the mammalian FAS I crystal structures (Jenni et al., 
2007; Maier et al., 2008). Therefore, to facilitate MAS crystallization, two ACP domain 
truncations of MAS were made and screened for crystallization as was done for the full 
length MAS. Furthermore, in situ proteolysis was also performed in the crystallization 
trails of MAS to further increase chances of obtaining crystals. Limited proteolysis was 
successfully used to separate more flexible TE domain from the core domains of animal 
FAS I (Mattick et al., 1983). Also, many studies have reported application of in situ 
proteolysis for obtaining crystals of proteins that had failed to yield crystals by 
conventional screening (Dong et al., 2007). Analysis of these proteolysis experiments 
indicated that the protease had modified the proteins by cleaving off flexible linkers, N- 
or C- termini, or surface residues from the original protein resulting in the formation of 
more stable domains or fragments that were more likely to crystallize (Gao et al., 2005). 
The full length MAS was tested in the in situ proteolysis screening trials using trypsin 
and chymotrypsin proteases since these were the most commonly used and successful 
proteases in such studies.  
Extensive screening of the MAS truncations and the full length MAS under these 
conditions also failed to yield any crystals. Investigation of the proteolytic cleavage 
products of MAS resulting from the treatment with trypsin and chymotrypsin by SDS-
PAGE revealed a number of fragments with no significant production of any major 
bands (Fig. 2-7). This indicated that the cleavage sites on MAS were easily accessible to 




suggested that the MAS protein was not suitable for crystallization screening by the 






Figure 2-7. Analysis of MAS proteolysis by chymotrypsin. MAS was incubated with 
different ratios (w/w) of chymotrypsin at three temperatures for 5-30 min. After the 
incubation period, reaction was stopped by addition of the gel loading dye and heating 
the samples at 95 °C for 5 min. Samples were run on a 4-20% SDS-PAGE gel and the 
cleavage products were visualized by staining with coomassie blue. MAS cleavage with 
trypsin was analyzed in the same manner (not shown). For reference, purified full length 
MAS (lane 1) and Perfect protein markers were run on the gel (M). The molecular 








 For successful crystal formation, an essential step is the formation of a stable 
crystal nucleus under the supersaturating conditions in the crystallization drop 
(McPherson, 2004). Crystal nucleation is an energy driven event that can be adversely 
affected by various parameters in the crystallization experiment. One of the ways to 
increase the likelihood of finding conditions suitable for stable nucleus formation is to 
systematically introduce heterogeneous nucleating agents in the crystallization trials. 
The heterogeneous nucleants provide a wide range of pores, cavities and other surface 
structural features that can confine protein molecules thereby raising their local 
concentration leading to increased instances of nuclei formation (Chayen et al., 2006; 
Thakur et al., 2007). Thus, they can help initiate crystal formation even in solutions 
which do not contain supersaturating concentrations of the protein of interest. Therefore, 
a similar crystallization screen was performed for MAS by addition of a 1:1 (w/w) 
mixture of seaweed and hydroxyapatite as heterogeneous nucleating agents to the 
screening drops. This screen led to the successful identification of a single condition 
employing PEG 4,000 and 2-propanol as precipitants, in which small clusters of MAS 
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Figure 2-8. Initial crystallization hit of MAS. (a) First crystals of MAS obtained by 
screening with a 1:1 (w/w) mixture of seaweed and hydroxyapatite in the crystallization 
drop. MAS crystals grew as small clusters in a single condition consisting of 20% (w/v) 
Polyethylene glycol 4,000 and 10% (v/v) 2-Propanol in 100 mM HEPES sodium (pH 
7.5) buffer. (b) Initial optimization of the hit condition gave larger crystals, but still 





Since the crystals in the initial hit were too small for mounting on the x-ray 
diffractometer, systematic grid screens were set up for optimization of the initial hit 
condition. Larger sized crystals were obtained from the optimization trials; however, 
their formation still required addition of the mixture of seaweed and hydroxyapatite (Fig. 
2-8b). Subsequent optimization screens using alternate precipitants and additives 
identified 15-20 % (w/v) PEG 3,350 as a suitable precipitant and 5-10% (v/v) glycrol as 
an additive that led to growth of well formed, large single crystals of MAS. The 
optimized MAS crystals were either bipyramidal or rectangular rod like in morphology 
with dimensions of 0.1-0.3 x 0.4-0.5 x 0.6-0.9 mm
3
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Figure 2-9. Optimization of MAS crystals. Refinement of crystallization conditions 
coupled with microseeding yielded well formed single crystals of MAS with (a) 
bipyramidal, or (b) rectangular rod like morphology. Crystals were obtained using 15-20 
% (w/v) PEG 3,350 and 8-10% (v/v) 2-propanol as precipitants, with 5-10% (v/v) glycrol 









  Initial diffraction images from the screening of the two crystal forms of MAS on 
the home source Bruker Daltonics diffractometer (Bruker Inc) showed diffraction spots 
in low resolution region (40 – 34 Å) indicating that these were indeed protein crystals 
(Figs. 2-10a and 2-10b). The bipyramidal form crystals gave much lower resolution 
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Figure 2-10. Initial diffraction from MAS crystals. Representative diffraction patterns 
from the initial screening of two different (a) bipyramidal, and (b) rectangular rod 
shaped, crystal forms of MAS, obtained using in-house Bruker X-ray diffractometer. 
The images were recorded on a CCD detector placed at a distance of 150 mm from the 
crystal that was exposed for 10 min at 1° oscillation per frame. The data was analyzed by 
proteum-II software and the resolution limits are indicated by black circles at ~40 Å for 







 In general, crystals of large macromolecules exhibit large asymmetric unit and 
unit cell dimensions. Thus, they diffract weakly and the diffraction spots are closely 
spaced on the detector as a consequence of long unit cell axes (Mueller et al., 2007). Due 
to the limitations of the lower x-ray intensities and the small detector area of in-house 
diffractometers, synchrotron radiation is the method of choice for screening and data 
collection from crystals of large macromolecular complexes. The synchrotron beamlines 
offer very high intensity x-rays that can compensate for weak diffraction from the 




detector distance to be adjusted to reduce the problem of overlapping spots (Mueller et 
al., 2007). Therefore, MAS crystals were also screened for diffraction on the beamlines 
23-ID B/D and 19-ID at the Advanced Photon Source (APS), Argonne National 
Laboratory. Indeed, high intensity beams resulted in more diffraction spots with the 
resolution extending up to ~27 Å for the same rectangular rod shaped MAS crystals that 
were screened at the home source, and the larger crystal to detector distances of 400 – 
800 mm also resulted in better spot separation (Fig. 2-11a).   
Due to the better diffraction and crystal handling properties of the rectangular rod 
shaped crystals of MAS, they were selected for further optimization by post-
crystallization treatments to improve their diffraction qualities. Crystal dehydration is a 
particularly suited technique for controlled removal of solvent from the crystals of large 
macromolecules. Solvent reduction in crystal by dehydration decreases unit cell volume 
that can alter the crystal contacts resulting in a better packing and ordering of the 
macromolecule leading to better diffracting crystals (Heras and Martin, 2005). 
Successful application of dehydration for improving the diffraction properties of the 
crystals of fungal FAS (improved from 8 Å to < 4 Å) (Jenni et al., 2007); yeast RNA 
polymerase II (from 6 Å to <2.6 Å) (Cramer et al., 2000) and DsbG (10 Å to 2 Å) (Heras 
et al., 2003), suggested that this method could be used for improvements in the 
diffraction properties of MAS crystals. Initial dehydration of MAS crystals was done at 
18 °C by sequential transfer of the crystals to solutions of increasing concentrations of 
PEG 3,350 (up to 30% in 5% increments) in the mother liquor with a 15-30 min 




showed slight improvements in the diffraction properties of the crystals with the 
resolution extending up to 20 Å (Fig. 2-11b). Subsequent screening with more crystals 
did not show further improvement in the diffraction. Therefore, two different 
dehydration protocols were designed and employed as detailed in the methods section. In 
the slow step-wise dehydration method, the crystals were transferred to 4 °C and 
dehydrated sequentially in the solutions containing small increments in concentrations of 
PEG 3,350 (up to 30%) and glycerol (up to 25%) over many days. In the second method, 
the crystals were transferred to a stabilizing solution and then equilibrated against air 
until only a thin film of the stabilizing solution remained around the crystals (Fig. 2-
12a). The crystals dehydrated using the gradual step-wise protocol showed marked 
improvement in their diffraction qualities and they diffracted up to ~9-10 Å at the APS 
(Fig. 2-11c), whereas the air dehydration method resulted in the complete loss of 
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Figure 2-11. Improvement in the diffraction properties of MAS crystals. Diffraction 
pattern of the rectangular rod shaped MAS crystals collected on the beamlines 23-ID 
B/D and 19-ID  at APS at wavelength of 1 – 0.979 Å and a detector distance of 600 – 
800 mm. (a) Diffraction at APS from the crystal that was also screened at home source 
(see Fig. 2-11(b)). (b) Diffraction pattern extending up to ~20 Å from the initial 
dehydration of MAS crystals at 18 °C. (c) Improved diffraction from the slowly 
dehydrated crystals at 4 °C extending up to ~9 Å. (d) Diffraction from a dehydrated 
crystal grown in agarose gel also extending up to ~9 Å. The resolution rings are shown 
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Figure 2-12. Post-crystallization treatment of MAS crystals. (a) Air dehydrated crystals 
of MAS. (b) Dehydration of MAS crystal grown in low melting agarose gel. The 
diffraction properties of this crystal were similar to the dehydrated crystals grown by 
sitting drop vapor diffusion method (see Fig. 2-12(d)). So crystals from the sitting drops 
were used for data collection due to ease of handling.  
 
 
A complete diffraction dataset was collected from a slowly dehydrated crystal 
that diffracted to 9 Å on the beamline 19-ID at the APS using an ADSC Q315 CCD 
detector at a wavelength of 0.97929 Å and a detector distance of 800 mm. The 
diffraction images were indexed in the tetragonal Bravais lattice, integrated and scaled 
using HKL2000. Analysis of the integrated and scaled dataset by XPREP and Xtriage 
indicated that the crystal belonged to the tetragonal space group P43212 or P41212, with 
unit-cell parameters a = b = 232.5 Å, c = 387.5 Å, α = β = γ = 90°. Solvent-content 
calculations (Matthews, 1968) based on the molecular weight of MAS (MW ~225,000 
Da) predicted either four or five molecules of MAS in the asymmetric unit. The 




, corresponded to a solvent 








) corresponded to a solvent content of 44% with a probability P(tot) of 0.54.  
The crystallographic data-collection statistics are summarized in Table 2-2. 
To calculate electron density maps from the collected 9 Å dataset, an attempt was 
made  to obtain the initial phases by molecular replacement (MR) using crystal 
structures of the mammalian FAS I (PDB codes 2cf2, 2vz9) and the KS-AT didomain of 
module 5 from DEBS (PDB code 2hg4).  MR trials using the full length FAS I or the 
KS-AT didomain did not give a solution. So another MR search with an ensemble of 
separated domains was performed and it was also unsuccessful in finding a solution. It 
has been reported that phasing of large macromolecules by MR can be difficult, 
particularly in the absence of a full length homologous structure, even though the 
template structures for individual domains may be available. MR is challenging in such 
cases because the domains represent only a small fraction of the total scattering mass 
thereby making it difficult to correctly place the component in the asymmetric unit 
(Maier et al., 2010). Similarly, the method of single heavy atom derivatization of native 
crystals for phasing is generally not suitable for large proteins due to a large number of 
potential binding sites in the asymmetric unit, which can lead to noisy Patterson maps, 
and thus decrease the likelihood of obtaining a solution (Mueller et al., 2007). Therefore, 
to overcome these limitations, heavy atom clusters have been used for initial phasing at 
intermediate (~10-4.5 Å) resolutions (Johansson et al., 2008; Maier et al., 2010). These 
clusters bind to fewer sites on the proteins leading to limited heavy atom sites in the 




enabling easy interpretation of the Patterson maps for the identification of correct sites 
(Dauter, 2005).  
Among the heavy atom clusters used for solving the structures of large 
macromolecular complexes, tantalum cluster (Ta6Br12
2+
) has been the most widely used 
since it can be easily synthesized in many different ways. The Ta6Br12 cluster was 
successfully used for phasing structures of 50S and 30S ribosomal subunits (Ban et al., 
2000); RNA polymerase II (Cramer et al., 2000); and the structures of T. lanuginosus 
FAS I and yeast FAS I (Jenni et al., 2006; Johansson et al., 2008). Therefore, a 
commercial Ta6Br12 cluster kit was used for preparing the Ta6Br12-derivatized crystals of 
MAS. The heavy atom derivatization was performed either by transferring the MAS 
crystals to a stabilizing solution containing 1 mM Ta6Br12 cluster, or by adding few 
flakes of the dry powder directly to the crystal drop, and incubating for 1-2 days. After 
incubation crystals were inspected under microscope for successful derivatization as 
indicated by the green color of crystals, and screened for diffraction. However, the 
soaked crystals diffracted to only very low resolution, indicating that the crystal soaking 
had adversely affected crystal lattice and hence, no datasets could be collected.  Further 
screening with other polynuclear metal clusters (for example, tungsten or platinum 
clusters) and refinement of back-soaking protocols will be needed for the successful 







Table 2-2. Data-collection and processing statistics for MAS crystals. Values in 
parentheses are for the highest resolution shell. 
 
 Mtb MAS 
Beamline 19-ID 
Wavelength (Å) 0.97929 
No. of crystals 1 
Temperature (K) 100 
Crystal-to-detector distance (mm) 800 
Exposure time (s) 12 
No. of images 320 
Oscillation range (°) 0.3 
Space group P41212/P43212 
Unit-cell parameters (Å, °) a = b = 232.5, c = 387.5, α, β, γ = 90 
Solvent content (%) 55.2 (4 molecules/asu)/44 (5 molecules/asu) 
Resolution range (Å) 50–8.96 (9.16–8.96) 
No. of observations 13540 (291) 
No. of unique reflections 7900 (281) 
Completeness (%) 92.8 (58.2) 
Multiplicity 3.2 (1.4) 
Rmerge (%)  12.8 (69.0) 





SUMMARY AND FUTURE DIRECTIONS 
 
 In this chapter, the development of the protocols for cloning, purification 
and crystallization of the 225 kDa full length MAS protein, a type I PKS and an essential 
enzyme of PDIM biosynthesis in Mtb, are described in detail. Furthermore, this is the 
first report, till date, of the successful crystallization and intermediate resolution data 
collection from the crystals of a recombinant full length type I PKS from Mtb. 
The full length mas gene was successfully cloned from the Mtb genomic DNA by 
using a combination of reaction conditions and a high-fidelity DNA polymerase from 
two different suppliers. A chimeric expression vector was constructed for the 
heterologous expression of His-tagged MAS protein in E. coli. Further, it was 
determined that the co-expression of MAS with the Mtb PPTase Rv2794c was essential 
for the production of phosphopantetheinylated holo-MAS in E. coli. The full length 
holo-MAS was successfully purified using a step-gradient protocol and it was 
determined to be a dimer in solution, similar to the MAS purified from M. bovis BCG 
strain (Rainwater and Kolattukudy, 1985). Extensive screening for the crystallization of 
MAS led to the identification of a single condition in which MAS crystallized in the 
presence of heterogeneous nucleating agents. Further optimization of the initial hit 
condition produced large single diffractable crystals of MAS. The diffraction properties 
of the MAS crystals were significantly improved by the application of post-
crystallization treatments. Crystal dehydration protocols were developed and employed 




was successfully collected at the synchrotron from a dehydrated MAS crystal. Our initial 
attempts for obtaining the electron density maps at the intermediate resolution by using 
tantalum clusters for phasing were unsuccessful, suggesting that a wider screening of the 
heavy atom clusters and soaking conditions would be needed for the successful phasing 
of the MAS crystals. Furthermore, significant improvements in the diffraction properties 
of the mammalian FAS I crystals (Maier et al., 2010) due to fine refinements and 
optimizations of the crystal growth and stabilization conditions suggests that such an 
approach can also help to improve the diffraction properties of the MAS crystals. 
Additionally, the availability of the helium cryostat and the free-standing mounting 
systems on the modern synchrotron beamlines (Mueller et al., 2007) can help in 
obtaining the best quality data from the MAS crystals, which should further improve 
their resolution.   
The methods and protocols described in this chapter were developed after a lot of 
troubleshooting of the technical challenges associated with the cloning, purification and 
crystallization of MAS, in E. coli as the heterologous host. The methods reported here 
should prove useful in devising strategies for initiating crystallographic studies on other 
PKS I systems in Mtb. It is hoped that such studies will provide atomic-level insights 
into the structure-function relationships of the core domains, as well as unravel the 
structural features required for their interaction with other proteins of the complex lipid 
biosynthesis pathways in Mtb.  Finally, this information can also guide the development 
of structure-based intervention strategies to target PKS I systems for developing novel 






Mycobacterium tuberculosis ACYL CARRIER PROTEIN SYNTHASE ADOPTS 






The crystal structures of acyl carrier protein synthase (AcpS) from 
Mycobacterium tuberculosis (Mtb) and Corynebacterium ammoniagenes determined at 
pH 5.3 and pH 6.5, respectively, are reported. Comparison of the Mtb apo-AcpS 
structure with the recently reported structure of the Mtb AcpS–ADP complex revealed 
that AcpS adopts two different conformations: the orthorhombic and trigonal space-
group structures show structural differences in the α2 helix and in the conformation of 
the α3–α4 connecting loop, which is in a closed conformation. The apo-AcpS structure 
shows electron density for the entire model and was obtained at lower pH values (4.4–
6.0). In contrast, at a higher pH value (6.5) AcpS undergoes significant conformational 
changes, resulting in disordered regions that show no electron density in the AcpS 
model. The solved structures also reveal that C. ammoniagenes AcpS undergoes 
structural rearrangement in two regions, similar to the recently reported Mtb AcpS–ADP 
                                                 
⃰
 Reprinted with permission from “Mycobacterium tuberculosis acyl carrier protein synthase adopts two 
different pH-dependent structural conformations” by Kuppan G., Aggarwal, A., Shipman, L., Besra, G.S.  






complex structure. In vitro reconstitution experiments show that AcpS has a higher post-
translational modification activity between pH 4.4 and 6.0 than at pH values above 6.5, 
where the activity drops owing to the change in conformation. The results show that apo-
AcpS and AcpS–ADP adopt different conformations depending upon the pH conditions 




The fatty-acid synthase type I (FAS-I) pathway is widely present in eukaryotes 
(Smith, 1994) and consists of a single large polypeptide containing multiple active 
centers. The fatty-acid synthase type II (FAS-II) pathway is present in all bacteria and 
plants and comprises a system in which discrete monofunctional enzymes encoded by 
specific genes carry out each reaction in the pathway (Magnuson et al., 1993). Fatty-acid 
biosynthesis is more complicated in Mycobacteria and Corynebacteria species compared 
with other bacteria owing to the presence of both the FAS-I and FAS-II pathways. 
Lipid biosynthesis is essential to the survival of M. tuberculosis (Mtb) (Taylor et 
al., 2010). There are two important components in fatty-acid biosynthesis, CoAs and 
acyl carrier proteins (ACPs), both of which are essential for priming and extending the 
growing acyl chain. Apo-ACP is post-translationally modified by the transfer of a 4'-
phosphopantetheine (4'-ppt) prosthetic group from coenzyme A to holo-ACP by acyl 




are synthesized by repeated cycles of reactions, namely the transacylation, condensation, 
dehydration and reduction reactions (Rock and Cronan, 1996).  
The AcpS enzyme was initially identified and characterized in Escherichia coli, 
in which it is an essential enzyme for bacterial growth (Lambalot and Walsh, 1995). The 
Mtb genome contains two phosphopantetheine transferases: AcpS and 4'-
phosphopantetheinyl transferase (PptT) (Cole et al., 1998). Both enzymes are essential 
for bacterial survival and synthesis of virulence factors (Chalut et al., 2006). AcpS is 
predominantly associated with the biosynthesis of fatty acids in both FAS systems, but it 
is also involved in polyketide synthesis (Shen et al., 1992), nonribosomal peptide 
synthesis (Baldwin et al., 1991), transacylation of oligosaccharides (Geiger et al., 1991) 
and protein synthesis (Issartel et al., 1991). A recent study showed that AcpS is 
predominately associated with post-translational modification of FAS-I and the AcpM 
subunit of the FAS-II system (Chalut et al., 2006). In contrast, the PptT enzyme is 
involved in post-translational modification of type I polyketide synthase enzymes. The 
Mtb genome contains more than 18 type I polyketide synthase enzymes (Cole et al., 
1998), which catalyze the biosynthesis of phenolic lipids (Dubey et al., 2003) in virulent 
strains. In the type II synthase, the hydrophobic fatty-acyl intermediates sequentially 
shuttle between enzymes through an ACP. All acyl chains undergoing biosynthesis by 
FAS are attached to the terminal cysteine thiol of 4'-ppt via a labile thioester bond, 
making AcpS an essential enzyme. In addition, the 4'-ppt prosthetic group has a long 
flexible arm that can reach into the active site of enzymes, where the sulfhydryl group is 
available for the attachment of an acyl group. The divalent Mg
2+




post-translational modification reaction and is essential for the biosynthesis of all 
bacterial fatty acids, several bacterial lipopolysaccharides and membrane lipids. 
Recently, it has been reported that the AcpS gene product is essential for the growth of 
Streptococcus pneumoniae (McAllister et al., 2000). The nature of FAS-II in bacteria is 
quite different from the mammalian lipid-biosynthetic pathway and provides various 
specific sites for selective inhibition by antibacterial agents. Furthermore, AcpS is 
widely present in Mycoplasma, Gram-positive and Gram-negative bacteria; thus, an 
AcpS inhibitor could alter the availability of holo-ACP for the acylation process and the 
availability of components for fatty-acid biosynthesis, making such inhibitors possible 
broad-spectrum antibacterial agents. In the past ten years, structures of AcpS have been 
solved for several pathogenic bacteria (Table 3-1), including Streptomyces coelicolor 
(PDB entry 2wdo; P. Dall’Aglio, C. Arthur, M. P. Crump, J. Crosby & A. T. Hadfield, 
unpublished work), Streptococcus pneumoniae (PDB entry 1fte) (Chirgadze et al., 
2000), Bacillus subtilis (PDB entry 1f80) (Parris et al., 2000), B. anthracis (PDB entry 
3hyk; Center for Structural Genomics of Infectious Diseases, un-published work) and 
Mycobacterium smegmatis (PDB entry 3gwm; C. Poulsen, M. Wilmanns & Y. H. Song, 
unpublished work), revealing the role of this enzyme in post-translational modification. 
We report here the crystal structures of C. ammoniagenes AcpS (with and 
without CoA) and Mtb apo-AcpS. Mtb apo-AcpS has an overall structure similar to those 
of the recently reported Mtb AcpS–ADP complex and the C. ammoniagenes AcpS 
structure described here. Despite their overall similarity, the two structures exhibit 




crystallized both at low pH values (4.4–6.0) and higher pH values (6.5 and 7.5); 
interestingly, AcpS showed higher post-translational modification activity at the lower 
pH. The Mtb and C. ammoniagenes AcpS structures suggest that pH may play a 
significant role in conformational change but that CoA binding has no effect on the 
structural rearrangement. The transfer of the 4'-ppt moiety from CoA to the Asp-Ser-Leu 
(DSL) motif of the mycobacterial ACP (AcpM) is likely to require the association of 
AcpS and apo-AcpM. To understand the interaction between these two proteins, the Mtb 
AcpS and Mtb ACP NMR structures (PDB entry 1klp) (Wong et al., 2002) were 
superimposed on the B. subtilis AcpS–ACP complex. The superimposed model of Mtb 
AcpS–ACP shows that the conserved DSL motif of AcpM occupies a dimer interface of 
AcpS and is in close enough proximity to interact with either 3',5'-ADP or CoA. 
 
 
Table 3-1. List of ACPS structures from several pathogenic bacteria and their sequence 
similarity to Mtb AcpS. 






to Mtb AcpS (%) 
R.m.s.d. (Å) 
Streptomyces coelicolor 2wdo 39 1.58 
Mycobacterium smegmatis 3gwm 84 1.07 
Bacillus anthracis 3hyk 32 2.07 
Staphylococcus aureus 3f09 26 2.12 
Streptococcus pneumoniae 1fte 27 2.18 





MATERIAL AND METHODS 
 
Cloning, expression and purification of C. ammoniagenes AcpS and Mtb AcpS 
 A 0.45 kb DNA fragment containing the AcpS gene was amplified by PCR using 
C. ammoniagenes genomic DNA as the template (forward primer, 5'-
CATATGCTCGACAACCGTGAAGCG; reverse primer, 5'-AAGCTTTTACCGCAG-
GTACCGCAG). The amplified DNA fragment was digested with NdeI and HindIII and 
subcloned into the corresponding restriction sites in the pET28a vector to yield N-
terminally His6-tagged AcpS. E. coli B834 (DE3) Met cells were trans-formed with the 
AcpS-pET28a/His vector. For the production of SeMet-incorporated protein the cells 
were grown in M9 minimal medium supplemented with all 19 standard amino acids and 
selenomethionine. Expression of AcpS was induced with 1 mM IPTG and cells were 
harvested after 6 h of growth at 289 K. 
 A 0.4 kb DNA fragment containing the AcpS gene (Rv2523c; Swiss-Prot 
accession No. O53228) was amplified by PCR using Mtb H37Rv genomic DNA as the 
template (for-ward primer, 5'-ATGGGCATCGTCGGTGTGGG; reverse primer, 5'-
TCACGGGGCCTCCAGGATGGCGAC). The amplified DNA fragment was digested 
with NcoI and BamHI and subcloned into the corresponding restriction sites in the 
pET28a vector to yield C-terminally His6-tagged AcpS. The AcpS-pET28a vector was 
transformed into E. coli BL21 (DE3) cells by heat-shock transformation. The 




medium containing kanamycin. Expression of AcpS was induced with 1 mM IPTG and 
cells were harvested after 6 h of growth at 289 K. 
 The harvested cell pellet was resuspended in buffer A (20 mM Tris–HCl pH 8.0, 
100 mM imidazole, 0.5 M NaCl) with 1 mM PMSF and Complete EDTA-free protease-
inhibitor cocktail (Roche). The cell lysate was disrupted by three passages through a 
cooled French pressure cell and repeatedly sonicated at 277 K with 30 s pulses. The 
resulting cell extract was centrifuged at 15 000g at 277 K for 1 h. The cleared 
supernatant was loaded onto a Hi-Trap Ni
2+
-chelating column (Pharmacia Biosciences) 
and washed with 300 ml buffer A. His-tagged AcpS was eluted with a 100 ml linear 
gradient of 100–500 mM imidazole in 20 mM Tris–HCl pH 8.0 and 0.5 M NaCl. After 
purification to near-homogeneity by size-exclusion chromatography on a Superdex G-75 
gel-filtration column (Pharmacia Biosciences), AcpS was dialyzed against 20 mM Tris–
HCl pH 8.0 buffer, concentrated to 8 mg ml
-1
 and stored in 20 mM Tris–HCl pH 8.0 at 
193 K. 
 
Cloning, expression and purification of Mtb ACP (AcpM) 
 A 0.35 kb DNA fragment containing the ACP gene (Rv2244; Uni-Prot accession 
No. POA4W6) was amplified by PCR from Mtb H37Rv genomic DNA (forward primer, 
5'-AAGAAGAGGCGGCCGCATGCCTGTCACTCAGGAGCCTGTCACTCAGG-





The amplified DNA fragment was digested with NotI and NcoI and subcloned 
into the corresponding restriction sites in the pET30b vector to yield C-terminally His6-
tagged AcpM. The AcpM-pET30b vector was transformed into E. coli BL21 (DE3) 
cells. The transformed cells were grown to mid-log phase at 310 K in Terrific Broth 
containing kanamycin. Expression of AcpM was induced with 1 mM IPTG and cells 
were harvested after 6 h of growth at 289 K. 
The harvested cell pellet was resuspended in buffer A (20 mM Tris–HCl pH 8.0, 
10 mM imidazole, 0.5 M NaCl) with 1 mM PMSF and Complete EDTA-free protease-
inhibitor cocktail (Roche). The cell lysate was disrupted by three passages through a 
cooled French pressure cell and repeatedly sonicated at 277 K with 30 s pulses. The 
resulting cell extract was centrifuged at 15 000g at 277 K for 1 h. The cleared 
supernatant was loaded onto a Hi-Trap Ni
2+
-chelating column (Pharmacia Biosciences) 
and washed with 300 ml buffer A. His-tagged AcpM was eluted with a 200 ml linear 
gradient of 10–500 mM imidazole in 20 mM Tris–HCl pH 8.0 and 0.5 M NaCl. The peak 
fractions were pooled and dialyzed against 20 mM Tris buffer pH 8.0. The concentrated 
protein was stored at 193 K until use. 
 
AcpS post-translational modification fluorescence assay 
 The 4'-ppt transferase activity of AcpS was assessed using BODIPY-labeled 
CoA. For this purpose, BODIPY-S-CoA was synthesized using CoA (Sigma) and 
BODIPY FL N-(2-aminoethyl)maleimide (Invitrogen) (La Clair et al., 2004). In the 




temperature in the dark in 20 mM HEPES pH 7.5 buffer containing 10 µl BODIPY-S-
CoA (60 µM final concentration) and 10 mM MgCl2. As a control, AcpM was also pre-
incubated with AcpS and 300 µM CoA for 1 h at room temperature in the dark before 
the addition of BODIPY-S-CoA to the reaction mixture. PKS11 was used as a negative 
control as it is not a substrate of AcpS in vivo. PKS11 was incubated with BODIPY-S-
CoA in the presence of AcpS, as performed for AcpM. After incubation, the reactions 
were stopped by the addition of 20% TCA to the mixture. The samples were incubated 
on ice for 15 min and then spun at 13 000g for 10 min. The supernatant was decanted 
and the pellets were washed twice with 200 µl ice-cold acetone. The pellets were dried 
in a speed vacuum, dissolved in a small amount of buffer and analyzed by SDS–PAGE. 
The resulting bands were analyzed under a UV-light scanner. The 4'-ppt transferase 
activity of AcpS was also measured at different pH values (3.4–8.0) using BODIPY-
labeled CoA. 
 
Crystallization and data collection 
 Initial crystallization conditions were screened by the hanging-drop method using 
a sparse-matrix kit (Crystal Screen and Crystal Screen 2, Hampton Research, California, 
USA; McPherson, 1982). C. ammoniagenes AcpS alone produced diffraction-quality 
crystals (space group P212121) in 4–8 d at 291 K from 4 µl hanging drops consisting of a 
1:1 ratio of AcpS (8 mg ml
-1
 concentration) and crystallization buffer consisting of 100 
mM MES buffer pH 6.5, 0.2 M ammonium sulfate and 30%(w/v) PEG MME 5K. AcpS–






) was mixed with an equal volume of precipitant solution to create 4 µl drops and 
incubated at 291 K. For protein crystals complexed with ligands, 0.5–2 mM CoA and 10 
mM magnesium chloride were pre-incubated with AcpS for 10 min at room temperature. 
The precipitant solution for AcpS–CoA crystals consisted of 25%(w/v) PEG MME 5K, 
0.1 M MES buffer pH 6.5 and 200 mM ammonium sulfate. The C. ammoniagenes 
AcpS–CoA complex crystallized in space group P1 with two trimers in the asymmetric 
unit. 
 The crystallization screen for Mtb AcpS was set up in hanging drops using the 
factorial screening method. Initial crystallization screening was carried out with AcpS 
alone in 10 mM MgCl2 and 14 mM KCl (24 h at 277 K). Diffraction-quality crystals 
were obtained at 291 K when drops (1:1 ratio of protein:reservoir solution) were 
equilibrated against 500 µl well solution consisting of 5.6%(w/v) PEG 4K, 0.07 M 
sodium acetate pH 4.6–5.5, 50 mM ammonium sulfate and 30%(v/v) glycerol. The 
crystal belonged to space group I222, with unit-cell parameters a = 83.12, b = 104.87, c 
= 105.19 Å, and contained one homotrimer per asymmetric unit. Diffraction-quality 
crystals were obtained after 3–4 d. Crystals belonging to space group R3 were obtained 
by the same method using a well solution consisting of 5.6% PEG 4K, 0.07 M sodium 
acetate pH 5.0–5.6, 50 mM ammonium acetate, 15% glycerol and 100 mM sodium 
iodide. The R3 crystals contained one molecule in the asymmetric unit. 
 A multi-wavelength anomalous dispersion data set for the C. ammoniagenes 
SeMet apo-AcpS crystal was collected on beamline 14-BM-D at the Advanced Photon 




Corporation Q4 area detector. High-resolution data sets for C. ammoniagenes AcpS–
CoA and native AcpS crystals were collected on beamline 14-BM-C at APS. PEG 400 
was used as a cryoprotectant for both apo-AcpS and the AcpS– CoA complex. The 
crystals were flash-frozen in a liquid-nitrogen stream at 120 K. Mtb apo-AcpS crystals 
(space groups I222 or I212121 and R3) were captured in cryoloops and flash-cooled in an 
N2 stream after brief soaks in mother liquor containing 20% ethylene glycol as a 
cryoprotectant. The data were reduced using DENZO (Otwinowski and Minor, 1997) 
and intensities were scaled with SCALEPACK (Otwinowski and Minor, 1997). 
Integrated and scaled data were analyzed by XPREP and indicated that the Mtb apo-
AcpS crystals belonged to space group I222 or I212121. Solvent-content calculations 




, VS = 
51.76%) in the asymmetric unit. Molecular replacement (MR) in space group I222 gave 
a higher correlation coefficient (74.4%) and lower R factor (39.3%) compared with 
space group I212121 (correlation coefficient of 34.2% and R factor of 58.9%). Therefore, 
I222 was the correct space group. The crystallographic data-collection statistics and 










Table 3-2. Anomalous data-collection (a) and phasing statistics (b) for C. 
ammoniagenes  apo-AcpS. Values in parentheses are for the highest resolution bin. 
 
(a)  
 Inflection  
(maximum f ') 
Peak 
(maximum f '')  
High 
remote 
Wavelength (Å) 0.979 0.979 0.963 
Resolution range (Å) 99.0-2.48 99.0-2.48 99.0-2.48 
Completeness 
 
(%) 100 (100) 100 (100) 100 (100) 
Completeness, 2 (%) 86 (67) 83 (56) 94 (85) 
< I/(I)> 
 13.7 (2.8) 15.9 (2.6) 23.1 (7.2) 
Rmerge 0.10 (0.31) 0.10 (0.32) 0.09 (0.35) 
f ' (e
-
) -11.03 -8.49 -4.93 
f '' (e
-
) 3.20 5.28 3.44 
 
(b)  
Resolution bin (lower limit) (Å) 8.53 5.42 4.25 3.61 3.19 2.89 2.66 2.48  
FOM initial (SOLVE)  0.61 0.40 0.36 0.31 0.23 0.17 0.12 0.10 
FOM final (SHARP, 
   DM NCS averaging) 










Table 3-3. Data-collection, refinement and geometry statistics. Values in parentheses are 
for the highest resolution bin. 
 
  
C. ammoniagenes  
Mtb-Apo-AcpS 
Apo-AcpS AcpS-CoA 
Space group I222 R3 P212121 P1 
Unit cell parameters     
     a (Å) 83.12 67.89 51.40 54.78 
     b (Å) 104.87 67.89 59.00 56.02 
     c (Å) 105.19 83.94 153.56 88.28 
     α 90.00 90.00 90.00  80.88  
     β 90.00 90.00 90.00 76.23  
     γ 90.00 120.00 90.00 60.92  
No. of crystals 1 1 2 1 








Unique reflections  15471 (1254) 6051 (855) 16881 (2038) 52264 (5869) 
Completeness (%) 95.7 (75.5) 100 (100) 94.7 (78.6) 73 (51.0) 
Rmerge 
 0.03 (0.14)  0.03 (0.19) 0.05 (0.15) 0.05 (0.18) 
< I/σ(I)> 13.83 (1.22) 54.00 (4.00) 17.35 (7.01) 58.10 (7.30) 
Free R value (random 5%)  0.30 (0.35) 0.27 (0.38) 0.27 (0.28) 0.25 (0.29) 
R value           0.23 (0.36) 0.24 (0.39) 0.20 (0.21) 0.21 (0.21) 
No. of protein residues 387 129 399 804 
B Factor (Å2) 74.14 43.75 30.14 24.91 
Wave length (Å) 1.54 0.97 0.97 0.97 
No. of ADPs 0 0 0 6 








Table 3-3. Continued.     
  
C. ammoniagenes  
 Mtb-Apo-AcpS  
Apo-AcpS AcpS-CoA 
R.m.s.d. bond lengths (Å) 0.03 0.03 0.02 0.031 
R.m.s.d.  bond angles (°)   1.48 1.66 1.64 2.036 
Overall coordinate error (Å)  0.30 0.28 0.23 0.26 
Real- space CC (REFMAC5)  0.94 0.94 0.92 0.93 
Ramachandran plot, residues in     
    Most favored region 332 (87.30) 338 (88.70) 387 (96.99) 774 (96.27) 
    Allowed region 45 (12.0) 41 (10.7) 7 (1.75) 17 (2.11) 
    Generously allowed region 3 (0.7) 2 (0.3) 0 (0) 0 



















 The experimental phases for the C. ammoniagenes apo-AcpS structure were 
obtained by multi-wavelength anomalous dispersion phasing (Hendrickson and Ogata, 
1997). SHELXD (Sheldrick, 2008a) located three selenium sites in the asymmetric unit 
consistent with a homotrimer in the asymmetric unit and SOLVE (Terwilliger and 
Berendzen, 1999) was used to refine the sites and calculate the initial protein phase, 
resulting in an overall figure of merit of 0.7 (Table 3-2) for data in the resolution range 
100–2.48 Å. The heavy-atom parameters were then refined and the phase was calculated 
in SHARP (de La Fortelle and Bricogne, 1997). Further phase improvement with solvent 
flattening in autoSHARP (Bricogne et al., 2002) resulted in high-quality density-
modified maps showing clear electron density for the correct hand for three molecules of 
protein in the asymmetric unit. The initial protein model was built using XFIT (McRee, 
1999) and a final high-quality model was produced after several cycles of manual model 
building and NCS-restrained maximum-likelihood refinement with REFMAC5 
(Murshudov et al., 2011) against the high-remote data set (Table 3-3). Water molecules 
were manually added during iterative cycles of building and refinement. 
The structure of the C. ammoniagenes AcpS–CoA binary complex was solved by 
molecular replacement with EPMR (Kissinger et al., 1999) using the final model of C. 
ammoniagenes apo-AcpS as the search model for data extending from 25 to 3.5 Å 
resolution. After model building and fitting, bias-minimized electron-density maps were 
obtained using the Shake&wARP protocol (Kantardjieff et al., 2002). Clear electron 




building. After repeated cycles of refinement and manual model building, water 
molecules were added to the structure using XFIT (McRee, 1999) (Table 3-3). 
The structure of Mtb apo-AcpS was solved by molecular replacement with 
EPMR, giving a correlation coefficient of 0.45, using the final C. ammoniagenes apo-
AcpS model as the search model for data extending from 25 to 3.5 Å resolution. The 
initial molecular-replacement model was mutated according to the Mtb AcpS sequence 
and manually rebuilt using XFIT into bias-minimized multiple-averaged electron-density 
maps obtained from the Shake&wARP map server. The initial electron-density map 
allowed the construction of a model with 129 residues (residues 2–130) in each subunit. 
Rigid-body refinement was carried out using REFMAC5. After repeated cycles of 
refinement and manual building, water molecules were added to the structure using XFIT 
(McRee, 1999). The final model has a crystallographic R factor of 23% and an Rfree of 
30% to a resolution of 2.51 Å with good stereochemistry (Table 3-3). Mtb apo-AcpS 
also crystallized in space group R3 with one molecule in the asymmetric unit. The R3 
crystal structure was solved by molecular replacement using a single chain from the final 
model of Mtb apo-AcpS solved in space group I222. Several cycles of manual model 
building and likelihood refinement in REFMAC5 yielded a final 1.9 Å resolution model 
for the R3 crystal (Table 3-3). Water molecules were manually added during iterative 







RESULTS AND DISCUSSION 
 
 The initial phases for the C. ammoniagenes apo-AcpS crystal diffraction data 
were obtained by MAD (Hendrickson, 1991) using crystals of selenomethionyl protein 
in space group P212121. The unit-cell parameters and scaling with diffraction amplitudes 
showed that the AcpS–CoA binary complex crystallized in space group P1 with two 
trimers in the asymmetric unit. The initial map allowed the construction of a model with 
136 residues in each subunit. The crystal structure of AcpS from C. ammoniagenes 
revealed that it assembles as a tightly packed homotrimer. The final structure consists of 
residues 5–47 and 61–153 (Fig. 3-1a) in three subunits designated A, B and C. The three 
polypeptide chains can be superimposed with r.m.s.d.s of 0.43 Å between chains A and B 
and of 0.53 Å between chains A and C. In an experimental map and in an unbiased 
electron-density map of native C. ammoniagenes AcpS the structure shows no electron 
density for the four N-terminal residues (1–4) or for residues 48–60 (the α2–α3 
connecting loop). The C. ammoniagenes apo-AcpS structure has an α/β-fold (Fig. 3-1a) 
similar to those of the B. subtilis and S. pneumoniae AcpS structures (Chirgadze et al., 
2000; Parris et al., 2000). The main core of the protein is the long α3 helix. One side of 
the α3 helix is covered by antiparallel β-sheets (consisting of β1, β4 and β5), while the 
other side of the helix is covered by a β-sheet composed of strands β2, β3 and β4 
together with α1 and α2. 
 The C. ammoniagenes AcpS–CoA binary complex structure was solved by 




structure as a starting model. The crystallographic data-collection statistics and 
refinement parameters are summarized in Table 3-3. To obtain the molecular-
replacement solution for Mtb AcpS, we used the coordinates of C. ammoniagenes AcpS 
as an initial search model. The structural data reveal that native Mtb AcpS (Fig. 3-1b) 
assembles as a tightly packed homotrimer and each subunit consists of residues 2–130. 
 AcpS forms a homotrimer in which the polypeptide chain is folded into four α-
helices and five β-strands and trimerization is mediated through the residues of the 
antiparallel β-strands (β1, β4 and β5) of all three subunits. The three antiparallel β-
strands of each subunit are arranged together and form a tunnel-like structure at the 
center of the trimer that runs through the entire length of the protein (Figs. 3-1a and 3-
1b). The tunnel contains mainly hydrophobic residues that stabilize the biological unit, 
with intersubunit interactions occurring predominantly between the β1 strand of one 
subunit and the β4 strand of another subunit. The active site of AcpS is formed at the 
intermolecular interface between two subunits, specifically where the β-sheets of two 
AcpS molecules intersect in the trimer. The amino acids from one subunit surround one 
half of the active site and those from the second subunit surround the other half. 
Examination of the active site of the C. ammoniagenes native AcpS structure reveals a 
bowl-shaped depression (Figs. 3-1a and 3-1b) that is surrounded by charged residues and 
bound ordered water molecules. In the C. ammoniagenes and Mtb AcpS native structures 
the active sites are occupied by sulfate ions (Figs. 3-1c and 3-1d). In addition, 






Figure 3-1. Overview of the C. ammoniagenes and Mtb AcpS structures with ribbon 
representation of the homotrimer. In the final model of the C. ammoniagenes AcpS structure 
each monomer contains residues 5–47 and 61–153. In the Mtb AcpS structure each monomer 
contains residues 2–130. The view is from the top of the trimer. (a) Ribbon diagram of the C. 
ammoniagenes AcpS homotrimeric structure: subunit A (magenta), subunit B (cyan) and subunit 
C (yellow). (b) Ribbon diagram of the Mtb AcpS homotrimer structure: subunit A (sea green), 
subunit B (plum) and subunit C (orange). The sulfate ion (shown in ball-and-stick representation) 
binds at the dimer interface, specifically in the cleft region that is formed by the two monomers. 
(c) Structural superposition of the Mtb and C. ammoniagenes AcpS active-site residues with 
sulfate ions. The bound sulfate ions are shown in stick representation. In Mtb AcpS His49 
swings 101° compared with His65 of C. ammoniagenes AcpS. (d) Electron-density map of the 
substrate-binding pocket of Mtb AcpS. The carve feature in PyMOL was used to limit display of 
the electron density of the model. A 2Fo - Fc map contoured at 1.4σ (blue) and an Fo - Fc map 




Sequence and structural comparison of Mtb AcpS and C. ammoniagenes AcpS with 
other bacterial AcpSs 
 Multiple sequence alignments of known AcpS sequences are presented in Fig. 3-
2 and show that Mtb AcpS has a lower sequence identity to B. subtilis AcpS and S. 
pneumoniae AcpS (29 and 27%, respectively) than to C. ammoniagenes AcpS, which 
displays 34% sequence identity to the homologous enzyme. The KEAXXKA motif, 
containing the Lys62 residue, is within hydrogen-bonding distance of the 5'-phosphate 
and is conserved in the prokaryotic AcpS enzymes; the SXXXH motif interacts with 
either the 3'-phosphate of CoA or with ADP. Other conserved motifs include GXD 
(involved in chelating the Mg
2+
 ion), and RW and GRP, which are part of the CoA-
binding regions. The RRXA and SXXXH sequence motifs are not conserved in the 
prokaryotic AcpS and surfactin synthetase enzymes. The SXXXH motif is highly 
conserved in AcpS enzymes from Mycobacterium and Corynebacterium species and is 
located in the vicinity of the CoA-binding pocket. In the Mtb apo-AcpS structure His49 
(His65 in C. ammoniagenes AcpS) interacts with the sulfate ion. The present structural 
study also shows the participation of a second histidine in the active site. In B. subtilis 
AcpS the hydrophobic Phe49 residue occupies the place of His49 and does not 
contribute to active-site formation. The sequence alignment also shows that C. 








Figure 3-2. Sequence alignment of AcpS. (a) Multiple sequence alignment of AcpS 
enzymes. The sequence alignment shows that C. ammoniagenes AcpS has an additional 
12-residue (RDAAADATNSSL) insertion sequence between the α2 and α3 helices 
which is disordered in the structure. (b) Sequence alignment of AcpS enzymes from 
Mycobacterium and Corynebacterium species. The conserved SXXXHLA motif is shown 













Least squares superposition of the structures indicate the close resemblance of Mtb AcpS 
and C. ammoniagenes AcpS to the B. subtilis and S. pneumoniaee enzymes (r.m.s.d for 
112 C
α
 carbon atoms ~1.67 and 1.8 Å respectively; (Chirgadze et al., 2000; Parris et al., 
2000); Figs. 3-3a-3-3c). In B. subtilis AcpS and S. pneumoniae AcpS three short α-
helices (α1, α2, and α3) are located between the β1 strand and the long α4 helix (Fig. 3-
3b). In contrast, in C. ammoniagenes AcpS and Mtb AcpS the two short α-helices (α1 
and α2) are located between the β1 strand and the long α3 helix (Fig. 3-3b). Structural 
alignment shows that the β1 strand and the α3 helix are connected by 30 residues in 
known AcpS structures. In the Mtb and C. ammoniagenes AcpS structures these 30 
residues form two short α-helices (α1 and α2). In contrast, in the S. pneumoniae and B. 
subtilis AcpS enzymes the equivalent 30 resides (12-43) form three well ordered short α-
helices (α1, α2, and α3). Because of the absence of one short α-helix (equivalent to α2 in 
B. subtilis), the connecting loop between the α1 and α2 helices is much larger and more 
flexible in the Mtb and C. ammoniagenes AcpS proteins. Furthermore, in C. 
ammoniagenes AcpS and Mtb AcpS the β3 and β4 strands are connected by a well 
defined α4 helix (residues 115-129 and 98-105, respectively; Fig. 3-3c), while in B. 
subtilis and S. pneumoniae the β3 and β4 strands are not connected by an α-helix but by 
a short loop (91-96). The topological rearrangements of the α-helix in Mtb AcpS and C. 
ammoniagenes AcpS may be required for their interactions with ACP, as Mtb AcpS and 







Figure 3-3. Structural superposition of the AcpS enzymes. (a) Backbone superposition 
of the AcpS enzymes. Color key: orange, Mtb; yellow, C. ammoniagenes; cyan, B. 
subtilis; purple, S. pneumoniae. (b) The structural superposition reveals that the B. 
subtilis and S. pneumoniae AcpS structures have three short helices (α1, α2 and α3) 
between the β1 strand and the α3 ‘core’ helix. The Mtb and C. ammoniagenes AcpS 
structures contain two short helices between β1 and the core helix. (c) The β2 and β3 
strands of the Mtb and C. ammoniagenes AcpS structures are connected by a short helix 










Structural differences between the open and closed structural forms of Mtb AcpS 
 A crystal structure of Mtb AcpS has recently been reported in which AcpS was 
crystallized in space group P23 and contained one molecule in the asymmetric unit 
(Dym et al., 2009). The reported AcpS–ADP structure is disordered in three regions 
(residues 22–30, 41–44 and 75–78) accounting for 13% of the AcpS model. Mtb apo-
AcpS crystallized in space groups I222 and R3. Most notable was that in the I222 and R3 
space groups AcpS had clear density for the entire model. AcpS crystallized as a 
homotrimer in space group I222, but in space group R3 it crystallized with a monomer in 
the asymmetric unit. The trimeric structure was maintained by the symmetry. The 
monomeric form was superimposed individually on chains A, B and C of the trimeric 
apo-AcpS structure with r.m.s.d.s of 0.91, 1.02 and 0.85 Å, respectively. Structural 
superposition of C
_
 atoms revealed that AcpS–ADP crystallized in space group P23 
retained an overall fold analogous to those of previously reported AcpS structures 
(Chirgadze et al., 2000; Parris et al., 2000). However, superposition of the C
α
 atoms 
reveals significant conformational changes of the C
α
 atoms in two regions, the α2 helix 
(residues 30–40; r.m.s.d. of 12 Å) and the connecting loop located between the α3 and 
α4 helices (residues 67–73; r.m.s.d. of 9 Å), when compared with the Mtb AcpS 
structure crystallized in space groups other than P23 (Figs. 3-4a and 3-4b). In contrast, 
the closed conformation was not observed in the C. ammoniagenes AcpS structure. The 
crystallographic data for C. ammoniagenes AcpS suggest that both the apo-AcpS and the 
AcpS–CoA complex structures adopt an open conformation. It is possible that in some 




proteins. However, our current structural data show that Mtb AcpS crystallizes in three 
different space groups at lower pH and no structural changes were observed between 
them. In contrast, the structure of a crystals obtained at higher pH (unreported low-
resolution data for apo-AcpS crystallized in space group P23, unit-cell parameters a = b 
= c = 73.74 Å, α = β = γ = 90.0°) superposes very well with the recently reported AcpS–
ADP complex (Dym et al., 2009). The crystals obtained at higher pH show three 
disordered regions and also structural movement in two regions. Taken together, these 
results suggest that the pH of the crystallization condition plays a significant role in the 
conformational changes of Mtb AcpS. 
 
The effect of pH on the structure of the α2 helix 
 At lower pH values (between 4.4 and 6.0), the α1–α2 connecting loop is well 
ordered in the Mtb apo-AcpS structure. Residues from this loop make hydrogen-bonding 
interactions with residues in the α2 helix that result in close packing of the α1 and α2 
helices on one side of the α3 or ‘core’ helix. Likewise, residues from helix α2 interact 
with residues from helix α3. In particular, the distance between the hydroxyl group of 
Thr25 and the main-chain N atom of Phe27 is 3.06 Å and the guanidinium group (NH1) 
of Arg53 from the α3 helix interacts with the acidic side chain of Glu35 (OE2) from the 
α2 helix (3.19 Å) at low pH. At higher pH values the AcpS structure undergoes a 
significant conformational change in which the α2 helix moves 12 Å away from the α1 






Figure 3-4. Overview of the α2-helix movement and the open and closed conformations 
of the α3–α4 connecting loop. (a) Structural superposition of helices α1, α2 and the 
connecting loop of the Mtb AcpS–ADP complex (green), Mtb apo-AcpS (yellow) and 
the C. ammoniagenes AcpS–CoA complex (red) represented by ribbon diagrams. Mtb 
apo-AcpS is shown as a surface representation; the surface of subunit C is shown 
partially in order to view the movement of the α2 helix at higher pH. (b) The α3–α4 
connecting loop is shown in both the open and closed conformations. At higher pH 
values the α3–α4 connecting loop of the Mtb AcpS–ADP complex adopts an open 
conformation (purple). In the apo-AcpS structure (yellow) this same loop adopts a closed 
conformation. (c) Electron-density map of the Mtb apo-AcpS structure contoured at 
1.4σ. At lower pH values the α1 and α2 helices are packed together; electron density is 




The rearrangement of the α2 helix also leads to the destabilization of the 
connecting loops at both ends, resulting in disordered electron density for residues 21–30 
and 41–44. This movement increases the flexibility of the connecting loop, thereby 
altering the hydrogen bonds and hydrophobic interactions with the α2 helix as well as 
the ionic interaction between the α2 and α3 helices. The ionic interaction between the 
Glu35 and Arg53 residues is lost; instead, the side chain of Arg53 interacts with the 
phosphate group of ADP. Superposition of the higher pH structure of Mtb apo-AcpS 
with that of C. ammoniagenes AcpS–CoA shows that the Arg69 residue and the Mtb 
Arg53 residue overlay each other. It is clear that the ionic interaction is lost as a 
consequence of the change in pH and not the ligand binding. 
 
Open and closed conformations of the connecting loop between helices α3 and α4 
 Structure-based sequence alignment revealed that the connecting loop between 
helices α3 and α4 of Mtb AcpS contains six additional residues compared with the 
known AcpS structure, resulting in the loop adopting an open conformation (Fig. 3-4b) 
(Dym et al., 2009). In our structure, the α3–α4 connecting loop adopts a closed 
conformation despite the presence of the additional six residues (Fig. 3-4b). The pH of 
the conditions used for crystal growth is the only difference between these two 
structures. At lower pH values (4.4–6.0) the α3–α4 connecting loop adopts a closed 
conformation. Structural superposition reveals that the closed conformation of Mtb AcpS 
is similar to those in the structures of AcpS from B. subtilis (Parris et al., 2000) and S. 




loop adopts two different conformations based on the pH of the crystallization 
conditions. The r.m.s.d. value of the individual residues of the α3–α4 connecting loop of 
AcpS at pH 6.5 compared with the low-pH structure is approximately 6 Å. At lower pH 
values, the α3–α4 connecting loop points towards the connecting loop between the α3 
helix and the β2 strand of the same subunit. The Phe69 side chain is buried in the 
hydrophobic pocket formed by Val4, Leu105, Val108 and Ala129. At higher pH values, 
residues 68–72 flip 150° in the opposite direction and move towards the connecting loop 
between the β2 and β3 strands of the neighboring subunit. In the open conformation, the 
Phe69 residue shows the most deviation (the r.m.s.d. of the C
α
 atom is 9.6 Å), followed 
by Ala70 (the r.m.s.d. of the C
α
 atom is 9.2 Å), when compared with the closed 
conformation (Figs. 3-4b and 3-4d). 
 Dym and coworkers postulated that in C. ammoniagenes AcpS the α3–α4 
connecting loop will adopt an open conformation as in the Mtb AcpS–ADP complex 
structure owing to their sequence conservation and identity (Dym et al., 2009). Here, we 
report the crystal structure of C. ammoniagenes AcpS with and without CoA. Both apo-
AcpS and AcpS-CoA crystallized as homotrimers and superimposed very well (r.m.s.d. 
of 0.45 Å). Superposition of the Mtb apo-AcpS structure with the C. ammoniagenes 
AcpS structure (apo-AcpS and AcpS–CoA) shows that the α2 helix (residues 33–43) 
moves 12 Å towards the β2 and β3 strands and the α3–α4 connecting loop (residue 82–
88) undergoes a conformational change resembling the open structure of the Mtb AcpS–
ADP structure. The open and closed conformations of AcpS cannot be correlated with 




 Another unexpected observation is that a portion of the α4 helix (residues 73–78) 
is disordered in the Mtb AcpS–ADP complex. It has been hypothesized that this loop 
(74–78) may be stabilized by the interaction of AcpS with AcpM. In contrast, the pH 5.3 
crystal structure of Mtb AcpS and the pH 6.5 crystal structure of C. ammoniagenes AcpS 
exhibit electron density for all of the backbone and side-chain residues of the α4 helix 
(Fig. 3-4d). This suggests that the interaction between AcpM and AcpS is not required 
for stabilization of the α4 helix of AcpS. In the lower-pH AcpS structure the connecting 
loops and the α4-helix region have higher B factors in comparison with the remaining 
region, indicating that these regions are highly flexible and are beginning to undergo 
conformational change. This pH-induced conformational change in AcpS may provide 
insight into a possible mechanism of protein–protein interaction. At higher pH values the 
Arg48 and His49 residues of the α3 helix do not participate in the CoA-binding 
mechanism; these residues are highly conserved in AcpS enzymes from Mycobacterium 
species. In contrast, at low pH these two residues actively participate in sulfate binding 
in the apo structure of Mtb AcpS (Figs. 3-1c and 3-1d). Similarly, in C. ammoniagenes 
the equivalent residues (Glu64 and His65) participate in both sulfate and CoA binding. 
The His65 residue is highly conserved in Corynebacterium AcpS enzymes; it is located 
in the active site and forms a hydrogen bond to the phosphate group of CoA (Fig. 3-2c). 
AcpS crystallized in space group P23 does not show an interaction with the second 






Active site of the apo-AcpS structure 
 The active sites of Mtb AcpS and C. ammoniagenes AcpS are formed at the 
interface of the trimer. Electron density for a sulfate ion is visible in the unbiased 
electron-density maps of both the Mtb and C. ammoniagenes AcpS native structures 
(Fig. 3-1d). The locations of the identified sulfate ions are adjacent to a series of well 
conserved residues, specifically Arg48, His49 and His116 in Mtb AcpS, and Arg46, 
Glu64, His65 and His138 in C. ammoniagenes AcpS. These sulfate ions are associated 
with residues found in the CoA-binding pocket identified in the B. subtilis AcpS 
structure (Parris et al., 2000). The sulfate ion occupies the same position as the 3'-
phosphate of CoA. Previous studies have shown that the active sites of S. pneumoniae 
AcpS are occupied by sulfate ions (Chirgadze et al., 2000). Of particular interest are the 
two O atoms (O1 and O2) of the sulfate that form hydrogen bonds to Arg48 NH1 
(distances of 2.48 and 2.89 Å, respectively) of subunit A. The guanidinium group of 
Arg48 is at a favorable distance to form a hydrogen bond to the carbonyl groups of the 
highly conserved Ser43 (3.01 Å; Fig. 3-1d). O atoms O1 and O3 of the sulfate ion also 
form hydrogen bonds to NE2 of His49 and His116 (2.82 Å), respectively. Of the three 
active sites, two contained one sulfate ion and one was occupied by two sulfate ions. A 
similar result was also observed in the C. ammoniagenes apo-AcpS structure (Figs. 3-1a 
and 3-1b). In C. ammoniagenes AcpS the Glu64 residue is replaced by Arg48, which 
occupies an identical location as in the Mtb AcpS structure. However, the location and 
orientation of His65 and the sulfate ion in the active site of the C. ammoniagenes AcpS 




Firstly, in C. ammoniagenes AcpS the His65 and His138 residues are surrounded by 
Glu64 on one side and Arg46 on the other. Owing to the negative charge of Glu69 the 
sulfate ion is located in a favorable position to interact with the basic residue Arg46. 
Secondly, owing to the long side chain of Arg48 the sulfate ions occupy a different 
location in Mtb AcpS, making the side chain of His49 swing approximately 101° 
compared with His65 of C. ammoniagenes AcpS and facilitating interaction with the 
sulfate ion (Fig. 3-1c). Nevertheless, the structural data clearly indicate that in the 
absence of CoA the active sites are occupied by sulfate ions. 
 
The binary complex of AcpS and CoA 
 The CoA-bound C. ammoniagenes AcpS structure was solved by molecular 
replacement. This binary complex crystallized in space group P1 and contained six 
monomers arranged as two groups of trimers. In the AcpS–CoA complex density for 
ADP was very clear in each binding site and allowed unambiguous positioning of ADP. 
Superposition of the carbon backbone of native AcpS with the ADP-bound binary 
complex reveals that binding of CoA does not alter the structural conformation of the 
biological unit. The adenine ring of ADP fits between the β2 and β3 loops, consisting of 
residues 108–112 of subunit A and residues 81–86 of subunit B of the AcpS trimer. The 
adenine base is immobilized by a network of interactions created by Ser81, Trp108 and 
Gly109 (Fig. 3-5). The ribose is present in the 3'-endo conformation, with axial 
orientation of the 2'-hydroxyl group and equatorial orientation of the 3'-phosphate group. 




interactions, specifically with the imidazole rings of His65 and His138, and His46 and 
Arg69 make contacts with the 3'-phosphate through a water molecule. The 5'-α-
phosphate is packed against the β1 strand and the α3 helix of the second molecule and is 
positioned within hydrogen-bonding distance of the main chain of His105, the N
ε
 group 
of Lys78 and the hydroxyl group of Ser137. The 5'-β-phosphate group of CoA does not 
interact with any of the protein residues. The 4'-ppt arm and the β-mercaptoethanol-
binding pocket extend away from the adenine base and are surrounded by mostly hydro-
phobic residues, specifically Ile77B, Pro93B, Phe98B and Trp108A. The involvement of 
the imidazole rings of His65 and His138 in CoA binding probably contributes to the 
strict pH-dependence of AcpS activity. 
 
Mtb AcpS can selectively transfer BODIPY-labeled CoA to Mtb apo-ACP 
 The activity of Mtb AcpS in post-translational modification of apo-ACP was 
assessed. We incubated recombinant Mtb AcpS with BODIPY-labeled CoA (a 
fluorescent dye is attached to the sulfhydryl group of CoA) and apo-ACP and an aliquot 
of the reaction was analyzed by SDS–PAGE. When the SDS gel was viewed under a UV 
illuminator, the post-translationally modified holo-ACP was visualized as a fluorescent 
band with the expected molecular size. The fluorescent SDS gel clearly demonstrated 
that Mtb AcpS was able to transfer the 4'-phosphopantetheine arm to ACP upon 
incubation with BODIPY-CoA and Mtb apo-ACP. We used two different concentrations 
of AcpS, 0.2 and 2 µM, and the fluorescence intensity of holo-ACP clearly showed that 




(Fig. 3-6a). Similarly, AcpS was pre-incubated with unlabeled CoA and then assessed 
for post-translational modification activity in the presence of BODIPY-CoA and apo-
ACP. The result shows that the fluorescence intensity decreases upon pre-incubation 
with CoA, as part of the holo-ACP contains nonfluorescent 4'-phosphopantetheine and 
part contains fluorescent BODIPY-4'-phosphopantetheine (Fig. 3-6a). Owing to the 





Figure 3-5. ADP binds in the dimer interface between two subunits. The active-site 
residues of one subunit are colored yellow, those of the second subunit are colored 









Figure 3-6. AcpS post-translational modification activity assay. (a) Lane M, molecular-
weight markers; lane 1, 0.2 µM AcpS; lane 2, 2 µM AcpS; lane 3, pre-incubation of 
AcpS with CoA; lane 4, incubation with PKS11; lane 5, incubation of AcpS and 
BODIPY-CoA alone. (b) Mtb AcpS activity was assessed from pH 3.4 to pH 8.0. The 






 Next, we assessed the specificity of the AcpS post-translational modification 
activity. PKS11 was used as a negative control since it is not a substrate of AcpS in vivo. 
In this experiment, we incubated Mtb AcpS with BODIPY-labeled CoA and Mtb PKS11 
in order to determine whether AcpS is able to transfer 4'-ppt to PKS11 (as this protein 
has a malonyl-CoA-binding tunnel). Mtb AcpS was unable to transfer the 4'-ppt moiety 
to PKS11 despite the presence of a CoA-binding tunnel, which demonstrates the 
specificity of AcpS. This experiment shows that Mtb AcpS is functionally active and is 
able to convert apo-ACP to holo-ACP. The crystal structure reveals that Mtb AcpS 
adopts one conformation at low pH and a different conformation at higher pH. This led 
us to assess the post-translational modification activity of AcpS at different pH values 
from 3.4 to 8.0. The fluorescence SDS gel clearly shows that AcpS is unable to transfer 
the 4'-ppt arm to ACP at lower pH values (3.4–4.0), but it is able to transfer the 4'-ppt 
arm to ACP at pH 4.4–8.0. However, the relative florescence intensity was higher 
between pH 4.4 and 6.0 compared with pH 6.6–8.0 (Fig. 3-6b). Recently, the Mtb FAS-I 
enzyme has been expressed and purified from E. coli and a reconstitution experiment 
showed that the FAS-I enzyme was inactive. In contrast, co-expression of the Mtb FAS-I 
enzyme with Mtb AcpS (in a duet vector) resulted in a FAS-I enzyme which was 
biochemically active (Qingan & Sacchettini, unpublished work). During co-expression, 
Mtb AcpS post-translationally modifies the ACP domain of the FAS-I enzyme via a 
CoA-derived 4'-ppt group. It is evident that AcpS modifies the ACP domain of FAS-I as 





Comparison of the B. subtilis AcpS–ACP complex with a proposed model of the 
Mtb AcpS–AcpM complex 
 ACP is a key component in both fatty-acid biosynthesis and polyketide 
biosynthesis. Initially, ACP is post-translationally modified by AcpS. During this 
process, AcpS recognizes the conserved Asp-Ser-Leu motif in apo-ACP and transfers 
the 4'-ppt moiety from CoA to a serine residue. The crystal structure of the B. subtilis 
AcpS–holo-ACP complex has been reported (Parris et al., 2000). In B. subtilis the 
Arg14, Arg21, Arg22 and Arg28 residues of AcpS interact with the Asp38 and Glu46 
acids of holo-ACP. Multiple sequence alignments indicate that Mtb AcpS does not 
contain an Arg residue in the N-terminal region (residues 14, 21, 22 and 28); rather, it 
contains Asp, Gln and Glu in place of Arg (Fig. 3-7a). C. ammoniagenes AcpS has 
similar residues to those of Mtb AcpS, with the exception of the Arg22 residue. In 
contrast, the ACP amino-acid sequence alignment indicates that the EKS, DED and 
IPDED motifs and the 4'-ppt-binding motif (DSL) are highly conserved in all bacteria. In 
B. subtilis, the conserved residues of ACP interact with AcpS. In order to understand the 
interaction between AcpS and AcpM in Mtb, we superimposed the Mtb AcpS structure 
(the current model) and the AcpM NMR structure (PDB entry 1klp; (Wong et al., 2002); 
residues 1–90) with the B. subtilis AcpS–holo-ACP complex structure (Fig. 3-7a). The 
superimposed model of the AcpS–holo-ACP complex was energy-minimized using the 
Discovery III suite of the INSIGHT II software. The complex shows that the location and 
orientation of Mtb ACP are very similar to those of B. subtilis ACP; however, the 




Glu77 and Arg81 of AcpS are responsible for Mtb ACP binding. In particular, AcpS 
residues Ser45, Arg48 and His49 are close enough to interact with Asp38 of ACP (Fig. 
3-7b). The conserved IPDED motif of ACP is sufficiently near to form a hydrogen-
bonding network with Glu77 and Arg81 of AcpS. Another conserved residue, Asp46, of 
ACP is close enough to interact with Glu19 and Gln22 of AcpS. The minimized AcpS–
AcpM model shows that Arg48 and His49 of AcpS are at a favorable distance to interact 
with AcpM residues in addition to binding CoA or ADP. This model contains residues 
1–90 of ACP but does not address the role of the C-terminal region of ACP and its 
interaction with AcpS. We are currently working to produce an ACP–AcpS complex to 
answer these questions. 
 
 
         
Figure 3-7. Comparison of AcpS-AcpM complex. (a) Structural superposition of AcpS–holo-
ACP from B. subtilis with Mtb AcpS and the solution structure of AcpM. (b) The interacting 
residues of Mtb AcpS and AcpM are shown as stick models. ACP occupies the space between 





Figure 3-7. Continued 
 
CONCLUSIONS 
 We have determined the structures of both apo-AcpS and AcpS in complex with 
CoA from Mtb and C. ammoniagenes and have found that AcpS adopts different pH-
dependent conformations. The active sites of the apo-AcpS and CoA-bound AcpS 
structures show that His49 and His116 (His65 and His136 in C. ammoniagenes) 
participate in either sulfate binding or CoA binding. The fluorescence assay 
demonstrates the functionality of AcpS, which converts apo-ACP to holo-ACP. The 
structural differences observed between Mtb AcpS and C. ammoniagenes AcpS may be 
essential for interaction with ACP. Finally, the structural basis of AcpS–ACP 
interactions in the Corynebacterium subgroup is fundamentally different from the 




ADDITIONAL UNPUBLISHED RESULTS 
 
 Mtb AcpS represents an attractive target for inhibitor discovery as it is critical for 
the activation of FAS-I and FAS-II systems in Mtb (Chalut et al., 2006). To identify 
novel chemical scaffolds that can be developed as leads we have applied a fragment-
based ligand discovery (FBLD) approach. The FBLD paradigm requires relatively 
smaller number of compounds (hundreds to few thousands) in contrast to conventional 
high-throughput screening, to sample large chemical space enabling rapid and efficient 
identification of small molecular-weight (Mr ~ 120-250) chemical fragments that can 
serve as starting points for lead generation and drug development (Rees et al., 2004). 
Differential scanning fluorimetry (DSF) is particularly suited for fragment screening in a 
high-throughput manner as it is an inexpensive and efficient technique for identifying 
small ligands that bind to the target protein (Niesen et al., 2007). In DSF, thermal 
unfolding of proteins in presence of ligands is monitored using fluorescent dyes that 
fluoresce highly upon interaction with the exposed hydrophobic sites on the unfolded 
protein, by using a real-time PCR instrument (Fig. 3-8). DSF enables efficient detection 
of ligands that bind and stabilize a protein as they cause a rightward shift in the thermal 
unfolding curve of the protein with a concomitant increase in its melting temperature 








Figure 3-8. Schematic representation of DSF experiment. SYPRO orange (three ring 
molecule) has low fluorescence when the globular protein (spherical shape) is folded at 
the room temperature. The protein begins to unfold as the temperature increases, 
exposing its hydrophobic patches (grey) which interact with SYPRO orange causing an 
increase in fluorescence intensity. As the protein continues to unfold, the fluorescence 
also increases until it reaches a peak, and then it declines due to aggregation and 
precipitation of the denatured protein.  Figure adapted from Niesen et al., Nat Protoc. 





















Figure 3-9. Typical fluorescence intensity plots from DSF. (a) Fluorescence intensity 
plotted as a function of temperature from raw amplification data gives a sigmoidal curve. 
The melting temperature (Tm) is calculated by fitting the data to Boltzmann equation. (b) 
Another representation of the fluorescence intensity data from DSF plotted as a first 
derivative plot. This simple method is implemented in most RT-PCR data analysis 
software packages in which Tm is calculated by determining maximum of the first 





Fragment based screening for ligands of Mtb AcpS 
  To establish a hit selection criteria, AcpS was characterized by DSF to determine 
its melting temperature (Tm) both without and with its ligand CoA. AcpS alone had an 
average Tm of 50 °C, whereas in the presence of CoA the average Tm increased to 68 °C 
(∆Tm of 18 °C) (Figs. 3-9a and 3-9b). For fragment screening, a total of 780 compounds 
from an in-house fragment library (obtained from Chris Abell lab at University of 
Cambridge) were screened for binding to AcpS by DSF. The primary screen yielded 24 
fragments that caused the melting temperature of AcpS to increase by more than 3 °C 
(Table 3-4). To confirm the binding of the hits from the primary screen, 6 out of the 24 
hit compounds were repurchased based on their commercial availability, and tested by 
re-screening AcpS at different concentrations of the compounds using DSF.  This 
titration assay confirmed 4 of the compounds as valid and reproducible hits (Fig 3-10). 
These fragments will serve as initial scaffolds for the design of more potent leads against 
Mtb AcpS with structure guided rational chemical modifications. Further, as more 
fragments become available, they will also be validated by titration assay and put into 







Figure 3-10. A representative plot of the compound titration assay. Concentration-
dependent increase in the thermal stability of AcpS confirms the compound 1 (shown in 
line diagram) as a valid hit.   
 
 




Hit fragment identified by DSF 
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ADDITIONAL UNPUBLISHED EXPERIMENTAL METHODS 
 
Differential scanning fluorimetry (DSF) of Mtb AcpS 
The DSF experiments were performed in 96-well PCR plates using Stratagene 
Mx3005P RT-PCR system. For fragment screening, 19 µL of AcpS master-mix 
containing 4 µM AcpS in 0.2 M MES, pH 5.2 buffer with 4 mM MgCl2, and 2.5x 
SYPRO orange (Life Technologies) was dispensed in 96-well assay plates. To this 1 µL 
of compounds from the fragment library were added and mixed well. Then the plates 
were sealed and spun at 300g for 1 min to make sure no bubbles were trapped and no 
solution was sticking to the walls. As a positive control, 40 µM CoA was included in 
each assay and 1 µL DMSO was added to all the control wells since the fragment 
compounds were dissolved in 100% DMSO. The data from the assay was analyzed using 
MxPro v4.10 software that came pre-installed with the instrument. 
The compound titration assays for validating the primary screen hits were done 
in 96-well PCR plates as was done for the initial screen. The reaction mix contained 4 
µM AcpS in 0.2 M MES, pH 5.2 buffer, 2.5x SYPRO orange dye and varying 
concentrations of the selected hit compound in a total volume of 20 µL. The compounds 
were dissolved in 100% DMSO and the final concentration of DMSO in the reaction mix 
was 5%. Two types of controls were also setup for the assay- one without CoA and the 
other with 40 µM CoA, and both of these control reactions also contained 5% DMSO. 
All the reactions were setup in duplicates and a total of 6 compounds were tested at 4 






Prospects for PPTases as targets for inhibitor discovery  
In microorganisms, PPTases are essential enzymes that activate carrier domains 
on proteins involved in primary and secondary metabolic pathways that produce a wide 
variety of pathogenesis related virulence factors and toxins (Lambalot et al., 1996). 
Some of the representative virulence factors from pathogenic organisms include 
complex lipids PDIM and mycolic acids of Mtb cell wall, toxin mycolactone from M. 
ulcerans, and siderophores such as mycobactin in Mtb or pyoverdine in P. aeruginosa 
(Kosa et al., 2014). Thus, as a result of their involvement in host viability and virulence, 
PPTases have started to attract attention as promising new targets for drug development 
(Joseph-McCarthy et al., 2005), especially against the pathogens that have developed 
significant clinical drug resistance and threaten health-care efforts worldwide. For 
example, Mtb is among the top threats to global health for which there is an urgent need 
to identify drugs that can shorten treatment duration, and are also active against MDR 
and XDR strains. In Mtb, PPTases participate in activation of carrier domains in >20 
proteins belonging to FAS I & II, PKS and NRPS systems (Cole et al., 1998). These 
enzyme systems synthesize a diverse array of complex lipids that are essential for the 
viability, virulence and pathogenicity of Mtb (Neyrolles and Guilhot, 2011). Therefore, 
discovery and development of inhibitors of the two non-redundant PPTases in Mtb offers 
attractive prospects for the development of novel broad-spectrum anti-tubercular drugs 




other mycobacterial pathogens such as M. leprae, M. avium and M. ulcerans also have 
orthologs of the two Mtb PPTases, suggesting that the inhibitor discovery efforts can be 
extended to include these pathogens too.  
However, despite the knowledge of the essential nature of this family of 
enzymes, only a limited number of studies have been done for inhibitor screening and 
development targeting these enzymes. The major reason for this has been lack of a 
simple and robust PPTase assay that is adaptable to automated high-throughput 
screening of compound libraries. The traditionally used assays for the PPTase activity 
have utilized technically complex HPLC or radiolabelling and involved cumbersome 
treatment steps (Chalut et al., 2006). To overcome these limitations, recently many 
spectrophotometry based assays that are suitable for HTS have become available for 
screening PPTases. Two studies have reported development of fluorescence based assays 
that use fluorescence resonance energy transfer (FRET) (Yasgar et al., 2010) and 
fluorescence polarization (FP) techniques (Duckworth and Aldrich, 2010) to 
spectrophotometrically monitor the PPTase activity. These assays utilized fluorescent 
CoA conjugates for HTS of PPTase Sfp from B. subtilis, and the FRET-based method 
was successfully used to screen a LOPAC
1280
 library of bioactives for inhibitors of Sfp 
(Yasgar et al., 2010). Furthermore, another study reported the use of blue pigment 
indigoidine synthesizing, single module NRPS BpsA as a reporter for assessment of 
PPTase activity in a HTS (Owen et al., 2011). These developments have enabled rapid 
screening of promiscuous Sfp-type PPTases, however, they have not been adopted for 




natural substrates as they required fluorophore labeled substrates, modifications of these 
methods have been reported that allow direct and continuous assay measurements (Kosa 
et al., 2014). 
More recently, a scintillation proximity assay (SPA) using radiolabeled CoA for 
HTS was reported for Mtb PPTase PptT (Leblanc et al., 2012). Moreover, we have used 
DFS to screen a fragment library in a high-throughput manner to identify compounds 
that bind Mtb AcpS, suggesting that DSF is also amenable for HTS of compound 
libraries. In addition, we have successfully demonstrated transfer of a fluorescent label 
on acyl carrier protein AcpM, the natural substrate of AcpS in Mtb, so this in vitro assay 
can be also used for the HTS of inhibitors, or to validate hits from the DSF screens. 
Availability of these simple and robust assays for HTS will facilitate anti-Mtb inhibitor 
discovery, and coupled with the structural information reported in this chapter, the 
identified inhibitors can be improved through structure-guided rational development.       
 
       












TARGETING Mtb PKS13 THIOESTERASE DOMAIN FOR 




Tuberculosis (TB) continues to be a major health problem worldwide. 
Emergence of multidrug-resistant Mycobacterium tuberculosis (Mtb), the etiologic agent 
for TB, has created an urgent need for the discovery and development of new 
antitubercular drugs that are effective against the drug-resistant bacteria. We report here 
biochemical and structural studies detailing mechanism of inhibition by a novel 
benzofuran class inhibitor that was found to inhibit Mtb growth. Our studies establish 
that the inhibitor has a unique mode of inhibition whereby it targets the thioesterase 
activity of the essential mycolic acid condensing enzyme Pks13 in Mtb. Structure of the 
Pks13 thioesterase domain in complex with the inhibitor revealed important interactions, 
and studies with analogs led to the identification of structural features required for 
effective inhibitors. Two mutations, D1607N and D1644G, conferred resistance to the 
thioesterase domain against inhibition by the benzofuran compound, further confirming 
it as the target of the compound. Structure of the D1607N mutant allowed us to 
determine molecular basis for the mechanism of resistance. This study identifies a novel 




discovery. The structural studies reported here provide a platform for structure-based 




 The mycolic acid biosynthesis pathway is well-establish to be an essential 
pathway for survival of M. tuberculosis.  A number of clinically-used drugs target genes 
on this pathway, including the first-line drug isoniazid, as well as ethionamide.  M. 
tuberculosis is the causative agent of tuberculosis, which causes more than 1.5 million 
deaths annually, and for which drug resistance, including multi-drug resistance, has 
become an increasing problem worldwide.  Like other mycobacteria, M. tuberculosis 
produces a waxy outer cell-wall layer of very-long-chain fatty acids called mycolic 
acids, and disruption of mycolic acid synthesis is lethal.  Isoniazid targets the enoyl-acyl-
ACP reductase (InhA) enzyme that one of several proteins of the FAS II system 
participating in the elongation of long-chain (C40-C60) fatty acid components of 
mycolic acids (after being activated by catalase-peroxidase (KatG) and forming an 
adduct with NADH) (Banerjee et al., 1994).  However, resistance to isoniazid is 
increasingly observed and is currently estimated at around 5% worldwide (including 
both monoresistance as well as MDR/XDR-TB). 
We recently reported the identification of a benzofuran-based compound from a 
whole-cell screen that targets polyketide synthase Pks13, a different enzyme in mycolic 




mutants revealed resistance mutations in the thioesterase domain of Pks13. Pks13 is a 
large, multi-modular polyketide synthase that performs the final condensation of a long-
chain (C40-C60) fatty acid (synthesized by the FAS II system) with a ~C26 fatty acid 
(synthesized by the FAS I system) to form an alpha-hydroxy meromycolate.  Pks13 is 
essential in vitro, but is not targeted by any existing drugs in clinical use, making this a 
promising route for development of new drugs that interfere with the sensitive pathway 
of mycolic acid synthesis.    
 Pks13 is comprised of five domains that harbor all the activities required for the 
single round of condensation of the two long fatty-acyl chains. Pks13 has two acyl 
carrier protein domains, ACPN and ACPC, a β-ketoacyl-synthase (KS), an acyltransferase 
(AT) and a C-terminal thioesterase (TE) domain.  The two ACP domains accept distinct 
substrates – the ACPN accepts activated meroacyl-AMP from FadD32 and transfers it to 
the KS domain, and the ACPC is loaded with 2-carboxyacyl-CoA chain by the AT 
domain. The KS domain then performs the Claisen-type condensation to produce α-alkyl 
β-ketoester attached to the ACPC which is then released by the TE domain for 
subsequent modification reactions (Takayama et al., 2005).  Recently, a pyrrole-based 
compound identified through another high-throughput screen, with an MIC of 0.5 uM 
against H37Rv, was proposed to inhibit the N-ACP domain of Pks13 (Wilson et al., 
2013), adding evidence that chemical inhibition of this enzyme, which is a critical step 
in the mycolic acid biosynthesis pathway, is lethal to M. tuberculosis. 
 Herein, we report the biochemical and structural validation of  the Mtb Pks13 




based on compound 1 (Fig. 4-1). We confirmed the inhibition of TE activity by 1 
biochemically, and we determined the binding mode by solving the crystal structure of 
the Pks13 TE domain in complex with 1. We performed a preliminary structure-activity 
relationship (SAR) study by testing several structural analogs of 1 for enzyme inhibition 
and whole cell activity. Furthermore, we solved the structures of four of these analogs in 
complex with the TE domain to identify structural requirements for active inhibitors 
against the Pks13 TE domain. In addition, to elucidate the mechanism of resistance, we 
also solved the structure of mutant forms of the TE domain. Our structural analysis of 
Pks13 and the sensitivity of mycobacterial cells to its chemical inhibition show that it 
has the potential to make a good platform for development of new inhibitors of the well-















Cloning and overexpression of Mtb Pks13 TE domain constructs 
The TE domain constructs corresponding to the predicted TE domain in Mtb 
Pks13 gene (Rv3800c) were made by PCR from the Mtb H37Rv genomic DNA as the 
template. The amplified DNA fragments were incorporated into the pMCSG-19b vector 
by ligation independent cloning (LIC) to yield TEV protease cleavable N-terminal His6-
tagged TE domain constructs(Donnelly et al., 2006). The TE-pMCSG-19b vectors were 
transformed into E. coli BL21(DE3)pLysS cells (Novagen) and the transformed cells 
were grown at 37 °C in LB media containing carbenicillin (100 µg/ml) and 
chloramphenicol (34 µg/ml) to an OD600 of 0.6. Expression of TE constructs was 
induced with 0.5 mM IPTG, and cells were harvested after 16 hours of growth at 20 °C.  
The D1607N and D1644G mutants of Pks13 TE domain were constructed using the 
QuikChange site-directed mutagenesis kit (Stratagene). The mutations were confirmed 
by DNA sequencing. Mutant plasmids were transformed into E. coli BL21(DE3)pLysS 
cells, and mutant proteins were expressed by induction with 0.5 mM IPTG at 20 °C for 
18 h. 
 
Purification of Pks13 TE domain 
The harvested cells were resuspended in the lysis buffer (50 mM Tris-HCl pH 
8.0, 0.5 M NaCl, 10% (v/v) glycerol, 1 mM β-mercaptoethanol (BME) and DNase) and 




x g at 4 °C) for 1 hour. The cleared supernatant was loaded onto a Ni-affinity column 
and the His-tagged TE domain constructs were eluted with a linear gradient of 10-250 
mM imidazole in 20 mM Tris-HCl, pH 8.0 and 0.5 M NaCl. The peak fractions were 
pooled and the His-tag was cleaved by overnight incubation with TEV protease in 
dialysis buffer (20 mM Tris-HCl pH 8.0, 10% (v/v) glycerol and 1 mM DTT). The TEV 
cleaved protein was passed through Ni-column to remove any uncleaved His-tagged 
protein using 20 mM Tris-HCl (pH 8.0) with 100 mM NaCl and 1 mM BME. His-tag 
cleaved protein eluted in the flow-through and was concentrated for loading onto a 
Superdex-200 gel filtration column (GE Healthcare). The TE domain constructs eluted 
under a single peak as a monomer (~32 kDa) from the gel filtration column and were 
>95% pure as observed by SDS-PAGE. The purified protein was concentrated to 20-25 
mg/ml, flash-frozen and stored at -80 °C. The TE domain mutants were purified using 
the same protocol as for the wild-type TE domain constructs. Both the mutants and the 
wt TE domain protein constructs have the amino acids SNA from the TEV cleavage site 
appended to the N-terminus. 
 
Crystallization and soaking with ligands 
Initial screening for crystallization conditions for the soluble TE domain 
constructs was done by sitting drop method using 1 µl of purified protein (15-20 mg/ml) 
and 1 µl of crystallization buffer from the well solution. After extensive screening, 
crystals were obtained for only the 283 residue long construct of the TE domain starting 




crystals were obtained in crystallization buffer containing 0.1 M Tris-HCl, pH 8.5 and 
2.0-1.8 M ammonium sulfate as precipitant. The crystals were further optimized by 
using polypropylene glycol P-400 as an additive at 2%-5% (v/v) in the original 
condition. To obtain TE1451-inhibitor complex crystals, soaking of the inhibitors was 
done by transferring apo-TE1451 crystals into a drop consisting of 0.1 M Tris-HCl, pH 
8.5 and 2-2.2 M ammonium sulfate with 1-2.5 mM inhibitor added from a DMSO stock 
keeping the final DMSO concentration at <5%, and incubated at 18 °C and 4 °C for 4-20 
hours. 
Crystals of the TE11451:D1607N mutant were obtained by sitting drop method 
at 18 °C. The crystallization drops contained an equal volume of the protein solution 
(15-20 mg/ml) and mother liquor (0.1 M HEPES, pH 7.5, 2%-4% (v/v) PEG 400, and 
1.8-2 M ammonium sulfate), and the diffraction quality crystals were obtained within 2 
weeks. 
 
 Data collection and processing 
For diffraction data collection the crystals were cryo-protected using either 
Fomblin (Sigma) or 2.4 M malonate (Hampton Research) and flash frozen in liquid 
nitrogen.  High resolution data was collected at a wavelength of 0.98 Å on the beamlines 
19-ID and 23-ID at the Advanced Photon Source (APS) of the Argonne National 
Laboratory. All the data sets were processed and scaled with HKL2000 (Otwinowski and 
Minor, 1997). Analysis of the integrated and scaled data by Xprep indicated that TE1451 




indicated the presence of two molecules (VM 2.16, VS 43.2%) in the asymmetric unit 
(Matthews, 1968). 
 
Determination of TE1451 structures and model refinement 
The structure of the TE domain was solved by molecular replacement method 
(MR) using E. coli EntF (PDB entry 3TEJ), as search model. A single MR solution was 
obtained using Phenix AutoMR(Adams et al., 2010) which was input into the AutoBuild 
wizard to generate the initial model for apo-TE1451. The initial model was improved by 
further manual rebuilding in COOT (Emsley and Cowtan, 2004). The final model was 
obtained after iterative cycles of model building and Phenix refinement with simulated 
annealing yielding a 1.72 Å resolution apo-TE1451 model with Rcryst of 17% and an Rfree 
of 20% with good stereochemistry (Table 4-1). The final refined apo-model has two 
chains, designated A and B, and 388 water molecules in the asymmetric unit.  
To solve the TE1451-inhibitor complex structures, as well as the D1607N mutant 
structure, only the protein atoms from chain A of the apo-TE1451 structure were used as 
search model in the initial rigid body refinement of the isomorphous P21212 crystals in 
the Phenix Refine module. Inspection of electron density maps showed clear |Fo-Fc| 
positive difference density for the ligands which were fit into the density using Ligandfit 
routine in Phenix (Terwilliger et al., 2006). The ligand model and geometry restraint 






Table 4-1. Data collection and refinement statistics for TE1451. 
 ApoTE1451 TE1451:1 TE1451(D1607N) 
Data collection    
Space group P21212 P21212 P21212 
Cell dimensions    
    a, b, c (Å) 88.5, 106.7, 57.7 89.2, 109.5, 57 88.7, 108.9, 58.1 
 ()  90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å) 39.19-1.72 (1.78-1.72)* 50-1.94 (1.97-1.94) 
 
44.36-1.88 (1.95-1.88) 
Rmerge 0.089 (0.508) 0.172 (1.78) 0.141 (1.44) 
I / I 23.81 (4.33) 18.8 (2.3) 8.64 (0.53) 
Completeness (%) 99.34 (96.09) 94.67 (93.29) 92.47 (59.25) 
Redundancy 7.6 (6.7) 6.6 (5.2) 4.9 (2.9) 
    
Refinement 
   
Resolution (Å) 1.72 1.94 1.88 
No. reflections 58442 40142 42956 
Rwork / Rfree 0.17/0.20 0.19/0.23 0.18/0.22 
No. atoms    
    Protein 4277 4217 4257 
    Ligand/ion 27 63 44 
    Water 388 210 309 
B-factors    
    Protein 22 47 35 
    Ligand/ion 31 48 54 
    Water 28 45 40 
R.m.s. deviations    
    Bond lengths (Å) 0.011 0.007 0.014 
    Bond angles () 1.35 1.17 1.44 
Data from 1 crystal was used to solve each structure. 
 *Values in parentheses are for highest-resolution shell. 
 
 
Iterative cycles of model building and NCS-restrained maximum likelihood 
refinement with simulated annealing in Phenix refine yielded high quality models for 
TE1451-inhibitor complexes (Table 4-2). Since the thioesterase domains have many 




built into the model due to the missing electron density and some residues are modeled 
as alanine due to ambiguous side chain electron density.  In all of the structures >98% of 
residues are placed in the favoured region of the Ramachandran plot as determined by 
MolProbity(Chen et al., 2010) validation tool in Phenix. 
 
Enzyme assay 
Activity of TE1451 was assessed using 4-methylumbelliferyl heptanoate (4-
MUH, Sigma) as a fluorogenic substrate in a 96-well plate format (Richardson and 
Smith, 2007). To make initial velocity measurements, TE1451 (1 µM) in 0.1 M Tris-
HCl, pH 7 buffer was incubated with different concentrations of 4-MUH (2-150 µM in 
DMSO) in a 100 µl reaction volume, and the fluorescence of the hydrolyzed product 4-
methylumbelliferone was read (Ex at 355 nm and Em at 460 nm) using PolarStar Omega 
plate reader (BMG Labtech) at 5-10 min intervals over 60-70 min. The reaction rate was 
observed to be linear in the measured range. 4-MUH in buffer alone was included as a 
control to quantify its background hydrolysis. Data points were plotted as an average of 
triplicates and each experiment was repeated 2-3 times independently. The initial 
velocity data was curve fit to Michaelis-Menten equation by nonlinear regression using 
Prism software (Graphpad) to determine the kinetic parameters Km and Vmax. The assay 
and data analysis for TE1451 mutants was done the same way as that for the wild-type 







Table 4-2. Data collection and refinement statistics for analogs of 1. 
 TE1451:3 TE1451:4 TE1451:5 TE1451:6 
Data collection     
Space group P21212 P21212 P21212 P21212 
Cell dimensions     
    a, b, c (Å) 89.4, 109.4, 56.9 89, 110.2, 57.5 88.9, 109.7, 57.4 88, 109.4, 57 
 ()  90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 








Rmerge 0.114 (1.15) 0.158 (2.01) 0.153 (1.04) 0.124 (0.936) 
I / I 14.1 (1.5) 9.0 (0.8) 11.5 (1.6) 9.9 (1.3) 
Completeness (%) 87.8 (84.4) 87.8 (84.9) 94.0 (91.6) 99.0 (93.9) 
Redundancy 5.2 (4.5) 4.3 (3.7) 5.5 (4.6) 4.3 (4.1) 
     
Refinement     
Resolution (Å) 1.99 2.04 2.05 1.99 
No. reflections 34387 32201 33776 38083 
Rwork / Rfree 0.20/0.24 0.21/0.24 0.20/0.24 0.19/0.21 
No. atoms     
    Protein 4232 4238 4203 4235 
    Ligand/ion 54 34 28 50 
    Water 156 102 218 390 
B-factors     
    Protein 44 56 34 34 
    Ligand/ion 33 79 33 29 
    Water 45 53 34 38 
R.m.s. deviations     
    Bond lengths (Å) 0.009 0.005 0.007 0.008 
    Bond angles () 1.27 0.95 1.10 1.12 
Data from 1 crystal was used to solve each structure. 
 *Values in parentheses are for highest-resolution shell. 
 
 IC50 determination 
 To determine the potency of 1 and its analogs against wt TE1451, the 
compounds were tested at concentrations ranging from 0.012 to 20 µM in a 96-well plate 
format. The reaction mix contained 1 µM TE1451 in 0.1 M Tris-HCl, pH 7 buffer with 1 




was initiated by addition of 1 µl of 2 mM 4-MUH in DMSO (20 µM final, equal to its 
Km for TE1451) to the reaction mix. Initial velocity data was obtained by monitoring 
increase in the fluorescence due to hydrolysis of the substrate using PolarStar Omega 
plate reader at 10 min intervals over 60 min. The data points were collected in triplicate 
and the averaged value was used to generate concentration-response plots for 1 and its 
analogs. The IC50 value for each compound was obtained by nonlinear regression curve 
fitting of a four-parameter variable slope equation to the dose-response data using Prism 
software. The IC50 values of 1 for TE1451 mutants were determined in the same way as 
that for wt TE1451, however, the testing concentration of 1 ranged from 0.04 to 40 µM 
and the substrate 4-MUH was used at 20 µM for ease of comparison. 
  
Whole cell and cytotoxicity testing 
 Whole cell testing for determining MIC was done using Alamarblue assay in 96-
well plates (Franzblau et al., 1998). Mtb mc
2
-7000 strain cells (Sambandamurthy et al., 
2006) were grown in 7H9 media supplemented with OADC (Middlebrook), 0.05% 
Tyloxapol (Sigma), and 25 mg/ml pantothenate to an OD600 of 1–2. The cells were then 
diluted into testing media (7H9 media with 0.2% dextrose, 0.085% NaCl, 0.05% 
Tyloxapol, and 25 mg/ml pantothenate) to an OD600 of 0.01 and dispensed into testing 
plates at 200 µl per well. Then the compounds were added as a 2-fold serial dilution in 
DMSO (2% DMSO final in each well). The test plates also had a DMSO only control 
and a Rifampicin control. The plates were incubated with shaking at 37 °C for 6 days 




the fluorescence of reduced resazurin was read (Ex 544 nm, Em 590 nm) using PolarStar 
Omega plate reader. The fluorescence data were plotted as percent growth inhibition 
against the compound concentration and curve fitting was done by nonlinear regression 
using Prism software. Minimum inhibitory concentration (MIC) values were determined 
from the fitted curves.  
  Compounds were tested for toxicity by the Human Dermal Fibroblast (HDF) 
cytotoxicity assay. HDF cells were purchased from ATCC (Manassas, VA).   The cells 
were cultured in DMEM (Lonza) media supplemented with 10% fetal bovine serum 
(Lonza) and penicillin/streptomycin (Lonza).  For setting the cytotoxicity assay, 
compound stocks were serially diluted in phosphate buffered saline (PBS) plus 10% 
DMSO.  On the day of assay, HDF cells were trypsinized, counted and resuspended at a 
concentration of 64,000 cells/ml in the media.  Cells were plated, overlaid with the 
compound serial dilutions and incubated at 37 °C.  After 48 h, resazurin dye was added 
and the assay plates were cultured for another 24 h.  The next day the absorbance of the 
resazurin was measured on a microplate reader (BMG Labtech) to assess cell death.   












Discovery of benzofuran 1 and identification of Pks13 as its target using forward 
chemical genetics 
  The benzofuran 1 was identified from a whole-cell screen for growth inhibition 
of Mtb strain H37Rv (Ioerger et al., 2013).  The minimum inhibitory concentration 
(MIC) of 1 was determined to be 2.0  against H37Rv. To identify the molecular 
target of 1, spontaneous resistant mutants of Mtb were selected on agar plates with the 
concentration of 1 at 8x the liquid MIC (16 . Sequencing of the genome of four 
resistant colonies identified only non-synonymous single nucleotide polymorphisms 
(SNPs) in the pks13 gene. These SNPs result in two different amino acid substitutions in 
the TE domain region of the Pks13 protein: D1644G (one isolate) and D1607 (three 
isolates). Recombineering (oligo-mediated transfer of SNPs into the parental strain) was 
used to confirm that each SNP alone was sufficient to confer Mtb six- to eight-fold 
increased resistance to 1 (Ioerger et al., 2013).  
Three different recombinant expression constructs encompassing different start 
and stop sites for the TE domain of Mtb Pks13 were designed based on the sequence 
alignments and the secondary structure from homologs. These were cloned into E. coli 
recombinant vector and tested for expression. One of the three protein constructs 
encompassing the residues 1400-1733 of Pks13 expressed His6-tagged protein that was 
soluble even after removal of the tag. This construct containing residues 1451-1733 of 




appended to its N-terminus produced single diffraction quality crystals. An enzyme 
assay was developed using this purified recombinant TE domain (hereafter called 
TE1451), with a fluorescence fatty acid, 4-Methylumbelliferyl heptanoate (4-MUH) as a 
substrate (Richardson and Smith, 2007). TE1451 showed good esterase activity using 4-







3). The IC50 of 1 against TE1451 was determined to be 0.26 µM (Table 4-4). Next, in 
order to confirm the two mutations observed in isogenic resistant isolates, we expressed 
and purified the mutant proteins using an identical recombinant expression system as 
was used for the wt TE domain construct. 
 
 
Table 4-3. Kinetic parameters of wild-type TE1451 and D1607N, D1644G mutants. 






 Relative activity 
Wt. 19.5 ± 3.4 140 ± 9 x10
-4
 7.2 ± 1.3 x10
-4
 1 
D1607N  8.5 ± 0.9 105 ± 3 x10
-4
 12.3 ± 1.4 x10
-4
 1.7 
D1644G  6.9 ± 1.1 166 ± 6 x10
-4
 24 ± 3.8 x10
-4
 3.3 
*Kinetic values were obtained by fitting the raw data to Michaelis-Menten equation. All 








Table 4-4. Preliminary SAR of 1 and its analogs. 
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No binding ND 
IC50 values were determined using the Mtb Pks13 TE domain as described in the 
methods section.  MIC values were determined for mc
2
7000 in liquid medium in 96-well 






Biochemical consequences of TE domain mutations D1607N and D1644G  
The mutants (TE1451:D1607N and TE1451:D1644G) were characterized by 
determining the basic kinetic parameters (Table 4-3). Interestingly, both mutations had 
increased kcat/Km with the D1607N mutant showing an increase of ~1.7-fold and the 
D1644G >3-fold over the wt-TE1451. The D1644G mutation increased the IC50 of 1 by 
more than 66-fold from 0.26 µM to 17.4 µM against the TE domain, whereas the 





Figure 4-2. Comparison of IC50 values of 1 against wt TE1451 and D1607N, D1644G 
mutants. IC50 values were determined for the wt TE1451 and the mutants as described in 






Preliminary SAR by inhibition studies with analogs of 1 
To establish a preliminary SAR for 1 based inhibition, a pharmacophore search 
was conducted and a set of six commercially available structural analogs of 1 were 
identified and evaluated for inhibition of TE1451 activity in vitro. These analogs 
differed primarily in replacements for the piperidine ring at R3 of the benzofuran core by 
other saturated heterocycles (Table 4-4). 
The IC50 values ranged from 0.12 – 1.57 µM against the TE domain (Table 4-4). 
IC50 data shows that only 2 was more potent (0.12 µM) compared to 1 (0.26 µM) against 
TE1451. The only difference between these two positional isomeric compounds is that 
the methyl group on the piperidine ring is in para position in 1 and in meta position in 2. 
Compounds 3 and 4 have five- and seven-membered rings respectively at R3, and they 
exhibit IC50 similar to 1. However, 5 which has a six-membered morpholine ring with a 
polar oxygen atom has ~3-fold higher IC50 against TE1451 compared to 1 (Table 4-4). In 
contrast to the compounds with the cyclic amine substituents at R3, when we tested the 
compound 6 with acyclic dimethyl amine at the R3, there was >6-fold decrease in the 
inhibitory potency compared to 1. In comparison to 1 and compounds 2-6, 7 which lacks 
a group at R3 and has a morpholine ring at R2 in place of the ethyl ester, did not show 
any appreciable binding to TE1451 even at a concentration of 30 µM. Taken together, 
this SAR data suggests that the presence of a hydrophobic cyclic amine group at the R3 
position on the benzofuran core is important for potency of the compound, compared to 




We next tested the structural analogs of 1 for anti-Mtb activity in a whole-cell 
growth inhibition assay using the Mtb strain mc
2
7000 (Sambandamurthy et al., 2006). 
All the compounds which were active against TE1451 in vitro also inhibited the growth 
of bacteria to varying extents (Table 4-4). Inhibitor 1 showed the most potent inhibitory 
effect on bacterial growth, with a minimum inhibitory concentration (MIC) of 2.3 µM. 
Compounds 2, 3 and 4 had IC50 values comparable to 1 against TE1451, but they 
exhibited ~2-fold higher MICs against the bacteria. In comparison, 5 and 6 exhibited 6- 
and 3-fold higher MICs compared to 1. Interestingly, 5 had an IC50 value >2-fold lower 
than 6 against TE1451 in vitro, but in whole cell testing its MIC was ~2-fold higher than 
6. Since 5 is more polar, it is possible that this compound had reduced cell penetration 
resulting in an increase in its MIC. However, other effects like efflux or metabolism of 5 
that can lead to an increase in its MIC cannot be ruled out. 
To assess the potential of 1 and analogs that demonstrate whole cell activity (2-5) 
as suitable candidates for further development, we tested them for cytotoxicity against 
human dermal fibroblast (HDF) cells using resazurin dye assay (O'Brien et al., 2000). 
Compound 1 and analogs 2, 4 and 5 did not show any growth inhibition in HDF cells up 
to 40 µM, whereas 3 exhibited a half-maximum inhibitory concentration of >15 µM 









Figure 4-3. Cytotoxicity profile of 1 and its analogs. For cytotoxicity profile, 
compounds were evaluated by incubating with human dermal fibroblast cells as 
described in experimental methods section. The compounds were tested in a two-fold 
dilution series starting at a concentration of 40 µM. Cell growth is plotted as the percent 




Structural basis of inhibition of TE1451 by 1 
In order to understand the molecular basis of the interaction of TE1451 with 
inhibitors, we determined the crystal structures of TE1451 in apo and inhibitor 
complexed forms. 
Thin plate like crystals of apo TE1451 were obtained by vapor-diffusion method 
in a condition with ammonium sulfate as precipitant at pH 8.5. The crystals diffracted to 
a maximum resolution of 1.7 Å and they belonged to the space group P21212 with two 




TE1451 structure was determined by molecular replacement method using the crystal 
structure of the E. coli EntF (PDB entry 3TEJ) as the search model. The final apo-
structure contained molecules A and B with 278 and 272 residues built out of 283 
residues, respectively, and was refined to a resolution of 1.72 Å (Rwork = 17% and Rfree = 
20%) with good stereochemistry (Table 4-1).  
Since the  two protein molecules in the asymmetric unit show a fairly similar 
overall structure (RMSD of 1.6 Å over 264 Cα atoms) with minor differences only in the 
mobile smaller mobile lid domains (Fig. 4-4), structure of the more complete molecule A 
is hereafter used to describe the overall structure of the TE domain. The TE1451 
structure is divided into two domains (lid and core), with the larger core domain 
(residues 1451-1570, 1646-1660 and 1680-1733) possessing the canonical α/β-hydrolase 
fold comprised of a central seven-stranded β-sheet (β1- β7) flanked by four α-helices 
(α1-α3 and α11) with the N-terminal β1 strand anti-parallel to other strands (Cantu et al., 
2010; Chakravarty et al., 2004; Nardini and Dijkstra, 1999) (Fig. 4-5). The smaller lid 
domain (residues 1575-1645) is inserted between strands β5 and β6 of the core domain 
and consists of four α helices α4-α7 adjacent to the core domain.  Two small helices α8 
and α9 (residues 1665-1675) that are present on a long loop between strands β6 and β7 
of the core domain are intermediate between the core and the lid domain. Analysis of the 
TE1451 structure with VAST server (Gibrat et al., 1996) uncovered >100 structures 
belonging to thioesterase, hydrolase and lipase class enzymes with structural alignment 
scores well above the threshold of significance (VAST -log(p)>10). The top hit (VAST -




ribosomal peptide synthetase (PDB entry 2CB9) from B. subtilis. However, regardless of 
the enzyme class, the structural similarity was within the α/β-hydrolase core domain, the 
lid domain did not show significant structural conservation among the hits.  In a VAST 
search using only the coordinates of the lid domain (1575-1645), only three hits were 
returned with alignment scores well below the significance threshold (VAST -log(p)<4) 
which had no structural or functional relationship with the lid domain. This finding is 
consistent with the role of lid domains in substrate recognition and binding in a variety 
of α/β-hydrolase enzymes, which accounts for their highly variable shapes and substrate 
specificities (Tsai and Ames, 2009). 
 
 
(a)       (b) 
                  
Figure 4-4. Overall structure of Pks13 TE domain. (a) Two molecules in the asymmetric 
unit (asu) are shown as cartoons with one monomer in white and the other in orange 
color. The two monomers are related by a two-fold rotation axis. (b) Superimposed 







Figure 4-5. Overall fold and structural elements of the TE domain. The monomer 
structure is composed of two domains – lid domain (shown in cyan, comprised of helices 
α4-α9) and the core domain (shown in orange, comprised of a seven-stranded β-sheet 
and helices α1-α3, α11). The topology of the TE domain in the TE1451-1 complex 









Active site and binding mode of 1 
Active sites of all α/β-hydrolase thioesterases contain a canonical Ser-His-Asp 
catalytic triad in a conserved topology (Nardini and Dijkstra, 1999). Superimposition of 
TE1451 structure on E. coli EntF structure (PDB entry 3TEJ) helped us to identify 
Ser1533 as the active site nucleophile, and Asp1560 and His1699 as the other two 





Figure 4-6. Identification of the catalytic residues of TE1451. Structural alignment of 
TE domain (in orange) with the E. coli EntF (white, PDB code 3TEJ) structure showing 
conserved catalytic residues Ser1533, Aps1560 and His1699. The hydrogen bonding 
network between the catalytic residues is shown by black dashed lines. The nitrogen and 







The active site pocket is formed at the interface of the two domains and it is 
situated at the proximal end of a long surface groove on the lid domain. This groove 
spans the full length of the lid domain (~30 Å) with a total surface area ~1290 Å
2
, as 
calculated using the CASTp server (Dundas et al., 2006) (Fig. 4-7). The residues 
forming this hydrophobic groove are primarily contributed by the structural elements of 
the lid domain. The bottom of the groove is lined by residues from helices α4, α5, α7, 
α8, and the loop connecting α4 to α5, namely Trp1579, Tyr1582, Ile1597, Leu1602, 
Tyr1637 and Phe1670.  Residues that form the wall of the groove are contributed by 
helices α4 (Phe1585, Ala1586, Phe1590), α6 (Val1614, Val1618) and α8 (Met1669) 
along with Ile1594 from the loop connecting end of α4 to α5. A similar hydrophobic 
surface groove (~ 20 Å long) leading to the active site serine was also observed on the 
all α-helical lid domain in the crystal structure of bovine palmitoyl-protein thioesterase 1 
bound to palmitate (Bellizzi et al., 2000).  
In the apo-TE domain structure, we observed a fragment of the additive 
polypropylene glycol (C12O5H25, Fig. 4-8) bound in the active site. Thus, the structure 
strongly suggests that the surface groove presents the substrate binding site that can 
accommodate the C26 α-chain of mycolic acid and leads into the catalytic pocket formed 









Figure 4-7. Surface groove on the lid domain in TE1451 structure. TE domain in the 
TE1451-1 complex structure is shown in molecular surface representation depicting the 
surface groove on the lid domain. The colors reflect the domain division as in Fig. 4-5. 
Compound 1 is shown as sticks in magenta color. The active site residues His1699 and 
Ser1533 at the interface of the lid and the core domains are shown as ball and stick. The 
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Figure 4-8. Polypropylene glycol binding in the TE1451 active site. (a) Vertical cross-
sectional view of the active site pocket and substrate binding groove on the lid domain of 
TE1451 showing a fragment of the additive polypropylene glycol (yellow sticks) bound 
near the catalytic Ser1533. The oxygen atoms are shown in red color. (b) Chemical 













Crystals of TE1451complexed to 1 were obtained by soaking the apo-TE1451 
crystals with 1. The complex structure was determined by MR to a resolution of 2 Å 
(space group P21212 and unit cell similar to apo-TE1451) with 273 and 274 residues 
built out of a total of 283 residues for molecules A and B, respectively, and refined to a 
final Rwork = 20% and Rfree = 24% (Table 4-1). 1 binds at the mouth of the substrate 
binding groove close to the opening to the catalytic site, and thus, binding of the 
inhibitor effectively blocks access of the substrate to the active site (Fig. 4-7).  The four 
different side groups attached to the benzofuran core of 1 interact mainly with the 
residues from helix α7 of the lid domain (Gln1633, Ser1636, Tyr1637, Asn1640, 
Arg1641, Ile1643 and Asp1644) and the two supporting helices α8-α9 along with the 
loop that connects them to strand β6 of the core domain (Tyr1663, Ala1667, Phe1670, 
Glu1671 and Tyr1674) (Table 4-5). There are several changes that occur upon binding 
of 1, most notably the flipping of Phe1670 located at the end of helix α8 to form a planar 
stacking interaction (3.6-3.7 Å) with the five membered ring of the benzofuran and 
hydrophobic interactions with the core phenyl ring (Fig. 4-9). Phe1670 side chain also 
forms van der Waals interactions with the R1 phenyl ring and the ethyl group of the ethyl 
ester attached to the R3 position of 1, respectively ( ~ 4 Å). The side chains of Tyr1582 
and Tyr1637 also participate in van der Waals interactions with the phenyl ring of the 







Table 4-5. Interactions of compound 1 with the residues of TE domain.  
TE domain residue  Type of interaction  Interacting group of 1  
Phe1670  Planar stacking, 
hydrophobic  
Benzofuran core  
Asp1644  Hydrogen bond (2.4 Å)  -OH at C-5  
Asn1640  Hydrogen bond (3 Å)  Basic N of piperidine at C-4  
Gln1633, Ser1636  van der Waals  Phenyl at C-2  
Tyr 1674, Tyr1663, 
Ala1667  
van der Waals Piperidine ring at C-4 
Glu1671  van der Waals -OH at C-5 
Tyr1582, Tyr1637 van der Waals Phenyl ring of core 
Arg1641, Ile1643  Hydrophobic  Phenyl ring of core and 















Figure 4-9. Cartoon representation of the binding interactions of 1 with the TE lid 
domain. 1 is shown as sticks with carbons in magenta color and the residues of the lid 
domain that interact with 1 are shown as sticks with carbons in yellow color (other atom 
colors are: red, oxygen; blue, nitrogen). Hydrogen bond interactions are shown as black 
dashed lines with the distances ranging from 2.4 to 3.3 Å. The active Ser1533 is shown 











One of the key interactions for 1 binding involves Asp1644 which is located at 
the end of helix α7 of the lid domain. The carbonyl oxygen of Asp1644 forms a strong 
hydrogen bond (Jeffrey, 1997) (2.4 Å) with the R4 hydroxyl of 1. In addition to the direct 
interactions with 1, a carboxylate oxygen at Asp1644 also forms hydrogen bond 
interaction with the side chain hydroxyl of Tyr1674 (2.7 Å), helping to orient it to form a 
stacking van der Waals interaction with the R3 piperidine ring (Fig. 4-9). The basic N of 
piperidine acts as a bifurcated donor making one hydrogen bond with the side chain 
oxygen of Asn1640 (3 Å) and another with carbonyl oxygen of R2 ethyl ester (3.3 Å). 
Other residues that participate in the van der Waals interactions with 1 are Gln1633 and 
Ser1636 with the R1 phenyl ring; Tyr1663 and Ala1667 with the R3 piperidine; and 
Glu1671 with the R4 hydroxyl. Arg1641 and Ile1643 form hydrophobic interactions with 
the phenyl ring of the benzofuran core and the methyl group of R3 piperidine, 
respectively (Fig. 4-9). 
 
Structural basis for resistance of D1607N and D1644G mutants to 1 
The effect of D1644G mutation is direct, in that it removes the interaction with 
R4 hydroxyl of 1. The effect of D1607N mutation is less apparent, because it does not 
make any direct interactions with 1. Inspection of the interactions of Asp1607 in the 
mutant structure (refinement statistics in Table 4-1) revealed that in the wtTE1451- 1 
complex structure the side chain carbonyl oxygen atoms of Asp1607 form bidendate 
hydrogen bond interactions with the side chain amide group of Arg1641 (3.2 Å and 3.3 




Asp1644 to form hydrogen bond interaction with R4 hydroxyl of 1. In contrast, the 
D1607N mutation disrupts this hydrogen bond interaction with Arg1641 allowing it to 
adopt a different rotamer conformation (Fig. 4-10). This results in the loss of anchoring 
effect by Arg1641 causing the C-terminal end of helix α7 to move away from the 
substrate binding groove. The resulting flexibility also causes Asp1644 to move away 
from the substrate binding groove by 3 Å, altering its hydrogen bond interactions. The 
movement of Aps1644 disrupts its interaction with 1, in addition it also gets positioned 
within hydrogen bonding distance to Arg1641 (2.7 Å) (Fig. 4-10). Thus, the D1607N 
mutation introduces subtle changes in structural interactions, in contrast to the D1644G 
mutation, to disrupt TE domain interaction with 1 and impart resistance to the bacterium. 
 
Structural basis for inhibition of TE1451 by analogs of 1 
The structures of TE1451-analog binary complexes were refined using the 
TE1451-apo structure. As expected, there was clear positive |Fo|-|Fc| difference electron 
density for inhibitors 3-6 that was in a very similar position in the substrate binding 
groove. Ligands were fit into the electron density, and the structures were built and 










Figure 4-10. Structural basis for resistance of the TE1451:D1607N mutant to 1. 
Structure of TE domain-1 complex (TE in cyan color, 1 as magenta sticks) superimposed 
with the structure of D1607 mutant (yellow color) showing altered conformation of 
Arg1641 in the mutant. This results in an altered hydrogen bonding of Asp1644 to 
Arg1641 in the D1607N mutant (black dotted line). In the wt-TE structure, Asp1607 
hydrogen bonds to Arg1641 that anchors C-terminal end of helix α7 thereby allowing 
Asp1644 to form hydrogen bond interaction with 1 and Tyr1674 (black dashed lines). 
The mutation D1607N results in a loss of hydrogen bond mediated anchoring of helix α7 
that causes Asp1644 to move away by ~ 3 Å which consequently disrupts its strong 












Figure 4-11. Fitting of the inhibitors in the TE1451-analog complex structures. The 
panels show the 2mFo - DFc maximum-likelihood omit maps contoured at 2 σ (grey 
mesh) for the TE1451 complex structures with the following ligands: (a) analog 3, (b) 
analog 4, (c) analog 5, and (d) analog 6. Maps were calculated for the refined models 
with the ligand atoms omitted. The carbon atoms are colored green for 3, yellow for 4, 
orange for 5, and white for 6. The oxygen and nitrogen atoms are colored red and blue, 











The protein component of all of the complexes exhibit a nearly identical overall 
structure as compared to the TE1451-1 complex (RMSD of 0.4 Å for 4, 0.7 Å for 3, 0.9 
Å for 5 and 6 vs. 1 complex over 264 paired Cα atoms). In the structures, the variation in 
the tertiary amine group at R3 of the analogs did not affect their mode of binding; 
however, based on our biochemical data it did contribute to the variations in the efficacy 
of inhibition by different analogs (Table 4-4).  The crystal structures of TE1451-3 and 
TE1451-4 complexes revealed that the five- and seven-membered cyclic amine groups at 
R3 of 3 and 4, respectively, formed stacking interaction with Tyr1674 in a manner 
similar to 1. In addition, the non-polar rings at R3 of 3 and 4 also maintained multiple 
van der Waals and hydrophobic interactions with the side chains of Ile1643 and Tyr1663 
(3.5-4.1 Å), that were also formed by the piperidine ring of 1. The conservation of 
interactions observed in the structures of TE1451 in complex with 1, 3 and 4 suggests 
similar inhibitory potency for these compounds. Indeed, the IC50 values of 3 and 4 were 
determined to be similar to the IC50 of 1 (Table 4-4). The small differences in the IC50 
values among 1, 3 and 4 can be attributed to variations in the strength of stacking 
interaction of the planar side chain of Tyr1674 with the variably puckered rings at R3, 
similar to the sugar-ring Tyr interactions in the carbohydrate/sugar binding proteins 
(Weis and Drickamer, 1996) (Fig. 4-12). In the TE1451-5 complex structure, we 
observed that the polar cyclic amine at R3 also had a stacking interaction with Tyr1674, 
however, it formed only van der Waals interactions with side chains of Ile1643 and 
Tyr1663 (4-4.3 Å). Moreover, contrary to our expectations the oxygen atom of the R3 




Tyr1663, as its rotamer conformation positioned the hydroxyl at a distance of 4.2 Å. The 
effect of the reduced interactions of 5 on its inhibitory activity was reflected in ~3-fold 
increase in its IC50 (0.71 µM) compared to 1 (IC50 0.26 µM). In contrast to the cyclic 
groups at R3, the presence of an acyclic dimethyl amine group at R3 in 6 is expected to 
abolish the stabilizing stacking interaction with Tyr1674, and it was confirmed in the 
TE1451-6 complex structure. The structure also revealed that the smaller size of the side 
group at R3 led to reduced van der Waals and hydrophobic interactions with Tyr1674, 
Tyr 1663 and Ile1643. As a consequence of this loss of interactions there was >6-fold 




Figure 4-12. Binding mode of analogs of 1 to TE domain. Overlay of the structure of 1 
with analogs 3-6 (in stick representation with 1 in magenta, 3 in green, 4 in yellow, 5 in 
orange and 6 in blue color ) bound to TE domain as seen in the complex structures, 
reveals a binding mode similar to 1. The cyclic amine substituent groups at C-4 of the 







This is the first benzofuran based inhibitor reported to be active against M. 
tuberculosis. Molecule 1 has been validated biochemically and structurally to target the 
TE domain of Mtb Pks13. Inhibition of Pks13 represents an attractive alternative target 
for TB therapy as targeting it would inhibit cell wall biosynthesis leading to cell death, 
especially in the INH resistant strains (Stanley et al., 2013). In addition, it was recently 
reported that a combination of Pks13 inhibitors with other inhibitors of the mycolic acid 
biosynthesis (for e.g. INH) can potentially eradicate persisters as well as reduce the 
development of resistance (Wilson et al., 2013). Our preliminary SAR using structural 
analogs of 1 in an inhibition assay was conducted to determine the effect of different 
substituent groups at R3 of the benzofuran core on inhibitory activity of analogs. The 
MIC data from whole cell testing also correlated well with the IC50 data regarding the 
effect of R3 substitutions (Table 4-4). Notably, these compounds exhibited low 
cytotoxicity profiles suggesting that these could be used for structure guided 
development to further improve their activity profile and generate lead candidates for 
antitubercular drug development. 
Therefore, in order to gain insights into the structural features of TE domain-1 
interaction, we determined the first crystal structure of the Pks13 TE domain -1 complex. 
1 bound non-covalently at the entrance of the catalytic chamber of the TE domain, 
effectively blocking access of the substrate to the active site Ser (Fig. 4-7). In contrast, 




forming covalent adduct that mimics the acyl-enzyme intermediate (Pemble et al., 2007). 
Analysis of the binding mode of 1 and analogs suggested that the benzofuran core is 
critical for binding and orientation at the entrance of the active site. These structures also 
revealed the structural basis for our findings from the preliminary SAR studies, which 
indicated that the non-polar nature and planarity of the ring substituents at R3 are the key 
factors for potency of the compounds. From the structures, it can be seen that a ring with 
more planar conformation at R3 could form a stronger π-π interaction, rather than just 
van der Waals or stacking interaction with Tyr1663. We are currently pursuing design 
and synthesis of analogs based on these structural and the SAR studies.  
In order to design inhibitors which have a lower potential for resistance 
development, it is also important to understand the resistance mechanisms bacteria may 
deploy to render the inhibitor ineffective.  Structural studies on the two Pks13 TE 
domain mutations (D1607N and D1644G) that were identified to confer resistance to 
Mtb against 1, revealed that both  the mutations  disrupted the interaction between 
Asp1644 and 1, but interestingly the mechanism of disruption was found to be indirect 
and more subtle in the D1607N mutant. It is plausible that by increasing the flexibility of 
helix α7 in D1607N mutant, the bacterium is able to reduce the interaction and as a 
result the affinity for 1 just enough for the substrate to have a preferential binding, 
without distorting structural features of the substrate binding groove and hence 
preserving the substrate affinity. In contrast, the D1644G mutation has a direct effect on 
α7, which not only forms a part of the substrate binding groove, but may also interact 




substrate in the groove. In other PKS systems, TE domain interactions with the pPant 
arm of ACP domain have been reported to facilitate recognition and proper positioning 
of the substrate for catalysis (Xu et al., 2013). Although the in vitro activity and 
especially IC50 for the D1644G mutant was much enhanced in comparison to the wild 
type TE, remarkably it did not translate into a corresponding in vivo advantage for the 
bacterium, as indicated by the 2-fold higher MIC observed for the D1607N mutant 
strains compared to the D1644G mutants (Ioerger et al., 2013).  
In conclusion, our work presents the first report of elucidation of the structural 
basis for the mechanism of inhibition of Pks13, an essential type 1 PKS from Mtb that 
presents a promising candidate for anti-Mtb drug discovery (Wilson et al., 2013). The 
structural and biochemical analysis performed in this study validates the TE domain of 
Pks13 as the target of a novel inhibitor 1. Further, analysis of the structures of the TE 
domain in complex with 1 and its analogs has revealed important details on structural 
interactions that will aid in the design and development of more potent inhibitors. In 
addition, we have also determined the structural basis for the mechanism of resistance 
towards 1. Our work provides a foundation for initiating structure-based studies and 









ADDITIONAL UNPUBLISHED RESULTS 
 
Extended SAR with the newly synthesized analogs of 1 
⃰
 
 The results from our preliminary SAR studies with the analogs of 1 (Table 4-4) 
had suggested that the replacement of the R3 piperidine ring with a planar phenyl ring 
could lead to a stronger π-π stacking interaction with Tyr1674 in the binding pocket of 
TE domain (Fig. 4-12). To test this hypothesis, we synthesized an analog of 1 (MKP-
116L) with a phenyl ring in place of the R3 piperidine ring, and evaluated its inhibitory 
activity. Contrary to our expectations, the incorporation resulted in loss of activity of 
MKP-116L by >40-fold compared to 1 (Table 4-6). Since the inhibitors with puckered 
tertiary amine rings at R3 position showed good activity we have synthesized and tested 
an analog with a R3 cyclohexyl group to investigate the effect of ring N-atom. The 
cyclohexane ring of this analog (MKP-126) has a puckered chair conformation similar to 
the piperidine of 1. However, this analog showed a higher IC50 (20 µM) compared to the 
phenyl ring containing analog MKP-116L (IC50 12 µM), resulting in a loss of activity by 
>70-fold when compared to the original hit compound 1 (Tables 4-4 and 4-6). These 
results indicate that the presence of a non-tertiary amine ring either affects the 
conformation of the inhibitor, or results in an alteration in the interactions of the 
inhibitor with the binding pocked residues of the protein. This suggested that 
intramolecular hydrogen bond between the basic N-atom of piperidine and carbonyl 
oxygen of R2 ethyl ester might be important for maintaining the conformation, and 
                                                 





hence, the mode of binding of the ring at R3. Indeed, when the 4-methyl piperidine ring 
was replaced at R3 in the analog MKP-120, the analog showed an IC50 (0.3 µM) similar 
to the original hit compound 1 (IC50 0.26 µM), confirming that the tertiary amine is 
critical for the potency of the compounds. Interestingly, MKP-120 displayed ~5-fold 
lower MIC in the whole cell assays compared to 1 (Table 4-6). Since MKP-120 does not 
have the para-methyl group on the piperidine ring as 1, these results indicate that the 
methyl group does not make a significant contribution to the potency; however, its 
removal enhanced the whole cell activity. This finding has been further supported by the 
IC50 data from the analog AA-7 which contains an N-methyl piperazine group at R3 
(Table 4-6). The R3 substituent of AA-7 shares a similar puckered conformation with the 
piperidine of 1, but has a more polar ring. The IC50 of AA-7 was found to be 2.7 µM, 
which is ~10-fold higher than the IC50 of 1 (Tables 4-4 and 4-6). This finding is 
consistent with the results obtained in the preliminary SAR from the testing of analog 5 
which had a morpholine ring at R3 and displayed a ~3-fold higher IC50 compared to 1 
(Table 4-4). Overall, the results from these SAR studies of the R3 substituents suggest 
that the piperidine ring at R3 is critical for the potency of the compounds.  
       








Table 4-6. Pks13 TE domain SAR of the synthesized benzofuran analogs of 1. 
 
                 
     
Comp-
ound 












OH 0.26 ± 0.04 0.4 
MKP-
121    















OH 0.29 ± 0.01 0.2 
MKP-
130    
OH 
 









Table 4-6. Continued. 
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ound 



















OH 0.28 ± 0.01 2.6 
MKP-
149    

















2.7 ± 0.1 1.4 
IC50 values were determined using the Mtb Pks13 TE domain as described in the 
methods section.  MIC values were determined for mc
2
7000 in liquid medium in 96-well 
plates. MeO, methoxy; ND, not determined; NI, no inhibition. *Values are shown as 





We next performed SAR on the potentially labile R2 ethyl ester of the inhibitor 1. 
Since the ethyl ester can be hydrolyzed to corresponding acid by the non-specific 
esterases inside the mycobacterial cells, it is plausible that the acid form of 1 is the active 
compound.  This would suggest that the ester represents the prodrug form of 1 which 
upon cellular uptake gets converted to an active acid form. We tested this hypothesis by 
synthesizing the acid analog (MKP-121) of MKP-120 and evaluating it for enzyme 
inhibition and whole cell activity. MKP-121 had an IC50 of 6.6 µM, a ~20-fold loss in 
activity compared to MKP-120; moreover its whole cell activity was completely 
abolished (Table 4-6). The MIC data are consistent with the reported impermeability of 
the Mtb cell wall for the acidic compounds (Brennan and Nikaido, 1995). Also, in a 
study with the phenyl-diketo acid inhibitors of the Mtb malate synthase, it was shown 
that masking of the acid group via esterification was a good strategy to enhance the 
whole cell uptake of the inhibitors (Krieger et al., 2012). However, even though the lack 
of whole cell activity for MKP-121 could be attributed to its reduced permeability into 
the cells, the IC50 data clearly established that MKP-121 was not a potent inhibitor 
(Table 4-6). Since the R2 ethyl ester could also be subjected to hydrolysis by the serum 
esterases (Tsaioun and Kates, 2011), it still represented a metabolic liability that could 
lead to the production of the less active acid form of the inhibitor. Therefore, we 
synthesized analogs of MKP-120 that contain methyl- (MKP-128) or ethyl-amide 
(MKP-130) functionality at R2 (Table 4-6). Both methyl- and ethyl-amide groups are 
metabolically more stable and they provide a similar isoelectronic structure as the ethyl 




0.3-0.4 µM) as the ethyl ester containing MKP-120 (IC50 0.3 µM), which indicated that 
methyl- and ethyl-amide groups maintain the inhibitor potency, while at the same time 
they provided the desired metabolic stability at R2.  We determined their mode of 
interaction with the TE domain by solving the crystal structure of TE1451 in complex 
with MKP-128. The crystal structure of TE1451-MKP-128 complex was nearly identical 
to the TE1451-1 complex structure, and it showed that MKP-128 bound to TE1451 in a 




Figure 4-13. Binding mode of methylamide analog MKP-128. (a) Binding mode of 1 
(shown as magenta sticks). (b) Binding mode of MKP-128 (shown as yellow sticks) to 
the Pks13 TE domain. The grey mesh represents the 2mFo - DFc maximum-likelihood 
omit map contoured at 2 σ. Map was calculated for the refined model with the ligand 
atoms omitted. The carbon atoms are colored magenta for 1 and yellow for MKP-128. 






 All the major interactions of MKP-128 with the TE domain are very similar to 
inhibitor 1 complex structure including the H-bonding interactions with Asp1644 and 
Asn1640, and the stacking interactions with Tyr1674 and Phe1670, which provided the 
structural basis for the similar in vitro potency. When MKP-128 was tested for the whole 
cell activity, its MIC (0.2 µM) was found to be >10-fold lower than that of 1 (2.3 µM). 
In addition, it was also 2-fold lower than the MIC of MKP-120, suggesting that 
substitution of the ester with the amide at R2 had also enhanced whole cell activity 
(Table 4-6). Therefore, the R2 SAR data suggests that the replacement of the more labile 
ethyl-ester with the more stable amide group not only preserved the potency of the 
parent compound but also improved its whole cell activity. 
 The phenolic OH at the R4 of the benzofuran core was found to make a strong 
hydrogen bond to the side chain carbonyl of Asp1644 (distance 2.4-2.5 Å) of the TE 
domain in the crystals structures of 1 and its analogs. Since this R4 OH has a potential 
for oxidation, we performed a SAR with different substituents at this position to 
determine its role in inhibitor binding.  Two analogs of MKP-120 were synthesized in 
which the R4 OH was substituted with either a methoxy group (MKP-150) or a hydrogen 
atom (MKP-152) (Table 4-6). The IC50 for MKP-150 was determined to be ~36 µM, 
whereas it was 2 µM for MKP-152. Therefore, removal of the hydrogen bonding 
capability in MKP-150 caused a >100-fold decrease in its inhibitory activity. Some 
contribution to this loss of activity in MKP-150 could also be attributed to the presence 
of the bulky methoxy group at R4, since it can have some stearic clash with the side 




further supported by the inhibition data on MKP-152, which showed only a modest ~7-
fold decrease in activity due to substitution of the R4 OH with just a hydrogen atom. 
Thus, the SAR data from the R4 substitutions suggests that a hydrogen bond donor is 
required at that position for the potency of the inhibitor. In addition, analysis of the 
TE1451 complex structures with inhibitors suggests that the OH can be moved to the C-
6 position on the benzofuran core which could preserve the current hydrogen bonding 
pattern while eliminating the oxidation liability associated with the R4 OH. We are 
currently pursuing design and synthesis of new analogs based on these findings.  
 In the TE1451-1 complex structure, we observed that the R1 phenyl substituent is 
exposed to the solvent and does not make any interactions with the protein. However, 
the structure also indicated that the side chain carbonyl and amide groups of the Gln1633 
residue on the helix α7 are positioned at a distance of 3.3 and 4.4 Å, respectively, from 
the C-4 of the R1 phenyl substituent (Fig. 4-9). This suggested that incorporation of 
either a hydrogen bond donor or a hydrogen bond acceptor group at the C-4 of the R1 
phenyl would allow an additional hydrogen bond interaction of the inhibitor with 
Gln1633, which could improve the potency of the inhibitor. To address this point, we 
synthesized two analogs of MKP-120 containing a methoxy (MKP-148) and an OH 
(MKP-149) group at the C-4 of the R1 phenyl ring (Table 4-6). The IC50 of the methoxy 
substituent (MKP-148) was found to be similar to MKP-120 (Table 4-6), but the OH 
substituted compound (MKP-149) exhibited a slightly better IC50 (0.19 µM) compared to 




compounds with other H-bond donor and acceptor substituents at the C-4 of the R1 
phenyl group. These will then be evaluated to identify the most suitable substitution.    
 In addition to the structure-guided development of the analogs of the benzofuran 
1, we also performed a pharmacophore search to identify other structural mimetic of the 
benzofuran core. We identified and tested a benzimidazole derivative, AA-8 with a 
phenyl, a piperidine and an OH group substituted at the R1, R3 and R4, respectively, 
similar to the benzofuran 1 (Table 4-7). However, AA-8 did not have any substituent at 
R2. Interestingly, AA-8 exhibited moderate inhibition of TE1451 with an IC50 of ~6.8 
µM. We elucidated the structural basis for its inhibitory activity by solving the crystal 
structure of the TE1451-AA-8 complex. The structure showed that AA-8 bound to 
TE1451 in a pose similar to 1 (Fig. 4-14). The benzimidazole core of AA-8 is co-planar 
with R1 phenyl ring, and forms a stacking interaction with Phe1670 similar to the 
benzofuran core of 1. In addition, the structure showed that similar to 1, AA-8 also 
formed hydrogen bonding interactions with Asp1644 and Asn1640 through its R4 OH 
and the R3 piperidine, respectively. Furthermore, the piperidine also formed the stacking 
interaction with Tyr1674, similar to the piperidine of 1 (Fig. 4-14). Thus, the structure 
showed that the benzimidazole AA-8 has a binding mode similar to 1. We also tested an 
analog of AA-8 that contains a methyl group substituted at the R1 position (AA-9). This 
analog showed an IC50 of >100 µM, suggesting that the R1 phenyl is critical for inhibitor 






Table 4-7. Pks13 TE domain SAR of the benzimidazole analogs of 1. 
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ound 








6.8 ± 0.9 ~22 





IC50 values were determined using the Mtb Pks13 TE domain as described in the 
methods section.  MIC values were determined for mc
2
7000 in liquid medium in 96-well 




Screening of the whole cell active compounds for identification of novel inhibitors 
 In addition to our structure-guided inhibitor development, we also screened 
TE1451 against a collection of 560 compounds that were identified from an in-house 
library of 51K compounds to be whole cell active against Mtb strain mc
2
7000, to identify 
inhibitors with novel chemical scaffolds. The screening was performed as detailed in the      
Methods section, and the initial screening identified nine compounds that showed a 





Figure 4-14. Binding mode of benzimidazole analog AA-8. (a) Binding mode of 1 
(shown as magenta sticks). (b) Binding mode of AA-8 (shown as yellow sticks) to the 
Pks13 TE domain. The grey mesh represents the 2mFo - DFc maximum-likelihood omit 
map contoured at 2 σ. Map was calculated for the refined model with the ligand atoms 
omitted. The carbon atoms are colored magenta for 1 and yellow for AA-8. The oxygen 
and nitrogen atoms are colored red and blue, respectively, in both the structures. The 




These initial nine hits were then evaluated in a dose-response assay to determine their 
IC50 values (Table 4-8). Some of the compounds showed good inhibitor activity with the 
IC50 values ranging from 3-1.6 µM (Table 4-8), and these will used for co-crystallization 








Table 4-8. Hits from the whole cell actives screening of TE1451. 
Compound ID Structure IC50 (µM)* 
1:G11 
 
34.2 ± 1.7 
3:F8 
 
13 ± 1 
3:F9 
 






30 ± 2 
5:E8 
 










IC50 values were determined using the Mtb Pks13 TE domain as described in the 









The mycolic acid biosynthesis pathway is well-establish to be an essential 
pathway for survival of M. tuberculosis.  Many of the clinically-used antitubercular 
drugs in in the current TB therapy target enzymes in this pathway, including the first-line 
drug isoniazid.  However, resistance to isoniazid is increasingly observed and is 
currently estimated at around 5% worldwide (including both monoresistance as well as 
MDR/XDR-TB). Therefore, it is critical to identify novel druggable targets in this 
validated essential biosynthetic pathway. In this study, we have have performed 
biochemical and structural validation of the Mtb Pks13 thioesterase (TE) domain as the 
target of benzofuran-based whole-cell active inhibitors. We determined the binding 
mode of these inhibitors by solving the crystal structures of the Pks13 TE domain in 
complex with benzofuran 1 and its analogs. These preliminary SAR studies identified 
structural requirements for active inhibitors against the Pks13 TE domain. In addition, 
we also determined the structural basis for the mechanism of resistance toward 1 by 
solving the structures of the mutant forms of the TE domain. To develop lead 
compounds from the initial hits, we synthesized a number of analogs of 1 which were 
substituted with different functionalities at the R1, R2, R3 and R4 positions on the 
benzofuran core, and performed extensive SAR studies with these analogs. These studies 
revealed that for the potent inhibitor activity a cyclic tertiary amine group is required at 
the R3 position which participates in a stacking interaction with Tyr1674. The R4 OH is 




compound as it participates in a strong H-bond interaction with Asp1644. All of the 
findings from our extensive SAR are summarized in Figure 4-15. Based on the 
information obtained from the SAR studies, we have developed two lead compounds, 
MKP-128 and MKP-149, which exhibit 8- to 12-fold better whole cell activity compared 
to the original hit compound 1, while maintaining a similar in vitro potency.  These will 
be subjected to pharmacokinetic and animal model studies for evaluation as potential 
drug development leads.      
   
 
 











 The status of M. tuberculosis (Mtb), which causes TB in humans, as one of the 
deadliest and most successful of all human pathogens prompted the World Health 
Organization to declare it a global health emergency in 1993. Even though a successful 
treatment regimen exists which can cure over 95% of the infected individuals, TB 
continues to be one of the highest burden infectious disease worldwide. In addition, 
emergence of multi-drug resistant and extensively drug resistant TB threatens to 
jeopardize the global efforts to contain the TB pandemic. Therefore, there is an urgent 
need for the development of new TB drugs that are effective against drug resistant Mtb 
and can help shorten the treatment duration. To discover new anti-tubercular drugs, it is 
critical to identify novel targets in either pre- or newly validated esstential pathways in 
Mtb, and determine the molecular basis for their function. Structural studies of these 
proteins can provide important mechanistic insights into their function which can help 
guide structure-based inhibitor discovery against these targets. Here, we have employed 
various X-ray crystallographic techniques for the structural charatcterization of three 
different proteins that are involved in the complex lipid synthesis pathways in the Mtb.   
 Chapter I of this dissertation presented essential facts about TB and its etiological 
agent Mtb. The architecture of the cell envelope, which is essential for the survival and 




mycolic acids, which are the most abundant lipid of the Mtb cell envelope, were 
presented and their roles in the mycobacterial physiology and pathogenesis were 
described. The essential pathway of mycolic acid biosynthesis with its novel drug targets 
was also described in detail. In addition, a general description of all of the polyketide 
synthases in Mtb was presented, along with the details on the different methyl-branched 
fatty acids containing lipids of the cell envelope. Also, the biosynthetic pathway of the 
phthiocerol dimycocerosate esters, the most abundant non-covalently attached lipids of 
the Mtb cell envelope, was presented in detail. Lastly, the mechanism for the activation 
of the acyl carrier protein domains of the PKS and the FAS systems in Mtb was 
described.  
       Chapter II described the purification and initial crystallographic characterization of 
the large 225 kDa multifunctional methyl-branched fatty acid synthesizing MAS 
enzyme. The development of the methods for the successful cloning, expression and 
purification of the phosphopantetheinylated holo-MAS from E. coli was described in 
detail. The recombinantly expressed MAS was determined to be a dimer in solution. A 
screening protocol that utilized heterogeneous nucleating agents for obtaining first 
crystallization hits of MAS was developed and described. To improve the diffraction 
properties of the MAS crystals, extensive post-crystallization treatment protocols were 
developed and described in detail. Initial crystallographic characterization indicated that 
MAS crystallized in the tetragonal space group with four to five molecules in the 




chapter could prove useful for initiating crystallographic studies on other PKS I systems 
in Mtb. 
 In the Chapter III, structural studies on acyl carrier protein synthase (AcpS) from 
Mtb and C. ammoniagenes were presented. We determined the crystal structures of the 
AcpS at different pH which revelaed that AcpS adopted two different conformations – 
open and closed. At a lower pH (4.0 to 6.0) the helix α2 of Mtb AcpS was found to be 
well ordered, whereas at higher pH values it underwent structural rearrangement that led 
to the destabilization of the connecting loops at its ends. The structure showed that a 
change in the pH disrupted ionic interactions of the helix α2 leading to its open 
conformation. Futhermore, using in vitro reconstitution assays we determined that the 
Mtb AcpS had a higher modification activity between pH 4.4 to 6.0 than at pH above 
6.5, in agreement with the structural data. The structure also revealed the active site 
architecture and helped us to identify Arg48, His49 and His116 as the critical residues. 
This information will be useful for structure-based inhibitor discovery against AcpS 
which represents a good target for simultaneous disruption of several lipid biosynthesis 
pathways in Mtb. To this end, we have developed a differential scanning fluorimetry 
based assay for fragment-based ligand discovery to identify novel chemical scaffolds 
that can be developed as leads.  
 In Chapter IV, we described the biochemical and structural validation of the Mtb 
Pks13 thioesterase (TE) domain as the target of benzofuran-based whole-cell active 
inhibitors. Pks13 is the central condensing enzyme in the mycolic acid biosynthesis 




anti-Mtb drug discovery. We determined the binding mode of the inhibitors by solving 
the crystal structure of the Pks13 TE domain in complex with several benzofuran-based 
inhibitors. The crystal structure revealed that the TE domain belonged to the α/β-
hydrolase family of enzymes. The structures allowed us to determine the binding mode 
of the inhibitors and elucidate the structural basis for their mechanism of inhibition. We 
detmined that the critical interactions for the binding and the potency of the inhibitors 
included stacking interactions with Tyr1674 and Phe1670, and hydrogen bond 
interactions with Asp1644 and Asn1640. Furthermore, we also described the structural 
basis for the mechanism of resistance towards these inhibitors. Based on the results from 
our preliminary structure-activity relationship (SAR) studies, we designed and 
synthesized a number of analogs of the initial hit compound. Analysis of SAR data from 
these analogs identified two analogs, MKP-128 and MKP-149, that showed similar in 
vitro potency, but exhibited 8- to 12-fold better whole cell activity compared to the 
original hit compound. These will be further evaluated as potential drug development 
leads. Lastly, we identified a benzimidazole scaffold as a potential replacement for the 
benzofuran core, and determined that the benzimidazole analogs bind in a similar pose 
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